<SEC-DOCUMENT>0001129928-25-000062.txt : 20250808
<SEC-HEADER>0001129928-25-000062.hdr.sgml : 20250808
<ACCEPTANCE-DATETIME>20250808093856
ACCESSION NUMBER:		0001129928-25-000062
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250808
DATE AS OF CHANGE:		20250808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		251196514

	BUSINESS ADDRESS:	
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2R 0C5
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2R 0C5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>q22025form6-k.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i55c916910f2844009c1e2b020126d5ef_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;  </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">Form 6-K</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Report of Foreign Private Issuer Pursuant to Rule&#160;13a-16 or 15d-16 of the Securities Exchange Act of 1934</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the month of August 2025 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number 001-38512</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Oncolytics Biotech Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Suite&#160;804, 322 11th Avenue SW</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Calgary, Alberta, Canada T2R 0C5</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.725%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;20-F&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#254;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;40-F&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1)&#58;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7)&#58;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div id="i55c916910f2844009c1e2b020126d5ef_4"></div><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:174%">EXHIBIT INDEX&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant&#8217;s Management&#8217;s Discussion and Analysis of Operations and Financial Condition for the Three and Six Months Ended June&#160;30, 2025, included as Exhibit&#160;99.2 of this Form&#160;6-K and the Interim Financial Statements as of and for the Three and Six Months Ended June&#160;30, 2025, included as Exhibit&#160;99.1 of this Form&#160;6-K (Commission File No.&#160;001-38512), furnished to the Commission on&#160;August&#160;8, 2025, are incorporated by reference into the Registrant&#8217;s Registration Statement on Form&#160;F-10 (Commission File No. 333-281009).</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT<br>NUMBER</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION</font></td></tr><tr><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex991-interimfsjune302025.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Oncolytics Biotech&#174; Inc. June 30, 2025 Interim Financial Statements</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex992-q22025mda.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Oncolytics Biotech&#174; Inc. June 30, 2025 Management Discussion &#38; Analysis</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex993-q22025certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certification of June 30, 2025 interim filings - CEO</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex994-q22025certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certification of June 30, 2025 interim filings - CFO</a></font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Oncolytics Biotech Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;8, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;Kirk Look</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-interimfsjune302025.htm
<DESCRIPTION>EX-99.1 2025 SECOND QUARTER INTERIM FINANCIAL STATEMENTS
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i69868e7a4262403b9efa49a3d1444ba9_4"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Condensed Interim Consolidated Financial Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(unaudited)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Oncolytics Biotech</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"> Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">For the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">three and six months ended June&#160;30, 2025 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i69868e7a4262403b9efa49a3d1444ba9_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"></td><td style="width:67.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As at </font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (note 4)</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">14,626</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,942&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">72</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">3,174</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,885&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative (note 6)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,024</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">18,896</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,875&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">351</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets (note 5)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">727</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">19,974</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,187&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Shareholders' Equity</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities (note 4)</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">5,285</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,792&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities (note 4)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">982</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (note 5)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">291</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">6,558</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,687&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">6,730</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,730&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (note 5)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">597</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">13,885</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,204&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commitments (note 10)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' equity </font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share capital (note 7)</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Authorized&#58; unlimited</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Issued&#58; June&#160;30, 2025 &#8211; 97,407,903 </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;December&#160;31, 2024 &#8211; 80,020,131</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">451,142</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">438,193&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contributed surplus (note 8)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">44,792</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44,542&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">720</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">961&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(490,565)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(477,713)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders' equity </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">6,089</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,983&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders' equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">19,974</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,187&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i69868e7a4262403b9efa49a3d1444ba9_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts) </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:45.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development (note 14)</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2,809</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,558&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">6,892</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,301&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;General and administrative (note 14)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2,897</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,362&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">5,813</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,345&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Loss before the following</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(5,706)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,920)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(12,705)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(16,646)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Change in fair value of warrant derivative (note 6)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(196)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">44</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign exchange (loss) gain</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(282)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(333)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">701&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">104</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">227</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">786&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(6,080)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,161)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(12,767)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14,055)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Income tax expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(85)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(95)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(85)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(95)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(6,165)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,256)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(12,852)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14,150)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income items that may be reclassified to net loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Translation adjustment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(238)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(241)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(6,403)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,204)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(13,093)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,972)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per common share (note 9)</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(0.07)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(0.15)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of shares (basic and diluted) (note 9)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">90,999,586</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">76,090,406&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">87,833,107</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">75,667,521&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See accompanying notes</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i69868e7a4262403b9efa49a3d1444ba9_22"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.852%"><tr><td style="width:1.0%"></td><td style="width:39.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.287%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Share Capital</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Contributed Surplus</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">430,906&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42,116&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(446,003)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,563&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14,150)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,972)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan (notes 7, 8)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; Agreement (note 7)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,840&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,840&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 7)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(202)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(202)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (note 8)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">As at June 30, 2024</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">434,547&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">43,195&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(460,153)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,311&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2024</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">438,193&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44,542&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">961&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(477,713)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,983&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(241)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(12,852)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,093)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan (notes 7, 8)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,481)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; Agreement (note 7)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,714&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,714&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to share purchase agreement (note 7)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,841&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,841&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 7)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,087)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,087)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (note 8)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">As at June 30, 2025</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">451,142</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">44,792</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">720</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(490,565)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">6,089</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i69868e7a4262403b9efa49a3d1444ba9_25"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars)&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:65.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss for the period</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(12,852)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14,150)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment (note 14)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">51</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use-assets (note 14)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">140</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (notes 8, 14, 15)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,731</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">74</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign exchange loss (gain)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(576)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative (note 6)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(44)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,104)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net change in non-cash working capital (note 13)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(1,070)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in operating activities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(11,969)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14,288)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property and equipment</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(201)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in investing activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(201)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from &#34;At the Market&#34; equity distribution agreement, net (note 7)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">8,386</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,638&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from share purchase agreement, net (note 7)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">3,082</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(205)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(168)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Cash provided by financing activities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">11,263</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,470&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Decrease in cash and cash equivalents</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(706)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,019)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">15,942</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,912&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and cash equivalents</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(610)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">14,626</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,850&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i69868e7a4262403b9efa49a3d1444ba9_31"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2025</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated) </font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div id="i69868e7a4262403b9efa49a3d1444ba9_34"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 1&#58; Nature of Operations and Going Concern</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was incorporated on April 2, 1998, under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Market (the &#34;Nasdaq&#34;) and the Toronto Stock Exchange (the &#34;TSX&#34;). Our principal place of business is located at 804, 322 11</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue S.W., Calgary, Alberta, Canada.   </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Our primary focus is to advance our first-line metastatic pancreatic ductal adenocarcinoma program to a registration-enabled clinical study. In addition, we are exploring opportunities for registrational programs and investigator sponsored trials in hormone receptor-positive &#47; human epidermal growth factor 2-negative (HR+&#47;HER2-) advanced and metastatic breast cancer and other gastrointestinal cancers, including anal cancer, through our GOBLET platform study, and colorectal cancer through potential investigator sponsored trials.   </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue our research and development efforts. As at June&#160;30, 2025, we had an accumulated deficit of $490,565. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through issuing additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Going concern</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses our ability to continue as a going concern when preparing our condensed interim consolidated financial statements. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period. As at June&#160;30, 2025, we had cash and cash equivalents of $14,626. We estimate we can currently fund our operations into the first quarter of 2026. Factors that will affect our anticipated cash needs for the next twelve months include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue as a going concern is dependent upon raising additional financing through equity or strategic collaborations and transactions. We plan on raising additional funds through the sale of our common shares or other capital resources, such as strategic collaborations and debt, to fund our ongoing operations. However, given the difficulty for micro-cap market capitalization companies to raise significant capital, there can be no assurance that additional liquidity will be available under acceptable terms or at all. Furthermore, if we are unable to obtain additional financing when required, there can be no assurance that we will be able to sufficiently reduce or eliminate our planned expenditures to extend our operating runway. These material uncertainties raise substantial doubt on our ability to continue as a going concern and meet our obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These condensed interim consolidated financial statements were prepared in accordance with International Financial Reporting Standards (&#34;IFRS&#34;) applicable to a going concern. However, the use of the going concern assumption on which these condensed interim consolidated financial statements are prepared may not be appropriate based on the factors described above.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These condensed interim consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and statements of financial position classifications that would be necessary if we were unable to realize our assets and settle our liabilities as a going concern in the normal course of operations. Such adjustments could be material. </font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i69868e7a4262403b9efa49a3d1444ba9_37"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2025</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated) </font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 2&#58; Basis of Presentation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Statement of compliance</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These condensed interim consolidated financial statements have been prepared in accordance with IFRS and in compliance with International Accounting Standard (&#34;IAS&#34;) 34 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> as issued by the International Accounting Standards Board (&#34;IASB&#34;).</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed interim consolidated financial statements for the three and six months ended June&#160;30, 2025, were authorized for issue in accordance with a resolution of the Board of Directors on August&#160;7, 2025.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These condensed interim consolidated financial statements have been prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The notes presented in these condensed interim consolidated financial statements include only significant events and transactions occurring since our last fiscal year end and are not fully inclusive of all matters required to be disclosed in our annual audited consolidated financial statements. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with our most recent annual audited consolidated financial statements for the year ended December&#160;31, 2024.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed interim consolidated financial statements include our financial statements and the financial statements of our subsidiaries, Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc., and are presented in Canadian dollars, our functional currency.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed interim consolidated financial statements in conformity with IFRS requires us to make judgments, estimates, and assumptions that affect the application of accounting policies, the reported amounts, and disclosures in our condensed interim consolidated financial statements and accompanying notes. Management makes estimates based on our best knowledge of current events and actions that the Company may undertake in the future. We consider the potential impact of certain external factors outside of our control, including global political conflicts, supply chain disruptions, inflation, fluctuating interest rates, and liquidity, when making certain estimates and judgments relating to the preparation of these condensed interim consolidated financial statements. Estimates and underlying assumptions are reviewed on an ongoing basis. Actual results could differ from these estimates, and such differences could be material. </font></div><div style="text-align:justify"><font><br></font></div><div id="i69868e7a4262403b9efa49a3d1444ba9_40"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 3&#58; Material Accounting Policies</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies applied in these condensed interim consolidated financial statements are the same as those applied in our audited consolidated financial statements for the year ended December&#160;31, 2024.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accounting standards and interpretations issued but not yet effective</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">IFRS 18 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation and Disclosure in Financial Statements</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the IASB issued IFRS 18 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation and Disclosure in Financial Statements </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">which replaces IAS 1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">IFRS 18 introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals. It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation of financial information based on the identified roles of the primary financial statements and the notes. Narrow scope amendments have been made to IAS 7 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flows</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and some requirements previously included within IAS 1 have been moved to IAS 8 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">which has also been renamed IAS 8 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Preparation of Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. IAS 34 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">has also been amended to require disclosure of management-defined performance measures. IFRS 18 and the amendments to the other standards are effective for annual periods beginning on or after January 1, 2027, with early </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2025</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated) </font></div><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">application permitted. IFRS 18 applies retrospectively to both annual and interim financial statements. We are assessing the impact of adopting this standard on our consolidated financial statements.</font></div><div id="i69868e7a4262403b9efa49a3d1444ba9_43"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 4&#58; Balance Sheet Details </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of interest-bearing deposits with our bank totaling $10,569 as at June&#160;30, 2025 (December&#160;31, 2024 &#8211; $12,312).&#160;&#160;</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other liabilities</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we were selected by the Pancreatic Cancer Action Network (PanCAN) as the recipient of its Therapeutic Accelerator Award to conduct a clinical trial with pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor in pancreatic cancer patients. Under the terms of the award agreement, we are entitled to receive up to US$5&#160;million in funding for eligible research expenses, and we must comply with the conditions set out with the award agreement, including providing periodic performance progress reports. As at June&#160;30, 2025, we recorded US$719 ($982) (December&#160;31, 2024 &#8211; US$1,125 ($1,618)) in other liabilities representing unapplied funding received from PanCAN.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accounts payable and accrued liabilities</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:63.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,331</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">3,954</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,705&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">5,285</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,792&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div id="i69868e7a4262403b9efa49a3d1444ba9_46"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 5&#58; Leases </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have office space leases with initial lease terms generally between 3 to 6 years. We currently do not have leases with residual value guarantees or leases not yet commenced to which we are committed. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate, as rates implicit in the leases were not readily determinable. The weighted average rate applied was 15%.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liabilities as at June&#160;30, 2025, were as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:81.719%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2025</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liabilities</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div id="i69868e7a4262403b9efa49a3d1444ba9_49"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 6&#58; Warrant Derivative </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our common share purchase warrants (&#34;warrants&#34;) with a U.S. dollar exercise price, which differs from our functional currency, are treated as a derivative measured at fair value, and revalued each period end at fair value through profit and loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2025</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated) </font></div><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the value of our warrant derivative were as follows&#58;</font></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,731,085&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(52,456)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expired</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,579)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discount on warrants issued</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,605)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2024</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,667,050&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(980)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discount on warrants issued</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(226)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As at June 30, 2025</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">7,667,050</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(1,024)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding warrant derivative as at June&#160;30, 2025&#58;</font></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.210%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exercise price</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Issuance date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Expiry date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">US$2.81</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2023</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2028</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,667,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">US$2.81</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">September 7, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2028</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,000,050&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,667,050&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2023, pursuant to an underwritten public offering, we issued 6,667,000 units for gross proceeds of $20,185 (US$15,001) at a price of US$2.25 per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional 1,000,050 units for gross proceeds of $3,077 (US$2,250) at a price of US$2.25 per unit. Each unit consisted of one common share and one common share purchase warrant (&#34;warrant&#34;), which were immediately separable and issued separately in this offering. Each warrant entitles the holder to purchase one common share at an exercise price of US$2.81 up to 60 months from the date of issuance. Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $17,724 recorded in share capital and an initial warrant derivative liability of $7,360. The difference between the fair value of the warrants and their allocated proceeds was a discount of $1,822, which is amortized on a straight-line basis over the five-year expected life of the warrants and recorded under change in fair value of warrant derivative on our consolidated statement of loss and comprehensive loss. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2025, as the unamortized discount balance was greater than the fair value of the warrant derivative liability, the net balance was presented as an asset on our condensed interim consolidated statement of financial position. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates with an approximate equivalent remaining term in effect at the time of valuation, and the expected life represents the estimated length of time the warrants are expected to remain outstanding. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2025</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated) </font></div><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative was determined using the following assumptions&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">US$0.76</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">US$0.92</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2.6%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.9%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">3.1 years</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.6 years</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">36.5%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36.5%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">US$0.01</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">US$0.03</font></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div id="i69868e7a4262403b9efa49a3d1444ba9_52"></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 7&#58; Share Capital</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Authorized</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">74,423,960&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">430,906&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">133,572&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; (ATM) equity distribution agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,410,143&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,670&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52,456&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(751)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2024</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">80,020,131&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">438,193&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,256,646&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; (ATM) equity distribution agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,568,974&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,714&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to share purchase agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,562,152&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,841&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,087)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">As at June 30, 2025</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">97,407,903</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">451,142</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000 over a 25-month period through the facilities of the Nasdaq in the United States. This sales agreement was terminated on July 17, 2024. During the six months ended June&#160;30, 2024, we sold 2,432,099 common shares for gross proceeds of $3,840 (US$2,835) at an average price of $1.58 (US$1.17). We received proceeds of $3,725 (US$2,750) after commissions of $115 (US$85). In total, we incurred share issue costs (including commissions) of $202. </font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On August 2, 2024, we entered into an ATM equity distribution agreement with Cantor Fitzgerald &#38; Co. (Cantor). The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$50,000 over a 25-month period through the facilities of the Nasdaq in the United States. During the six months ended June&#160;30, 2025, we sold 8,568,974 common shares for gross proceeds of $8,714 (US$6,150) at an average price of $1.02 (US$0.72). We received proceeds of $8,453 (US$5,965) after commissions of $261 (US$185). In total, we incurred share issue costs (including commissions) of $328. On August 8, 2025, we voluntarily delisted from the TSX, effective August 22, 2025, causing us to terminate our ATM agreement (see note 16).  </font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On April 10, 2025, we entered into a share purchase agreement with Alumni Capital LP (Alumni), an institutional investor. Under the terms of the agreement, we have the right to sell, and Alumni has the obligation to purchase up to US$20 million worth of common shares over a 15-month period based on the market price at the time of each sale to Alumni. The agreement limits Alumni's beneficial ownership to 4.99% of our common shares outstanding immediately prior to each </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2025</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated) </font></div><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sale, which can be increased to 9.99% upon mutual agreement. The agreement also limits our sale of common shares to 19.99% of our total outstanding common shares as at the date that the share purchase agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. Subject to the terms of the agreement, we have sole discretion over the timing and amount of all common share sales. We issued an initial commitment fee of 816,326 common shares at the execution of the agreement. An additional 816,326 common shares will be issued on a pro rata basis upon the delivery of purchase notices as an additional commitment fee.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2025, we sold 6,650,000 common shares for gross proceeds of $3,233 (US$2,348) at an average price of $0.49 (US$0.35). We also issued 816,326 initial commitment and 95,826 additional commitment shares fair valued at $608 (US$435). In total, we incurred share issue costs (including the initial commitment and additional commitment fees) of $759. On August 8, 2025, we voluntarily delisted from the TSX, effective August 22, 2025, causing us to terminate the share purchase agreement (see note 16).  </font></div><div id="i69868e7a4262403b9efa49a3d1444ba9_58"></div><div style="margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 8&#58; Share-Based Compensation</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Stock options and share awards </font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Our amended and restated Stock Option Plan and Share Award Plan (collectively, the &#34;Equity Incentive Plans&#34;) were approved by our shareholders at the annual general meeting of shareholders on May 9, 2023. Pursuant to our Equity Incentive Plans, we may grant stock options, restricted share awards, and performance share awards. The number of common shares reserved for issuance under our Equity Incentive Plans in aggregate shall not exceed 14% of the total number of issued and outstanding common shares from time to time. As at June&#160;30, 2025, there were 6,269,415 common shares available for grant under the Equity Incentive Plans.  </font></div><div style="margin-top:10pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2025, we granted inducement equity awards to our new Chief Executive Officer (&#34;New CEO&#34;) and Chief Business Officer (&#34;CBO&#34;). These awards included stock options and performance-based stock options (&#34;Inducement Stock Options&#34;) and performance restricted share awards (&#34;Inducement Share Awards&#34;). The grants were made as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4), and therefore did not require shareholder approval. </font></div><div style="margin-top:10pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our share-based compensation expense was $523 and $1,731 for the three and six months ended June&#160;30, 2025 (June&#160;30, 2024 - $506 and $1,082, respectively).     </font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our stock option activity related to the Equity Incentive Plan and Inducement Stock Options for the six months ended June 30 was as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br>$</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br>$</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the period</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">6,876,345</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2.14</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,063,333&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.72</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">5,500,000</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">0.62</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">310,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.57</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(286,733)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1.84</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(95,535)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.25</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expired </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(5,263)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">7.60</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(65,263)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.93</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the period</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">12,084,349</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1.45</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,212,535&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.65</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of the period</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">5,116,947</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2.35</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,255,889&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.83</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2025</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated) </font></div><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at June&#160;30, 2025&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$0.57 - $1.12</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,500,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.0</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.62</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$1.13 - $1.50</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,720,900&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.8</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.14</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">785,658&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.13</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$1.51 - $2.20</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,099,517&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.5</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.90</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,665,209&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.92</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$2.21 - $3.11</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,610,489&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.0</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.60</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,512,637&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.59</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$3.12 - $5.42</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,153,443&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.7</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.50</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,153,443&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.50</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,084,349&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.6</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.45</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,116,947&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.35</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our option grants vest either immediately or annually over periods ranging from one to three years, except for our performance-based option grant, which vests upon achieving certain financing objectives during the service period.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant. The expected life of the options represents the estimated length of time the options are expected to remain outstanding. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the six months ended June 30 were determined using the following weighted average assumptions&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2.9%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.0%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">5.0 years</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">76.7%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">64.8%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$0.40</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</font></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Our share award activity related to the Equity Incentive Plan and Inducement Share Awards for the six months ended June 30 was as follows&#58;</font></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:63.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the period</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,118,510</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">398,440&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">3,369,636</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Released</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(1,256,646)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,140)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the period</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">3,231,500</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">397,300&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The weighted average fair value of the restricted share awards granted was $0.72 in 2025.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2025, we granted restricted share awards (&#34;RSA&#34;) to our independent members of the Board of Directors, our Interim Chief Executive Officer (&#34;Interim CEO), and our Former Chief Executive Officer (&#34;Former CEO&#34;). </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The RSAs granted to our independent Board of Director members were in lieu of their cash compensation for the first half of 2025. These RSA's and those granted to the Former CEO vested immediately upon grant. RSAs granted to our Interim CEO were subject to immediate vesting or cliff vesting in two years, depending on the terms of the individual award.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2025</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated) </font></div><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Inducement Share Awards granted to our New CEO and CBO will vest upon our entry into a definitive agreement involving either (i) the acquisition of our company or (ii) the exclusive license of pelareorep. Upon such triggering event, our New CEO will be entitled to receive a number of common shares equal to 2% of our then-outstanding common shares, and our CBO will be entitled to receive 500,000 common shares.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Compensation warrants</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of the services rendered by the underwriter as part of a public offering in 2023, we issued 536,693 compensation warrants. Each compensation warrant is exercisable into one common share at an exercise price of US$2.25 up to 60 months from the date of issuance. At issuance date, we used the Black-Scholes valuation model to estimate the fair value of the services rendered. As at June&#160;30, 2025, and June&#160;30, 2024, there were 536,693 compensation warrants outstanding. </font></div><div><font><br></font></div><div id="i69868e7a4262403b9efa49a3d1444ba9_64"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 9&#58; Loss Per Common Share</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share is calculated by dividing net loss for the period and the weighted average number of common shares outstanding for the three and six months ended June&#160;30, 2025, of 90,999,586 and 87,833,107, respectively (June&#160;30, 2024 - 76,090,406 and 75,667,521, respectively). The effect of any potential exercise of our stock options, share awards, and warrants outstanding during the period has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div><div style="text-align:justify"><font><br></font></div><div id="i69868e7a4262403b9efa49a3d1444ba9_76"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 10&#58; Commitments </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to payments of approximately $5,300 for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next two years. Approximately half of the committed payments relate to a</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">production service agreement with our primary toll manufacturer, which cannot be canceled without a significant penalty. We</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">are able to cancel most of the remaining agreements with notice.  </font></div><div style="text-align:justify"><font><br></font></div><div id="i69868e7a4262403b9efa49a3d1444ba9_79"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 11&#58; Capital Disclosures</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our objective when managing capital is to maintain adequate cash resources to support planned activities, including our clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection.&#160;See note 1 for the discussion on our ability to continue as a going concern. We include shareholders' equity and cash and cash equivalents in the definition of capital.    </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:63.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">14,626</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,942&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">6,089</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,983&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have no debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments relating to completing our research and development of pelareorep.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the associated costs. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that are converted to common shares upon exercise.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2025</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated) </font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2025, we had an effective Form F-10 short form base shelf prospectus (the &#34;Form F-10&#34;) that qualified for distribution of up to $150 million of common shares, subscription receipts, warrants, or units (the &#34;Securities&#34;) in either Canada, the U.S. or both. Under the Form F-10, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries. We may also sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be performed from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2025, the Company voluntarily delisted from the TSX effective August 22, 2025 (see note 16). Consequently, our Form F-10 will no longer be effective on August 22, 2025. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements, and there have been no changes in how we define or manage our capital in 2025.</font></div><div style="text-align:justify"><font><br></font></div><div id="i69868e7a4262403b9efa49a3d1444ba9_82"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 12&#58; Financial Instruments</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As at June&#160;30, 2025, and December&#160;31, 2024, the carrying amount of our cash and cash equivalents, other receivables, accounts payable and accrued liabilities, and other liabilities approximated their fair value due to their short-term maturity. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and, therefore, do not trade on an active market. As at June&#160;30, 2025, the fair value of our warrant derivative was presented as an asset of $1,024 (December&#160;31, 2024 - $980) (see note 6). </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;As at June&#160;30, 2025, we were exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts. Our foreign-domiciled bank accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that a financial instrument's fair value or future cash flows will fluctuate because of changes in market interest rates.&#160;We hold our cash and cash equivalents in bank accounts or high-interest investment accounts with variable interest rates. We mitigate interest rate risk through our investment policy that only allows the investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market interest rates do not significantly impact our results of operations due to the short-term maturity of the investments held.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. For the six months ended June&#160;30, 2025, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and Euro, as a portion of our financial assets and liabilities were denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our comprehensive loss in 2025 by approximately $44 (June&#160;30, 2024 - $179).&#160;The impact of a $0.01 increase in the value of the </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2025</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated) </font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Euro against the Canadian dollar would have increased our comprehensive loss in 2025 by approximately $30 (June&#160;30, 2024 - $19). </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies by purchasing foreign currencies or receiving foreign currencies from financing activities to settle our foreign accounts payable.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances denominated in U.S. dollars were as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.057%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,270&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,534&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,228)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,722)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,042&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,812&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances denominated in Euros were as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.057%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,072)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,114)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. See note 1 for the discussion on our ability to continue as a going concern.&#160;We manage liquidity risk by managing our capital structure as outlined in note 11. Accounts payable and accrued liabilities are all due within the current operating period. Other liabilities associated with funding received from PanCAN (see note 4) are expected to be applied within the current operating period. See note 5 for a maturity analysis of our lease liabilities.</font></div><div style="text-align:justify"><font><br></font></div><div id="i69868e7a4262403b9efa49a3d1444ba9_88"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 13&#58; Additional Cash Flow Disclosures</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Change in non-cash working capital</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(4)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,556)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(1,289)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(118)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">493</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(636)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">366</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(152)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(1,070)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other cash flow disclosures</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">301</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">85</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><div id="i69868e7a4262403b9efa49a3d1444ba9_91"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2025</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated) </font></div><div><font><br></font></div></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 14&#58;  Components of Expenses</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:45.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Research and development expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">588</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,164&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,104</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,966&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">592</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">662&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,170</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,840&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">119</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">268</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,256</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">3,156</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,559&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">219</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,111</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">35</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">83</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2,809</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,558&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">6,892</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,301&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,435</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,275&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">3,108</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">935</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,647</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,320&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">129</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">247</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">304</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">620</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">25</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">51</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">69</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">140</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2,897</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,362&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">5,813</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,345&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development personnel-related expenses included employee compensation and benefits of $1,127 and $2,820 for the three and six months ended June&#160;30, 2025, respectively (June&#160;30, 2024 - $1,253 and $2,524, respectively). </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our general and administrative personnel-related expenses included employee compensation and benefits of $935 and $1,647 for the three and six months ended June&#160;30, 2025, respectively (June&#160;30, 2024 - $577 and $1,121, respectively).</font></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><div id="i69868e7a4262403b9efa49a3d1444ba9_97"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2025</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated) </font></div><div><font><br></font></div></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 15&#58;  Related Party Transactions</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Compensation of Key Management Personnel</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel comprise the Board of Directors, Executive Officers, President, and Vice Presidents.   </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:45.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and short-term benefits</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">886</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">985&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,791</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">286</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,476</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">430</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">793</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,602</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">4,060</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,847&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Termination benefits included both cash and share-based compensation.</font></div><div style="text-align:justify"><font><br></font></div><div id="i69868e7a4262403b9efa49a3d1444ba9_103"></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Note 16&#58;  Subsequent Events </font></div><div style="margin-bottom:3pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2025, we announced that we are voluntarily delisting from the TSX, effective August 22, 2025. Once delisted from the TSX, our common shares will continue to trade on the Nasdaq. As a result of our voluntary delisting from the TSX, we have terminated our ATM equity distribution agreement with Cantor and our share purchase agreement with Alumni.  </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex992-q22025mda.htm
<DESCRIPTION>EX-99.2 2025 SECOND QUARTER MD&A
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img alt="oncolyticslogotaglineblueaa.jpg" src="oncolyticslogotaglineblueaa.jpg" style="height:297px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION &#38; ANALYSIS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">June&#160;30, 2025 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">August&#160;7, 2025 </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This discussion and analysis should be read in conjunction with our unaudited condensed interim consolidated financial statements and notes thereto as at and for the three and six months ended June&#160;30, 2025, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (&#34;MD&#38;A&#34;) contained in our annual report for the year ended December&#160;31, 2024. The financial statements have been prepared in accordance with International Financial Reporting Standards (&#34;IFRS&#34;) as issued by the International Accounting Standards Board (&#34;IASB&#34;). Unless otherwise indicated, all references to &#34;$&#34; and &#34;dollars&#34; in this discussion and analysis mean thousands of Canadian dollars.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All references in this MD&#38;A to &#34;the Company,&#34; &#34;Oncolytics,&#34; &#34;we,&#34; &#34;us,&#34; or &#34;our&#34; and similar expressions refer to Oncolytics Biotech Inc. and the subsidiaries through which it conducts its business unless otherwise indicated.  </font></div><div style="text-align:justify"><font><br></font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_7"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains forward-looking statements, within the meaning of Section 21E of the United States </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Exchange Act of 1934, as amended</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as &#34;forward-looking statements&#34;). Forward-looking statements, including&#58; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief as to the potential and mechanism of action of pelareorep, an intravenously delivered immunotherapeutic agent, as a cancer therapeutic&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our business strategy, goals, focus, and objectives for the development of pelareorep, including our primary focus on advancing our first-line metastatic pancreatic ductal adenocarcinoma to a registration-enabled clinical study and our exploration of opportunities for registrational programs and investigator sponsored trials in hormone receptor-positive &#47; human epidermal growth factor 2-negative advanced and metastatic breast cancer and other gastrointestinal cancers, including anal cancer, through our GOBLET platform study, and colorectal cancer through potential investigator sponsored trials&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that we will obtain regulatory clarity on a registration-enabled study for first-line mPDAC by the end of 2025&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that pelareorep&#8217;s ability to enhance innate and adaptive immune responses within the tumor microenvironment will play an increasingly important role as our clinical development program advances, and our belief that this approach increases opportunities for expanding our clinical program and business development and partnering opportunities, has the most promise for generating clinically impactful data and offers the most expeditious path to regulatory approval&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that by priming the immune system with pelareorep, we can increase the proportion of patients who respond to various cancer treatments, including immunotherapies, especially in cancers where existing treatment regimens have failed or provided limited benefit&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that we will incur substantial losses and will not generate significant revenues until and unless pelareorep becomes commercially viable&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimations that we can fund operations into the first quarter of 2026&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to fund ongoing operations by raising additional funds through the sale of our common shares or other capital resources, such as strategic collaborations and debt&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of additional liquidity and the terms thereof&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential consequences of failing to secure adequate additional funding&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to reduce or eliminate planned expenditures to extend our operating runway if additional financing cannot be obtained when required&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to continue working with various collaborators, academics, and stakeholders on the most effective path forward for breast cancer, anal cancer, and colorectal cancer&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the focus of and plans for our manufacturing program and our belief that we have sufficient drug supply to support our clinical development program&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to protect our intellectual property&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ongoing evaluation of all types of financing arrangements&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sale of securities under the Form F-10 (as defined herein) and our intention to establish a new base shelf prospectus in the near term on either Form F-3 or Form S-3&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intention to terminate our ATM equity distribution agreement with Cantor and share purchase agreement with Alumni&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intention to delist from the TSX&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that we will continue to access equity arrangements to help support our operations&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our objective to maintain adequate cash reserves to support our planned activities, including our clinical trial program, product manufacturing, administrative costs and intellectual property protection and the methods used to achieve such objective&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued management of our research and development plan, and potential changes to our contractual commitments and obligations that may result from changes to the plan&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation to fund our expenditure requirements and commitments with existing working capital&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the judgment applied in assessing our ability to continue as a going concern and the material uncertainties that raise substantial doubt on our ability to continue as a going concern&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that we are not able to fund our operations for at least the next twelve months from the balance sheet date with the cash and cash equivalents on hand&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the factors that affect our cash usage&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that we will increase our spending in connection with the research and development of pelareorep over the next several years as we look to advance pelareorep into later stages of clinical development and the increased costs associated with later stages of clinical development&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that we will continue to incur additional costs associated with operating as a public company&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the factors that may affect the probability of successful commercialization of pelareorep&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our approach to credit, interest rate, foreign exchange, and liquidity risk mitigation, and our expectations with respect to the likelihood of these risks&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated use of the remaining proceeds raised as part of our 2023 public offering of common shares and warrants&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our internal control systems&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">and other statements that are not historical facts or which are related to anticipated developments in our business and technologies. </font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In any forward-looking statement in which we express an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation, or belief will be achieved. Forward-looking statements involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development, and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process, and general changes to the economic environment.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the forward-looking statements made within this MD&#38;A, we have made numerous assumptions regarding, among other things&#58; our ability to recruit and retain employees, our continued ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep, and future expense levels being within our current expectations.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates, and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and&#47;or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake any obligation to update these forward-looking statements except as required by applicable law.</font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_10"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Company Overview</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep is a proprietary isolate of reovirus, a naturally occurring, non-pathogenic double-stranded RNA (dsRNA) reovirus commonly found in environmental waters. Pelareorep has shown promising results in changing the tumor microenvironment (TME). This creates a more immunologically favorable TME, making the tumor more susceptible to various treatment combinations. These treatments include chemotherapies, checkpoint inhibitors, and other immuno-oncology approaches such as CAR T therapies, bispecific antibodies, and CDK4&#47;6 inhibitors. Pelareorep induces a new army of tumor-reactive T cells, helps these cells to infiltrate the tumor through an inflammatory process, and upregulates the expression of PD-1&#47;PD-L1. By priming the immune system with pelareorep, we believe we can increase the proportion of patients who respond to various cancer treatments, including immunotherapies, especially in cancers where existing treatment regimens have failed or provided limited benefit. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As our clinical development program advances, we anticipate pelareorep's ability to enhance innate and adaptive immune responses within the TME will play an increasingly important role. This greatly increases opportunities for expanding our clinical program, business development, and partnering opportunities to address a broad range of cancers in combination with various other therapies. We believe this approach has the most promise for generating clinically impactful data and offers the most expeditious path to regulatory approval. </font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our primary focus is to advance our first-line metastatic pancreatic ductal adenocarcinoma program to a registration-enabled clinical study. In addition, we are exploring opportunities for registrational programs and investigator sponsored trials in hormone receptor-positive &#47; human epidermal growth factor 2-negative (HR+&#47;HER2-) advanced and metastatic breast cancer and other gastrointestinal cancers, including anal cancer, through our GOBLET platform study, and colorectal cancer through potential investigator sponsored trials.   </font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. As at June&#160;30, 2025, we had cash and cash equivalents of $14,626. We estimate we can currently fund our operations into the first quarter of 2026. We plan on raising additional funds through the sale of our common shares or other capital resources, such as strategic collaborations and debt, to fund our ongoing operations. However, given the difficulty for micro-cap market capitalization companies to raise significant capital, there can be no assurance that additional liquidity will be available under acceptable terms or at all. Furthermore, if we are unable to obtain additional financing when required, there can be no assurance that we will be able to sufficiently reduce or eliminate our planned expenditures to extend our operating runway. These material uncertainties raise substantial doubt on our ability to continue as a going concern. See further discussion in &#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources&#34;.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Program Development Updates and Outlook </font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following are the development updates and outlook for each of our programs for the three months ended June&#160;30, 2025, through to the date hereof&#58;</font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_16"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Clinical Trial Program</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2025, we presented data from GOBLET's first-line metastatic PDAC (mPDAC) cohort at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlights pelareorep's mechanism of action in PDAC, offering new insights into how this immunotherapy stimulates multiple arms of the immune system and primes tumors for treatment. Highlights from the poster include&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep initiates the expansion of reovirus-specific T cells that are associated with favorable clinical responses at week 24</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep increases cytokines and chemokines associated with altering the tumor microenvironment to allow anti-viral and anti-tumor T cells to attack the tumor</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The presence of tumor-infiltrating lymphocytes clones in the blood before treatment and the expansion of these clones in the blood post-treatment are associated with favorable clinical responses</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Previously reported efficacy results from GOBLET Cohort 1, which is evaluating the therapeutic regimen of pelareorep, nab-paclitaxel, gemcitabine, and atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">) in first-line mPDAC patients, showed a 62% overall response rate, an 85% disease control rate, and a 45% 12-month survival rate</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are actively evaluating multiple strategic partnership options to advance the development of pelareorep. We expect to obtain regulatory clarity on a registration-enabled study for first-line mPDAC by the end of 2025. In parallel, we continue to engage with collaborators, academic partners, and other stakeholders to determine the most effective path forward for pelareorep in breast cancer, anal cancer, and colorectal cancer.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">  </font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_19"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Manufacturing and Process Development </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While we currently have sufficient drug product supply to support our clinical development program, including for a registration-enabled study in mPDAC, we continued our activities to expand our production capabilities as we focus on advancing our active drug substance and finished drug product toward registration and commercial readiness. During the second quarter of 2025, we completed an engineering run with a secondary fill&#47;finish supplier. We also incurred storage and distribution costs to maintain our product supply. Ongoing bulk manufacturing and expanded filling capabilities are both part of the planned process validation. Continued process validation is required to ensure that the resulting product meets the specifications and quality standards and will form part of our submission to regulators, including the FDA, for product approval. </font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, our manufacturing program will focus on filling product with a secondary fill&#47;finish supplier, completing a formal assessment of the drug substance production process in preparation for performance qualification, executing a cGMP production run, completing the potency assay validation, and supply distribution for our ongoing and planned studies. </font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_22"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Intellectual Property</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the second quarter of 2025, we had 147 patents, including 11 U.S. and 7 Canadian patents, and issuances in other jurisdictions. We have an extensive patent portfolio covering pelareorep and formulations that we use in our clinical trial program. We also have patents covering methods for manufacturing pelareorep and screening for susceptibility to pelareorep. These patent rights extend to at least the end of 2031. We are continuing to analyze additional patent protections and have placed an emphasis on patent extension strategy. In addition, we have made patent applications that we expect to extend certain patent protection and grant new rights into the 2040s. </font></div><div style="text-align:justify"><font><br></font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_25"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Financing Activity</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. &#34;at-the-market&#34; (ATM) equity distribution agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2025, we sold 3,266,024 common shares for gross proceeds of $2,486 (US$1,823) at an average price of $0.76 (US$0.56). We received proceeds of $2,412 (US$1,768) after commissions of $74 (US$55). In total, we incurred share issue costs (including commissions) of $93. </font></div><div style="margin-bottom:3pt;margin-top:10pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share purchase agreement with Alumni Capital LP</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 10, 2025, we entered into a share purchase agreement with Alumni Capital LP (Alumni), an institutional investor. Under the terms of the agreement, we have the right to sell, and Alumni has the obligation to purchase up to US$20 million worth of common shares over a 15-month period based on the market price at the time of each sale to Alumni. The agreement limits Alumni's beneficial ownership to 4.99% of our common shares outstanding immediately prior to each sale, which can be increased to 9.99% upon mutual agreement. The agreement also limits our sale of common shares to 19.99% of our total outstanding common shares as at the date that the share purchase agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. Subject to the terms of the agreement, we have sole discretion over the timing and amount of all common share sales. We issued an initial commitment fee of 816,326 common shares at the execution of the agreement. An additional 816,326 common shares will be issued on a pro rata basis upon the delivery of purchase notices as an additional commitment fee. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2025, we sold 6,650,000 common shares for gross proceeds of $3,233 (US$2,348) at an average price of $0.49 (US$0.35). We also issued 816,326 initial commitment and 95,826 additional commitment shares fair valued at $608 (US$435). In total, we incurred share issue costs (including the initial commitment and additional commitment fees) of $759.   </font></div><div><font><br></font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_31"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Cash Resources </font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We ended the second quarter of 2025 with cash and cash equivalents of $14,626 (see &#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources&#34;)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_34"></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Other Corporate Matters</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2025, we appointed Jared Kelly as our new Chief Executive Officer and a member of our Board of Directors, and Andrew Aromando as our Chief Business Officer.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On July 22, 2025, we received a formal letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#34;Nasdaq&#34;) informing us that we have regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2) (the &#34;Minimum Bid Price Requirement&#34;). The Company is now in compliance with all Nasdaq listing standards. As previously announced in the first quarter of 2025, we received a delinquency notification letter from the Nasdaq that our common shares failed to maintain a minimum price of US$1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On August 8, 2025, we announced that we are voluntarily delisting from the Toronto Stock Exchange (&#8220;the TSX&#8221;), effective August 22, 2025. Once delisted from the TSX, our common shares will continue to trade on the Nasdaq Capital Market. As a result of our voluntary delisting from the TSX, we have terminated our ATM equity distribution agreement with Cantor Fitzgerald &#38; Co. and our share purchase agreement with Alumni.   </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_43"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Results of Operations</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Comparison of the three months ended June&#160;30, 2025, and 2024&#58;</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all amounts below are presented in thousands of Canadian dollars, except for share amounts.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the three months ended June&#160;30, 2025, was $6,165 compared to $7,256 for the three months ended June&#160;30, 2024. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses (&#8220;R&#38;D&#8221;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses decreased by $1,749 from $4,558 for the three months ended June&#160;30, 2024, to $2,809 for the three months ended June&#160;30, 2025. The following table summarizes our R&#38;D expenses for the three months ended June&#160;30, 2025, and 2024&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">588</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,164&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,576)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">592</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">662&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(70)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">119</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,256</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(32)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">219</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(91)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">35</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(27)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2,809</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,558&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,749)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&#38;D expenses decreased in the second quarter of 2025, primarily due to lower clinical trial costs. This reduction was largely driven by lower BRACELET-1 study costs as the study was completed in 2024. We also incurred planning-related expenses as part of our preliminary collaboration with the Global Coalition for Adaptive Research (&#34;GCAR&#34;) in the second quarter of 2024. In the second quarter of 2025, we focused our R&#38;D efforts on patient enrollment and sample analysis for Cohort 5 of the GOBLET study. These activities were supported by the PanCAN Therapeutic Accelerator Award, of which $827 of the funds received were applied.    </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses (&#34;G&#38;A&#34;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses decreased by $465 from $3,362 for the three months ended June&#160;30, 2024, to $2,897 for the three months ended June&#160;30, 2025. The following table summarizes our G&#38;A expenses for the three months ended June&#160;30, 2025, and 2024&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,435</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,275&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(840)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">935</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">129</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">304</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">25</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">69</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2,897</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,362&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(465)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">G&#38;A expenses decreased in the second quarter of 2025, primarily due to lower public company-related expenses. This change was caused by lower investor relations activities, reduced Board of Directors fees as restricted share awards were granted in lieu of cash compensation, and the timing of annual general meeting-related expenses, with the 2025 meeting scheduled to occur in the third quarter of 2025. The above decrease was partially offset by higher personnel-related expenses associated with changes to our management team.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Change in fair value of warrant derivative</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2025, we recognized a loss of $196 on the change in fair value of our warrant derivative compared to a gain of $235 in the second quarter of 2024. In the second quarter of 2025, the underlying market price of these warrants changed from US$0.55 at March 31, 2025, to US$0.76 at June&#160;30, 2025. In the second quarter of 2024, the underlying market </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">price of these warrants changed from US$1.07 at March 31, 2024, to US$0.99 at June 30, 2024. The number of outstanding warrants was 7,667,050 at June&#160;30, 2025, and March 31, 2025.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Exchange</font></div><div style="margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign exchange losses were $282 for the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">second</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> quarter of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> compared to gains of $184 for the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">second</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> quarter of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The foreign exchange impact mainly reflected the fluctuation of the U.S. dollar versus the Canadian dollar throughout the respective periods, primarily on our U.S. dollar-denominated cash and cash equivalents. </font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_46"></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Comparison of the six months ended June&#160;30, 2025, and 2024&#58;</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the six months ended June&#160;30, 2025, was $12,852 compared to $14,150 for the six months ended June&#160;30, 2024.    </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Research and development expenses (&#8220;R&#38;D&#8221;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses decreased by $3,409 from $10,301 for the six months ended June&#160;30, 2024, to $6,892 for the six months ended June&#160;30, 2025. The following table summarizes our R&#38;D expenses for the six months ended June&#160;30, 2025, and 2024&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,104</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,966&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,862)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,170</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,840&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,670)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">268</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">3,156</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,559&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,111</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">83</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">6,892</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,301&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,409)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&#38;D expenses </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">decreased </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">six</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2025, primarily due to the following&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased clinical trial expenses mainly due to lower BRACELET-1 study costs as the study was completed in 2024. We also incurred planning-related expenses as part of our preliminary collaboration with GCAR in 2024. During the</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">six</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2025, we focused our R&#38;D efforts on patient enrollment and sample analysis for Cohort 5 of the GOBLET study. These activities were supported by the PanCAN Therapeutic Accelerator Award, of which $1,663 of the funds received were applied&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased manufacturing and related process development expenses as we completed a cGMP production run and the related batch testing during the same period in the prior year.</font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The above decreases were partially offset by higher personnel-related expenses and share-based expense associated with CEO transition activities.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">General and administrative expenses (&#34;G&#38;A&#34;) </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses decreased by $532 from $6,345 for the six months ended June&#160;30, 2024, to $5,813 for the six months ended June&#160;30, 2025. The following table summarizes our G&#38;A expenses for the six months ended June&#160;30, 2025, and 2024&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">3,108</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,011)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,647</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,320&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">247</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">620</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">51</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">140</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(25)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">5,813</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,345&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(532)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">G&#38;A expenses decreased </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">six</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2025, primarily due to lower public company-related expenses. This change was caused by lower investor relations activities, reduced Board of Directors fees as restricted share awards were granted in lieu of cash compensation, and the timing of annual general meeting-related expenses with the 2025 meeting scheduled to occur in the third quarter of 2025.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The above decrease was partially offset by higher personnel-related expenses associated with changes to our management team and increased share-based compensation expense, reflecting the impact of the restricted share awards granted to our Board of Directors during the period and the vesting of options granted in prior periods.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Change in fair value of warrant derivative</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2025, we recognized gains of $44 on the change in fair value of our warrant derivative compared to $1,104 for the six months ended June&#160;30, 2024. For the six months ended June&#160;30, 2025, the underlying market price of these warrants changed from US$0.92 at December&#160;31, 2024, to US$0.76 at June&#160;30, 2025. For the six months ended June&#160;30, 2024, the underlying market price of these warrants changed from US$1.35 at December 31, 2023, to US$0.99 at June 30, 2024. The number of outstanding warrants was 7,667,050 at June&#160;30, 2025, and December&#160;31, 2024. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Foreign exchange </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign exchange losses for the six months ended June&#160;30, 2025, were $333 compared to gains of $701 for the six months ended June&#160;30, 2024. The foreign exchange impact mainly reflected the fluctuation of the U.S. dollar versus the Canadian dollar throughout the respective periods, primarily on our U.S. dollar-denominated cash and cash equivalents.    </font></div><div style="text-align:justify"><font><br></font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_49"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Quarterly Results</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Historical patterns of expenditures cannot be taken as an indication of future expenditures. Our current and future expenditures are subject to numerous uncertainties, including the duration, timing, and costs of R&#38;D activities ongoing during each period and the availability of funding from investors and prospective partners. As a result, the amount and timing of expenditures and, therefore, liquidity and capital resources may vary substantially from period to period.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Jun.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Mar.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dec.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Sept.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Jun.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Mar.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dec.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Sept.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,165)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,687)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8,017)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9,543)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,256)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,894)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,949)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9,925)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per common share</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19,974</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19,702</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,187</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,262&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32,069&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,750&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38,820&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46,089&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,626&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,303</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,942</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19,598&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,850&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,603&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,912&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39,981&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share were share-based compensation expenses of $523, $1,208, $1,196, $445, $506, $576, $759, and $599, respectively.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share were foreign exchange (losses) gains of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$(282)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$(51)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">, $382, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$(122)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">, $184, $517, $(392), and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$310</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">, respectively.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share were (losses) gains resulting from a change in fair value of warrant derivative of $(196), $240, $(91), $229, $235, $869, and $4,846, respectively.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We raised net cash proceeds of $5,475, $5,993, $3,439, nil, $2,040, $1,598, $1,846, and  $20,802, respectively, from issuing common shares. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We have not declared or paid any dividends since incorporation.</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended September 30, 2023, we completed an engineering production run, resulting in higher manufacturing and related process development expenses. We also incurred higher public company-related expenses associated with higher investor relations activities and the portion of the 2023 public offering transaction costs allocated to warrants. During the quarter ended September 30, 2024, we completed a cGMP production run, resulting in higher manufacturing and related process development expenses. During the quarters ended December 31, 2024, and 2023, we incurred expenses related to annual short-term incentive awards.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_52"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div><font><br></font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_61"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a clinical-stage biopharmaceutical company, we have not been profitable since our inception. We expect to continue to incur substantial losses as we continue our research and development efforts. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. See &#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Capital Requirements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34; below for the discussion on our ability to continue as a going concern. To date, we have funded our operations mainly through issuing additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. For the six months ended June&#160;30, 2025, we raised funds through our U.S. ATM and share purchase agreement.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have no assurances that we will be able to raise additional funds through the sale of our common shares. Consequently, we will continue to evaluate all types of financing arrangements, such as strategic collaborations and debt, to fund our ongoing operations. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As at June 30, 2025, we had an effective Form F-10 short form base shelf prospectus (the &#34;Form F-10&#34;) that qualified for distribution of up to $150 million of common shares, subscription receipts, warrants, or units (the &#34;Securities&#34;) in either Canada, the U.S. or both. Under the Form F-10, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries. We may also sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be performed from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement. Our Form F-10 allowed us to enter into our U.S. ATM equity distribution agreement and share purchase agreement (see note 7 in our condensed interim consolidated financial statements). </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2025, we voluntarily delisted from the TSX effective August 22, 2025. Consequently, our Form F-10 will no longer be effective, necessitating the termination of our U.S. ATM and share purchase agreements. We intend to establish a new base shelf prospectus in the near term on either Form F-3 or Form S-3.</font></div><div style="margin-bottom:3pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As at June&#160;30, 2025, and December&#160;31, 2024, we had cash and cash equivalents as follows&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">14,626</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,942&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have no debt other than accounts payable and accrued liabilities and lease liabilities. We have commitments relating to completing our research and development of pelareorep.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated&#58;</font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(11,969)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14,288)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,319&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in investing activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(201)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">11,263</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,470&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,793&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(610)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,567)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash and cash equivalents</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(1,316)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10,062)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,746&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash used in operating activities</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The decrease reflected lower net operating activities in 2025, partially offset by higher non-cash working capital changes.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the six months ended June&#160;30, 2025, consisted of a net loss of $12,852 offset by non-cash adjustments of $1,953 less non-cash working capital changes of $1,070. Non-cash items primarily included share-based compensation expense. Non-cash working capital changes mainly reflected increased prepaid expenses and accounts payable and accrued liabilities and decreased other liabilities (see note 13 of our condensed interim consolidated financial statements). </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the six months ended June&#160;30, 2024, consisted of a net loss of $14,150 less non-cash adjustments of $320 offset by non-cash working capital changes of $182. Non-cash items primarily included change in fair value of warrant derivative, share-based compensation expense, and unrealized foreign exchange gains. Non-cash working capital changes mainly reflected increased other receivables, accounts payable and accrued liabilities, and other liabilities (see note 13 of our condensed interim consolidated financial statements). </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash provided by financing activities</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2025, we sold, through our ATM, 8,568,974 common shares for gross proceeds of $8,714 (US$6,150) at an average price of $1.02 (US$0.72). We also sold 6,650,000 common shares for gross proceeds of $3,233 (US$2,348) at an average price of $0.49 (US$0.35) through our share purchase agreement. During the six months ended June 30, 2024, we sold, through our ATM, 2,432,099 common shares for gross proceeds of $3,840 (US$2,835) at an average price of $1.58 (US$1.17).</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Operating Capital Requirements</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our objective is to maintain adequate cash reserves to support our planned activities, including our clinical trial program, product manufacturing, administrative costs, and intellectual property protection. To do so, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the associated costs. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity. Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board. We continue to manage our research and development plan to ensure optimal use of our existing resources as we expect to fund our expenditure requirements and commitments with existing working capital.</font><font style="color:#ff0090;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses our ability to continue as a going concern. In our going concern assessment, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period. We have concluded that our cash and cash equivalents are not sufficient to fund our planned operations and meet our obligations for the twelve months following the balance sheet date without raising additional funding or reducing or eliminating our planned expenditures. Factors that will affect our anticipated cash usage for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&#38;D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken, and other factors described in the &#34;Risk Factors&#34; section of our most recent annual report on Form 20-F. The judgment and assumptions applied by management may prove to be wrong, and actual results could vary materially from our expectations as significant risks and uncertainties are involved.   </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect to increase our spending in connection with the research and development of pelareorep over the next several years as we look to advance our pancreatic, breast, and other gastrointestinal cancer programs into later stages of clinical development. A product candidate in later stages of clinical development generally has higher costs than those in earlier stages, primarily due to the increased size and duration of later-stage clinical trials. Additionally, we expect to continue to incur additional costs associated with operating as a public company.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We plan on raising additional funds through the sale of our common shares or other capital resources, such as strategic collaborations and debt, to fund our ongoing operations. However, given the difficulty for micro-cap market capitalization companies to raise significant capital, there can be no assurance that additional liquidity will be available under acceptable terms or at all. Furthermore, if we are unable to obtain additional financing when required, there can be no assurance that we will be able to sufficiently reduce or eliminate our planned expenditures to extend our operating runway until we obtain sufficient financing. These material uncertainties raise substantial doubt on our ability to continue as a going concern. Our condensed interim consolidated financial statements do not reflect the adjustments that may result from the outcome of these uncertainties. Such adjustments could be material. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we can raise additional funds by issuing equity, our shareholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that may impact our ability to conduct our business. If we are unable to secure adequate additional funding, we may be forced to make reductions in spending, including potentially delaying, scaling back or eliminating certain of our development programs, extending payment terms with suppliers, or liquidating assets where possible. Any of these actions could materially harm our business, results of operations and future prospects.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials necessary to obtain regulatory approval is costly and time-consuming. We may never succeed in achieving marketing approval. The probability of successful commercialization of our drug candidates may be affected by numerous factors, including clinical data obtained in future trials, competition, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements, and there have been no changes in how we define or manage our capital in 2025.</font></div><div style="text-align:justify"><font><br></font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_64"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant contractual obligations as at June&#160;30, 2025&#58; </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Less than 1 year</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1 -3 years</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">4 - 5 years</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">More than <br>5 years</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,285&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,285&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,433&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,690&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are committed to payments totaling approximately $5,300 for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next two years. Approximately half of the committed payments relate to a production service agreement with our primary toll manufacturer, which cannot be canceled without a significant penalty. We are able to cancel most of the remaining agreements with notice. The ultimate amount and timing of these payments are subject to changes in our research and development plan. </font></div><div><font><br></font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_67"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As at June&#160;30, 2025, we had not entered into any off-balance sheet arrangements.</font></div><div style="text-align:justify"><font><br></font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_70"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Transactions with Related Parties</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2025, and 2024, we did not enter into any related party transactions other than compensation paid to key management personnel. Key management personnel are those persons having authority and responsibility for planning, directing, and controlling our activities as a whole. We have determined that key management personnel comprise the Board of Directors, Executive Officers, President, and Vice Presidents.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and short-term benefits</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">886</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">985&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,791</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">286</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,476</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">430</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">793</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1,602</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">4,060</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,847&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Termination benefits included both cash and share-based compensation. </font></div><div><font><br></font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_73"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In preparing our condensed interim consolidated financial statements, we use IFRS as issued by the IASB. IFRS requires us to make certain estimates, judgments, and assumptions that we believe are reasonable based on the information available in applying our accounting policies. These estimates and assumptions affect the reported amounts and disclosures in our condensed interim consolidated financial statements and accompanying notes. Actual results could differ from those estimates, and such differences could be material. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies and estimates are described in our audited consolidated financial statements for the year ended December&#160;31, 2024, and available on SEDAR+ at www.sedarplus.ca and contained in our annual report on Form 20-F filed on EDGAR at www.sec.gov&#47;edgar. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes to our critical accounting policies in the six months ended June&#160;30, 2025.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accounting standards and interpretations issued but not yet effective</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">IFRS 18 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation and Disclosure in Financial Statements</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the IASB issued IFRS 18 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation and Disclosure in Financial Statements </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">which replaces IAS 1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">IFRS 18 introduces new requirements on presentation within the statement of profit or </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">loss, including specified totals and subtotals. It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation of financial information based on the identified roles of the primary financial statements and the notes. Narrow scope amendments have been made to IAS 7 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flows</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and some requirements previously included within IAS 1 have been moved to IAS 8 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">which has also been renamed IAS 8 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Preparation of Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. IAS 34 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">has also been amended to require disclosure of management-defined performance measures. IFRS 18 and the amendments to the other standards are effective for annual periods beginning on or after January 1, 2027, with early application permitted. IFRS 18 applies retrospectively to both annual and interim financial statements. We are assessing the impact of adopting this standard on our consolidated financial statements.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Upcoming change in issuer's GAAP</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2026, we will become a domestic issuer under the rules of the U.S. Securities and Exchange Commission, and will no longer qualify as a &#34;foreign private issuer&#34; under those rules. As a result, we will have to prepare our December 31, 2025 annual financial statements in accordance with US GAAP, with such changes being applied retrospectively. The extent of the impact of the adoption of US GAAP has not yet been fully determined.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_76"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Financial Instruments and Other Instruments</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As at June&#160;30, 2025, and December&#160;31, 2024, the carrying amount of our cash and cash equivalents,&#160;other receivables, accounts payable and accrued liabilities, and other liabilities approximated their fair value due to their short-term maturity. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and, therefore, do not trade on an active market. As at June&#160;30, 2025, the fair value of our warrant derivative was presented as an asset of $1,024 (December&#160;31, 2024 - $980). The change was mainly due to the revaluation of our warrants issued as part of our 2023 public offering. As the unamortized discount balance was greater than the fair value of the warrant derivative liability at June&#160;30, 2025, the net balance was presented as an asset on our condensed interim consolidated statement of financial position. An initial discount was recognized as the difference between the fair value of the warrants and their allocated proceeds, which is amortized on a straight-line basis over the expected life of the warrants (see note 6 of our condensed interim consolidated financial statements). We use the Black-Scholes valuation model to estimate fair value.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;As at June&#160;30, 2025, we were exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts. Our foreign-domiciled bank accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that a financial instrument's fair value or future cash flows will fluctuate because of changes in market interest rates.&#160;We hold our cash and cash equivalents in bank accounts or high-interest investment accounts with variable interest rates. We mitigate interest rate risk through our investment policy that only allows the investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market interest rates do not significantly impact our results of operations due to the short-term maturity of the investments held.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. For the six months ended June&#160;30, 2025, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and Euro, as a portion of our financial assets and liabilities were denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our comprehensive loss in 2025 by approximately $44 (June&#160;30, 2024 - $179).&#160;The impact of a $0.01 increase in the value of the </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Euro against the Canadian dollar would have increased our comprehensive loss in 2025 by approximately $30 (June&#160;30, 2024 - $19).</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies by purchasing foreign currencies or receiving foreign currencies from financing activities to settle our foreign accounts payable.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances denominated in U.S. dollars were as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.057%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,270&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,534&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,228)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,722)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,042&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,812&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances denominated in Euros were as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.057%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,072)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,114)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in note 11 to our condensed interim consolidated financial statements. Accounts payable and accrued liabilities are all due within the current operating period. Other liabilities associated with funding received from PanCAN (see note 4 in our condensed interim consolidated financial statements) are expected to be applied within the current operating period. See note 5 in our condensed interim consolidated financial statements for a maturity analysis of our lease liabilities. </font></div><div style="text-align:justify"><font><br></font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_79"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Use of Proceeds </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2023 public offering </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides an update on the anticipated use of proceeds raised as part of the 2023 public offering of common shares and warrants along with amounts actually expended. As at June&#160;30, 2025, the following expenditures have been incurred (in thousands of U.S. dollars)&#58; </font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amount to Spend</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Spent to Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Remaining to Spend</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pancreatic Cancer Program</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,500&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,136)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(528)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,836&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Breast Cancer Program</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,028)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative Expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,650&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(800)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,650&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,964)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,686&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ATM facility</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2024, we entered into an ATM equity distribution agreement with Cantor Fitzgerald &#38; Co. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$50.0 million through the facilities of the Nasdaq Capital Market in the United States until August 19, 2026. During the six months ended June&#160;30, 2025, we sold 8,568,974 common shares for gross proceeds of $8,714 (US$6,150). As at June&#160;30, 2025, approximately $56.3 million (US$41.3 million) remains unused under the ATM equity distribution agreement. On August 8, 2025, we voluntarily delisted from the TSX, effective August 22, 2025, causing us to terminate our ATM agreement (see &#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Corporate Matters&#34;)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Share purchase agreement</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 10, 2025, we entered into a share purchase agreement with Alumni Capital LP (Alumni), an institutional investor. Under the terms of the agreement, we have the right to sell, and Alumni has the obligation to purchase up to US$20 million worth of common shares over a 15-month period based on the market price at the time of each sale to Alumni. The agreement limits Alumni's beneficial ownership to 4.99% of our common shares outstanding immediately prior to each sale, which can be </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">increased to 9.99% upon mutual agreement. The agreement also limits our sale of common shares to 19.99% of our total outstanding common shares as at the date that the share purchase agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. During the six months ended June&#160;30, 2025, we sold 6,650,000 common shares for gross proceeds of $3,233 (US$2,348). As at June&#160;30, 2025, approximately $24.1 million (US$17.7 million) remains unused under the share purchase agreement. On August 8, 2025, we voluntarily delisted from the TSX, effective August 22, 2025, causing us to terminate the share purchase agreement (see &#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Corporate Matters&#34;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">).  </font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_82"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Other MD&#38;A Requirements</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have 100,361,117 common shares outstanding at August&#160;7, 2025. If all of our stock options and share awards (15,111,650) and common share purchase warrants (8,203,743) were exercised, we would have 123,676,510 common shares outstanding.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our 2024 annual report on Form 20-F is available on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov&#47;edgar.</font></div><div style="text-align:justify"><font><br></font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_85"></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures (&#8220;DC&#38;P&#8221;) are designed to provide reasonable assurance that information required to be disclosed by the Company in its reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in the securities legislation and include controls and procedures designed to ensure that information required to be disclosed by the Company in its reports filed or submitted under securities legislation is accumulated and communicated to the Company&#8217;s management, including its certifying officers, as appropriate to allow timely decisions regarding required disclosure. There were no changes in our DC&#38;P during the three months ended June&#160;30, 2025, that materially affected or are reasonably likely to materially affect, our DC&#38;P. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Internal Controls over Financial Reporting</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Chief Executive Officer (&#34;CEO&#34;) and Chief Financial Officer (&#34;CFO&#34;) are responsible for designing internal controls over financial reporting (&#8220;ICFR&#8221;) or causing them to be designed under their supervision in order to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS. The CEO and CFO have designed, or caused to be designed under their supervision, ICFR to provide reasonable assurance that&#58; (i) material information relating to the Company is made known to the Company's CEO and CFO by others&#59; and (ii) information required to be disclosed by the Company in its reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time period specified in securities legislation. The Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) 2013 framework provides the basis for management&#8217;s design of internal controls over financial reporting. There were no changes in our ICFR during the three months ended June&#160;30, 2025, that materially affected or are reasonably likely to materially affect, our ICFR. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management, including the CEO and CFO, does not expect that our internal controls and procedures over financial reporting will prevent all errors and all fraud. A control system can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </font></div><div><font><br></font></div><div id="i6e6cfe08d658412f9ce0f7a8c27fad29_88"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Risks and Uncertainties</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company. Prospects for biotechnology companies in the research and development stage should generally be regarded as speculative. It is not possible to predict, based on studies in animals, or early studies in humans, whether a new therapeutic will ultimately prove to be safe and effective in humans or whether necessary and sufficient data can be developed through the clinical trial process to support a successful product application and approval. If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users at a commercially reasonable price may not be successful. There can be no assurance that we will generate adequate funds to continue development or will ever achieve significant revenues or profitable operations. Many factors (e.g., competition, patent protection, appropriate </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">regulatory approvals) can influence the revenue and product profitability potential. In developing a pharmaceutical product, we rely on our employees, contractors, consultants and collaborators, and other third-party relationships, including the ability to obtain appropriate product liability insurance. There can be no assurance that this reliance and these relationships will continue as required. In addition to developmental and operational considerations, market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress we have made or are making.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investment in our common shares involves a high degree of risk. An investor should carefully consider, among other matters, the risk factors in addition to the other information in our annual report on Form 20-F filed with the U.S. Securities and Exchange Commission (the &#34;SEC&#34;), as well as our other public filings with the Canadian securities regulatory authorities and the SEC, when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the described material risks in our annual report or in subsequent reports we file with the regulatory authorities actually occur, they may materially harm our business, financial condition, operating results or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results, or cash flow. For information on risks and uncertainties, please refer to the &#34;Risk Factors&#34; section of our most recent annual report on Form 20-F and our other public filings available on www.sedarplus.ca and www.sec.gov&#47;edgar.   </font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ex993-q22025certificationx.htm
<DESCRIPTION>EX-99.3 Q2 2025 CERTIFICATION CEO
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i6ff8419607254d4c9ff0b520b0a86fea_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">FORM&#160;52&#8209;109F2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> <br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">CERTIFICATION OF INTERIM FILINGS <br>FULL CERTIFICATE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">I, Jared Kelly, CEO of Oncolytics Biotech Inc., certify the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.75pt">Review&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  I have reviewed the interim financial report and interim MD&#38;A (together, the &#8220;interim filings&#8221;) of Oncolytics Biotech Inc. (the &#8220;issuer&#8221;) for the interim period ended June&#160;30, 2025.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">No misrepresentations&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Fair presentation&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Responsibility&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&#38;P) and internal control over financial reporting (ICFR), as those terms are defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">National Instrument&#160;52&#8209;109 Certification of Disclosure in Issuers&#8217; Annual and Interim Filings</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, for the issuer.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Design&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  Subject to the limitations, if any, described in paragraphs&#160;5.2 and 5.3, the issuer&#8217;s other certifying officer(s) and I have, as at the end of the period covered by the interim filings&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">designed DC&#38;P, or caused it to be designed under our supervision, to provide reasonable assurance that&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer&#8217;s GAAP.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Control framework&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  The control framework the issuer&#8217;s other certifying officer and I used to design the issuer&#8217;s ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ICFR &#8209; material weakness relating to design&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Limitation on scope of design&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Reporting changes in ICFR&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer has disclosed in its interim MD&#38;A any change in the issuer&#8217;s ICFR that occurred during the period beginning on April&#160;1, 2025 and ended on June&#160;30, 2025 that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s ICFR.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; &#160;&#160;&#160;&#160;August&#160;8, 2025&#160;&#160;&#160;&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Jared Kelly</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Jared Kelly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">CEO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>ex994-q22025certificationx.htm
<DESCRIPTION>EX-99.4 Q2 2025 CERTIFICATION CFO
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie0dd1a6fb75d48379f11e6df78e992ec_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">FORM&#160;52&#8209;109F2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> <br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">CERTIFICATION OF INTERIM FILINGS <br>FULL CERTIFICATE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">I, Kirk Look, CFO of Oncolytics Biotech Inc., certify the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Review&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  I have reviewed the interim financial report and interim MD&#38;A (together, the &#8220;interim filings&#8221;) of Oncolytics Biotech Inc. (the &#8220;issuer&#8221;) for the interim period ended June&#160;30, 2025.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">No misrepresentations&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Fair presentation&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Responsibility&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&#38;P) and internal control over financial reporting (ICFR), as those terms are defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">National Instrument&#160;52&#8209;109 Certification of Disclosure in Issuers&#8217; Annual and Interim Filings</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, for the issuer.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Design&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  Subject to the limitations, if any, described in paragraphs&#160;5.2 and 5.3, the issuer&#8217;s other certifying officer(s) and I have, as at the end of the period covered by the interim filings&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">designed DC&#38;P, or caused it to be designed under our supervision, to provide reasonable assurance that&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer&#8217;s GAAP.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Control framework&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  The control framework the issuer&#8217;s other certifying officer and I used to design the issuer&#8217;s ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ICFR &#8209; material weakness relating to design&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Limitation on scope of design&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Reporting changes in ICFR&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer has disclosed in its interim MD&#38;A any change in the issuer&#8217;s ICFR that occurred during the period beginning on April&#160;1, 2025 and ended on June&#160;30, 2025 that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s ICFR.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; &#160;&#160;&#160;&#160;August&#160;8, 2025&#160;&#160;&#160;&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Kirk Look</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Kirk Look, CA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">CFO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>oncolyticslogotaglineblueaa.jpg
<TEXT>
begin 644 oncolyticslogotaglineblueaa.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  $! 0(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!
M 0$! @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" O_  !$(!H\/  ,!(@ "$0$#$0'_Q  ?  $
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M$0,1 #\ S^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                   -0  8WD
M F  #(     ,-@  ;R   U  !D
M
M
M
M
M
M
M
M
M
M
M                                                '57(=>< J I*
M]3KS*8X_]K_]@K;CF0H R"KSH<=9["F<;@%3G4XYE*?,AQSH8T7@-"KS*<<R
ME+K/8.=?0AD%7=3@I\R^KYAS+ZOF *@*?,OJ.=W>H [@Z;N]1QNOJ *ASN4N
M9?5\PYE]7S %7F4YYE*/,OJ'6>P K<RG/.I1YSGG0QIZC.A6ZSV'/.A1W0Y,
MF"MS(<[H4  2 4-SE'J8!6!3ZSV'9'H9!V!QN<@
M
M
M
M
M
M
M
M
M
M
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MN=T> 50=4>AV,@
M
M
M
M
M
M
M
M
M
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M>=0"9UGM'/[2)UGL.>= "8CD]2?$<[I[4(B*=N90"5OZE_"<HJ^Q2-SJ<H\
ME<WK11S(44D]ISS>Q/B )&YSS>M$(^_JW.R*OP@%?WOP'*;_  E#G.Z* 5.?
MUH=T4I<_QCL^#\ !6&Y33?X3GG0 K(\[HY"B!H"0"BCE0[H\ [@
M
M
M
M
M
M
M
M
M
M
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MM\"G;F7X0"O\'9[#GF5.]"DCD4[(X JHY%.Q2W1?8<]J %5%*B/(Z/13N 2
M4$4J(\P#N #(
M
M
M
M
M
M
M
M
M
M                            &Y25_J, [JY$*:NW.IPJF0<G"KL=.95[
MCA=D]J@'.ZKW''9\*G57'17?'\ !W5QT5VQU7VKM[#IOMW?+X[@#NJK\'X3I
MNB?E*:O^,IJX K*_VE-7E)7H4U?\0!55WK.BO*"O0IND^( KN?ZRFKR.LA35
MX!)=)[=BDLA'5Y3ZSQ^D D]8OC\Y35_CQL1ED]:^/C_(4EE\>H EK(GP^/9^
M-3JLGQ>/E(:RKM["FLGM\?$ 3%D\?IV.BRIX_-M^$A+*GZ3HLOP $[K?8=5E
M(/7>.PIK+\'R@$Y9/:=5D]I 67V_,<=;\(!/ZWX3CK/A+<LOA5.O6_  7'K?
M&XZU/"EMZSVH%E]H!<NO\=IUZ[QVENZWV_-^8=;[?F_, 7'KO':<I/X[2V];
M[?F_,.M]OS?F +GUJ>%'6IX4MG6^TYZSVH 7-)$.W6?"6OK?@.4E^#Y0"Z))
M[5.W6>W\!;$E^$[=;[?F +HDJ_H.R2^%+7UOP%1)O'> 7))4^#Q\:'=)/4OC
MXBV)+X4[I+X0 NG6>/TG?K/B_!^0MB2>WQ^ J)(H!<4?X\?D*K7KX\;ELZSQ
M^@JI(@!<$D*K9/;\1;DD]OCX#NC_ !^D N2/.[7^HMZ/\?F*B/ +BC_6=D<A
M!;)[2HC_ %@$Y'J5$?\ $0D?ZBHCP"9S;]_;[3LWV+\2D5'>H[H_U@$E'^OL
M*B+L1T=O[4.R>Q?B )&Z>E#GM3VE%'>OL.Z+Z@"JCMSL4D5%[_E.>U/:@!51
MVQ41Z%%'(<@$@%%'%5%W, Y !D
M
M
M
M
M
M
M
M
M
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MH"L#JCMSL-0  9
M
M
M
M
M
M
M
M
M
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M'='>CT@%;=4]J'=%**+\AV3V?( 52HU_K**..QAK4$@%%KMBJBC4'( ,@
M
M
M
M
M
M
M
M
M
M                                             '"KL%78HJNYA?U
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M[<J(OH7N!DK'*+L4>[N[4*B*#!71VYV(^Y6:[<P#L #.H
M
M
M
M
M
M
M
M
M
M                          &H!U<[8X<XI;F-/$'*J=54*NQ3[^U>XR#E
M>WX$.JKZ$[@J_(4G.]"?H .57U=YT7UKW^KU'&_RE%S_ % '=S_E*"N]9U<[
M8HN=ZP#NY_R%!7G1S_61G2 %1TGZ2.Y^WC\/YCJYY&<_X_'S %1S_;X_$1G2
M%)S_ %D=\@!5=)X\=Y'?*4'R$99 "LZ3QZ2@Z3])1=(A%?* 2'RD9\I'?(17
M2^$ )+Y2.Z4CND]9'?-MX_$ 25D^(H.E1/RJ1'2D=S_6 2GS?'\WX"BLGCQV
M?A(ZR>H^4^D7TW.%/"B'K->ZXP."M.B6:##R78[.?ML1$5'5<'46?)R1NW1J
M6%K,JM<YC7SMYF[_ +8^-9=-5U5SLG+E"N,IR?LC%-O\A^&1E54P=EMD*JX^
M=.R<807ME)I+ZV?5RR>/SG19%V5?0U%55]#41-U5?4B(G:O<B=JF*=TE?.7<
M;72Q1X2Z(ER4V[V09_6;Y*5!.QW)/'@L?,V_93]KO#/?QR[*NTBJFR^!G2'\
MI]QUXGOG;J?B%F(L;.[=N TZL>FL'!'NJMA;3Q#:\MEK.96I-DK-^X]OO9K,
MB$B;(ZK-I9*4KE7B0?X9[UNGJJAJT_59*MD:;9ZW-E8K<:79FV+A[PDJD_7=
M/1->NN-BXF>9T@/*+\%.&+)/U8\0\!1MQIS?4JC._-9N1.U$6/#X:.]D'IS)
MR.=U"1QN5$D>Q%W/$KCCYS3I2JL];AQPZSN;>WF;%E=7VZ>"HO<U5;UD>+Q<
M^5OS5WK[YCK%O'6.7]TJQN7E3#Q>JN>^1RJZ21RODD<JNDD>Y=W/D>[=SWN5
M55SG*JN555555.-O'CY"2]F=4VSJ4G>[<N??O2=5?U0J>_[=;)+U=Y%>U^N/
M:ES:Q84X<.*6[%7V\?&=J[/@N6E4=./%\-/8/C?Y=#I$:RZV&KJBIHRA(KT2
MKI/'5ZECJG;HD4F3N)<N*K=^R:NZK-NB>_39=_*;76N\[JG(.RVI\WF-295Z
M<KLEG\G=S%Y6^AONO(SV)T8G<UC7HQJ(C6M1J(B?RP) V?L7$Q5IC8U-'#36
MNN,9/Y4DMZ7UMD<[2VYF9CURLJ^_CJE99*4$_P 6&NY'^;%'5&[=W8GL.40Y
M!LMU&J2T  ,F0                           <;'(,;J!4H325;$-NK))
M5MUWI)7MUI'U[,$K>ULD%B%630R-_P 5\;VN3T*>CW _RN72%T%U,>-XC9;-
M48.Q,;J]6ZGK/3_%1]G)*_+<K$]ZQC<DV-C=FHS9K43S=!XLW9F/DQW<BBJ^
M/<K81L2]F\GH_6M&>[ VGDXLM_&ONQY>--DZ]?4U%I27J::]1E5<#O.:\C!U
M%?B/PVBOL3D9/E-&Y)M6WRJ[W\R8C,+[DFD1O[2!F3HQN5&HLS=W*GM-T>?+
M*='SB.L%?'ZVCTYE9^5&X36M;]3>125^W+"R>::QAKLO;VMQF6O-39WOMD-=
M=L<*Q%39414]2HBHOPG!;3ZJ]F7ZNJ-F+-\G3-RAKZZ[=]:>J$H>I]Q(>R>M
MW:^.TKI59D%P:N@H6:>JRK=X^N<9^M<M-L=C,O7N01VJ=F"W5F3>*S6FCL5Y
M4W[5CFB<^.3;M3=KE3T=BEQ23])J\N!G3"XI<-)HYM":]U)IQL:M5*=2^ZQB
MWHQW,V.;#WVV\3/#S?MH)J4D+_\ '8X]V.C7YREK7%=11XJ:1QFJZS5:V3/:
M81F S75HU$62SB9%DPMR=[]W.?3?AH6MV:RHKNU8VVOU2Y]"<L:=67!?!3[*
M[3Y$WV;^JUM]R9*6QNN39M^['*A;A3?PI+MJ=?#M*UOKVRIC%=\C,Z1_J7\?
MYRLV7;\W=X]FQYF=&?RM' GBDM2IA=;X_#YVWR,CTYJJ2/3V5DL.9S.K4_=\
MD=/(RHY'MCCHVIIY48LC848J'I*V3Y/1^9?T]WL4C;,P+\>?9WTV4S^+9"4'
MIXI22U7K6J)1P=HX^3!68]U5];^'59&R/L;BWH_4]&79DV_CM^0DMD]OQ%F2
M1/@*S9%\>/P'D/87ELI(;*69D_A?1\9);)Z@"\ME)+92R-E\>@DMD +TQY7;
M(6ALQ);( 7=DI*;)N6=K_C*[) "\->2F/\>.XM#)"2V0 NK7$AKRUMD^+QX_
M226O^/Q\WX "Y-?\:%=KRVM?X_+^8D-> 7!JE9KR"U_Q%9KMP":G;[#NCO61
M6NV*R+\@!(1=COMZ4(Z+M\'H*J* 5D4Y*7?VIW^H[H[< K-?ZRH1RHUWH,:
MJ  )@  R
M
M
M
M
M
M
M
M
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M9(:_UEL:\DM?\@!<FO\ 656N(#'_ "$AKOD )S7?(5$7;VI^ AM=Z4*['_H
M)*+Z4._?\)&1>WL^0JHNX!6:[T+WG<I)LO9W'=%]"@%9KO65".=VN]!AKP!5
M  3  !D
M
M
M
M
M
M
M
M
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M1%W *Z.]"G8I(N_9\BG9J^A0"LUWH*I'*C7&'^K_ +T!4 !G4
M
M
M
M
M
M
M
M
M
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MX2/[?5WH5$4 KM=Z%.Q2[_A3YSNUWR@%=KCN1T4K-=N8?B#L #(
M
M
M
M
M
M
M
M
M
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MP3=9V<Y7*YSE5SG.<]SG*KG.<Y5<YSG*JN<YSE5SG.57.5555W4X ):2T(=
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MB@$A%W.2@U=BN?/+V   ^@
M
M
M
M
M
M
M
M
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MN#!(!T8[<[GRO   'T
M
M
M
M
M
M
M
M
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MJ+Z4^, D]_PG=J_*444[KZP"JBE=%(Z*=VJ8!6 !D
M
M
M
M
M
M
M
M
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M_NC%<(1T2[VZ==).D>3M3*EDY+T^#55%ZPHKUX5P_7*7.<M6]."0 &^-"
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MD?Q(26Q^/'Z?85(XE]7XO'PDUD7LW7YOS&#)19#X\=Q+9%Z.Y"JR(ELB\>L
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MU#NUVX!78IW*"*5D4PP<@ R
M
M
M
M
M
M
M
M
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M2QWYP"0BG=?7Z"@U?1\A6;ZO6 5CNQWH*+/4=P"0#AJ[H<F$  #(
M
M
M
M
M
M
M
M
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M^ K(I&8XK)V+[% *^_I]7>5$4I-7Y#LWL78 K-=M\!6(Y6:[<^7X^ .P /H
M
M
M
M
M
M
M
M
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MH 2 =6=QV/E/N  !]
M
M
M
M
M
M
M
M
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M5OJ^0ZJW?X?45]O5^<Z*FX!%<PHJWUDQ?4ORG1S/T@$![",YGK+BYNQ0<WY
M"VO81GQES>SY",]@!:GQ[>@B21EV>SXT\>-O21)&;?  6:1GCU$-[/TEZDC(
M$C._QL 6:6/Q^(@21^/47R1A EC\?B +)+'OZ/S_ )_46][?D7UE]D9X_$6^
M5GI^4 LTC/017)\J%TD;Z/'A"$]@!B>>7L\F,DL60X\Z%I(DT#4FXDX>K!^[
MP-Y6IK"NV)%_98&\L>?W;[ZNC,F]Z+!:5^)8B^/'C\)M@\A0AM0S5K,,5BM8
MBDKV*\S&R0SP3,='-#+&Y%:^.6-SF/8Y%1S55J]YK^_+#>3HEX&:Z9D]/4I4
MX;:RELV=.3,:KX,)DF+UM_2]EZ)_@ZUF/;9PZ2\J6\<KV5EE?C;K89_ZL.F3
MMC'9N3+6RN+]RSD^,ZXK5TOQE7%-PYZUIKAN+>KCUM="%3*6U<6.E5DE[LKB
MGI"R3T5Z7)1L;4;%PTL:GQ<Y:>0(" FD@T   'ZCP1XS9_AWJ[3^M]+VUIYW
M362@R5"7OCE6-VT]*RQ>R6ED*SIJ5V%?>RU9Y6+LNSD_+@?G=5&R$H3BI0G%
MQG&2U4HR6DHM=Z:;37>F?I5;*N<+(2<)PE&<)1>CC*+3C)/N<6DT^YI,V@?1
M$Z4&!XPZ T_K[3KD95S%5/=E!9$DGQ.5@_8LEBK#DV7K*=E'QM>YC%EBZN7D
M1)$1/I]CO28%OD*>GNO"OB,[1&H+ZQ:&XB6*M-_7O<M;"ZL1R5\3E8T5W5P1
MY-KTQ.45C.:RB8N61RI0C:N>7&OQHOCX%^'MW[%*C],^C<MF9LZ5JZ+/?,>3
MUXUMZ;C??*N6L)=[T4]$I)%R^@W2F.UL"%[T5];[+)@NZV*7E)<-(6QTG'AH
MM7#5N+9>8W[D^)Y9H7[?B\?,7!COG.3.Q+W"\GL=^8LT3RXQNW0 N\+^XGL<
M6>-_CVEPC> 7:-WR>/'QDQB^@MD3_036* 7%CB2B^D@L=\Y*8OH )K5W^/\
M"56K\W81F*5D7M3V]_P@$A.U/@*C5W0I-78[-7T %9B]I6(Y7:NZ&&#D &0
M
M
M
M
M
M
M
M
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MK\AV1IV !RB;G9K=RHB&-0=4:=P!I_WX   R
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M!6.[%*+5]'J.^X!(!PBG(0
M
M
M
M
M
M
M
M
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M8[(@!P548<HW8[&.8  ,H
M            '56[E)4V*YPJ;F 4"GW=_<5G-V.ID%%6_(4E;Z4*W<OL4X5/
M5W $=4W3\*$=S=B6K?2GZ3HYO9[/P $!S?D(SV_(I/<W8H/;\@!;'L(KV>OQ
M^0N;V>@BO;ZP"T/9^DA2,\>HO$C=_'SD&1GYP"SR-_.098_'CU%XD807M_,
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M-R)8W;_"GCQ[?FUC/04Z5%W@QQ1TMKVMUSZ6.MI4U!4A]\^]IR_M7R]=L?\
MZ65E=5M5HMV\]FO$Q'LYE<FS$TKJBAFL;CLSB[4-[%Y:A3R>.NUWME@N4+]:
M.W3M0R,W;)%/7FCEC>U=G,<BIV%7^LSH[[BSNWKCI1F;UL4EPC:M.VAPY:MJ
MQ+1+2>D>$66PZJNDWN[9RHMEKDX6[3/5ZRG3I[Q9QXOR4ZY/GK7O2XRX_P!G
M"_<N$3BRQ.V5"YL<1N2@7J%Y<(W%FB=X]I<HG %VB=X]I/C=W%HC=X]I<8G
M%UC=Z/'L^0F1J6V-_9X^/U_"3F.[E +@QWI)35[2!&I+:O8 3.]/@_ 544H,
M=Z2JWTH 5]^U%]94*3>U-OC.[5[ "NQ3N46KVH5C'_\ @  ,@
M
M
M
M
M
M
M
M
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M/:5-@B;'9$!G4(FY61-@B;')@P  9
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M9KHKV(MC&QL>Y(GR([C^G.P?W0V==7%:W5+MZ/%VUJ3W%\Y%RK\-91;Y':=
M.D3V;M.BV3THN:Q\A=RKMDDK'\U/=L??NQDES-E4QW87*%^_CQ^DL5.U'+''
M-#(R6&9C)8I8W(Z.6.1J/CDC<G8YCV.1S7)V.:Y%3L4ND3ORIX^8J.7,+S$X
MN<+O'X2S1J7&)_C\(!>(U+A$_N\?"6F-WCV$^)P!=XW$Z-?'L_1VEJC=V%PC
M=W>/@ +C&OS$UB_.6V->WQ\1-8O9\ !-8OH)"+W+\2D1J]RDIOJ *Z*=T[%V
M*+5["KOW+\0!5*Z+V% J,4P^0*@ ,I@
M
M
M
M
M
M
M
M
M               ,%)ZE-5[#LJE-Z^CUA Z>CX2D]?1ZRJ[U>HHKW_ @!T>[
MYNPB.7L*S_01GJ 4'J0I%\?,2)'=_P Q#D4 C2N\?-^<@2N)4KNWV%NE=^4
MB2.^8@RN),B_E+?,[Q^  ARN_(6Z1WI^)"5*XMTSOF3\/Y@"'([M^ ^;^ECT
M@,=PLX<:RX@91T;:^F,':OP1/>V-;N2?RU</C8G/W;U^3R]BECX$5JM6:RSF
M3EW5/HJ1WSF*GYROTH4K8G1_"&A/M+E+":PU'&QZ?O&@^2I@Z\S-T=R37EM6
MV;\T<CJ;5['PM5.@Z+;']WY^-C:/<G8G;IW4P\NSCW-P3BG\9HYSI;MM;.V=
ME9>J4ZZVJ=>^^?D4K3O2G)2E^*F^XQ,=::PR6HLQE<_F+"V\MF\C<RN2LNW_
M &:[?GDLV'M1?VK.LD<V*-/>11(V-B(UK43^; +C0@HI1BDDDDDN"27!)+P2
MX+U%))2<FY2;<I-RDVVVY-ZMMOBVWQ;  /H^0%!RUKG*C6,=(]RHUC&-5[WO
M<NS6,8U%<Y[G*C6M:BN<Y41$551##![E^03Z&[>(G%J/6F8I+8TQPR6MFTZV
M-5JV]6.>KM.UGJK.63ZFRL?FUC21KDGJ4%>V2!\S%SPF)Z>]5/-WR4G1)_N.
M\%=+:?NPLCU+F(EU1JQZ(G,W-9IK;"4%<B>^;AJ'N3%(J*Z-\U6>Q&NUA=_2
M>-"I73O;_P"Z&T;9QEK12W11H_)=<&]9KYR6L]>>ZXKE%%R>K[HXMF[-IKE'
M=ON2R,G7FK+(K2M_-0W:_#>4I<Y,KQM^8G0LW[?B0CL;Z"XPM_(GXSC3MR3&
MWN]A<8F>/:1HFERA8 2(V[(3HV^/:48V_D0N$3 "M&SQ[2=&THQL^8GL;\P!
M48WN\?$2V,*;$])+8WT %1C2NUNYU:GH)+43XD .43Y?P>/P%5$V.K4])53L
M[?D .R)M\*_,=FIL<-3TG< Y1"LU-CAK=CL8Y@  R
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MO:J'< D X:O8<F$  #(
M
M
M
M
M
M
M
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M!V1#NB;_  ''L0J(FP!R5&-])U:G:5C#\/\ O0  &4
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M#N4F+VE4Q_W_ -_D  !D
M
M
M
M
M
M
M
M
MHO7M*Q051J#H_N*:]R)\9W?^,Z.7M *2]Z?*4'K\Y55>_P"0CO4 H/4AR+W^
M/82GKWD*10"+(I"E<2WK^ MTB]X!$E=X^ MSU)DSOR%OD=W@$*9WC\!;)7?D
M)TKBVR+^4 @SN^;\9;Y%]!*E7?Y57\?XD+?8F1B.>]=F,:KGKZFM3F<OMV1-
M]O9\0!AO^<P=(5<CJ[07#&E9<M;3.,NZKSE9C_V-^8SJQTL,V9FW[MC\34NS
M0N3_ -'G9&][5VQASZ[Z>_'MW$WC%Q UDD[;%/(ZANUL1(QW-$N&Q;UQN,=
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M0#NU/3\A5:GI.J)Z#NO?LG< =F)Z3N"HQ/2&P=VIL<@&$  #(
M
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MH+7DK)$:=:^Q/=>R;+(KWW"DLF'BX13C='7P[.3GPYRKB87B X0Y+2E2D
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MN1RNB@'(
M
M
M
M
M
M
M
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MX>PJH@!W;Z_45&=WPG1?0GJ*H!RB;E9#JQ#N8  !D
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M^JI09ZBKZ/@4 K%5B]A11>PJQ^D J  )@
M                                                          '&
MX!R#CQX[SD  X.0
M     <*H!R#A#D  X&X!R
M
M
M
M                                 #C<* <@'"@'(.-SD
M                                 '" '(!P <@Z[J=@
M                                             "F_T%)3N[O*3^X
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MQ.Q/'>2V)\P!W3O3V%9J>GU%-O<5/1\(!W9Z_6=T"%1B>D J( #"  !D
M
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M89HG-?'(QRM<U45%V+L5R:TX-:-<&O LVGKQ7%/DT  8,@
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M7--/BFO D6,E))IIII--/5-/DTUP:?<P #Y/H
M  'SQTBNECPWX38CZM\1M98'25!W/[F3*WHHKN1DC1%?!B<8Q7Y'*V6HY'+7
MQ]6S*UB]8YK6(KD_2FF=DHPKA*<Y/2,(1<I2?@HI-M^Q'Y7WPJ@YV3A7"*UE
M.<E"$5XN4FDE[6?0Y2GG9&Q\DCVQQQM<]\CW(QC&-17.>]SE1K6M:BN<Y51$
M1%5>Q##VZ7OG3]&O[IQG!'17U2F]]''JO7+9ZV/8NZ<LU33E&>&_<14WY?=F
M1QJ-=RO5DS>:-<:+I'^4OX\<69I7:XXFZDOTY'N<S"XV>+3N!@8N[6Q1X? 0
MXZD]L<:]5UUJ.S;FC3>U9L2*^1\D;'ZJ]HY*4[]S#@^ZW65VGS4.7LLG"7J(
MOVWUO;+Q6X8_:9UB_ Z1I7_O3X2]3KA9'\9&Q>Z0GE7.CWPO6:'5W%'3<%^%
M-WX?$3RZCS7=[U/J5@(LC=1'.]ZCWPMB1VZ.>U&O5OB_Q@\ZVX7X]TT&AN&V
MN-3OCZQC+N>LX72F.E<BJV.>NR&UJ#)R5W)ROY;=#&V%[8W1Q+[],%AC$3?9
M$3==U[-MU7?=5]:KZ57M5>U=^]:A).SNJ39M23OE?DR[]Z?95_5&K2:^NV1%
M^T>N7:ES?N>&/BQ[M(.ZQ<>^=OD/AIRJCWOO6F3IQ+\Z?XT9+G;IG1>A=,L]
M\D<EEN4SLZ(NZ-61)K%.!SF[IV,C8URHJ=RGQ#K;R_\ TJ\T]SX^(T."YG*O
M+@=-X&NQN[D=RL3(4LGLU-N5$57+RJJ*J]Z>-(.KQNA>RJO,P,;^?6K7^6US
M9QV5TYVQ=Y^T<KN^]S['EZJ56O;PX]YZ"ZB\J]TE,JKUN<:]>JKV.C=[CRK,
M9[U[G/=RIBZ])&.YG+M(Q&R-39K7-:UK4_@$\HAQ]^W7Q4_TZU%_;SXY!MX;
M'Q(K2.+C17A&BI+\BBC3V[9S)O6>7E2?C+(M;_KF?9U3RC72 AE9-'QKXH\\
M;D<WK-:YV=FZ=W-%/<DBD3_W9&.:OI0_6]->6-Z4.'V]Q<:M7JB(J<MY,-E4
M5KGMD<B_53%7'*JN8B(Y')(UBN8QS&.<B^:P/FW8N'-:3Q,:7RL>J2_K@?56
MW,ZOC7FY<'XPR+H_JFCW3T%YQMTHL*C&6=2:;U%&G5]9]6]+TW32(Q$:O[-C
MI:"1NDVW<YL2IS*JM8B;(GWYPM\Z^UK4=#'K+A1IW,PM3:6?3V=O86W(O9[_
M )+]7*UD5%W7E:UK51&M]ZJJ\Q, :7*Z"[)NUWL&A:]]<94OC\U*'U>!N\3I
M]MFC3<VC>TDEI;N7)Z?/1F_:]=7XFP;X&><[]'G4SXJNJJFMN'5MR1H^QF\+
M%FL(LKUVY(,CI>UE[J1M7;GL9##8V%J*CWN:Q'JWVJX'=+GACQ*K):T%KS2V
MJHUY45F(S%.S9C>YJOZN6HDGNJ*5&HO/%)"U[.54<U%134=%RPF;O8RW'?QE
MVYC;T/;#=Q]F>E;B7=%_8[-9\4S.UJ+[UZ=J-7T'';3ZH,*:;Q;[L>7=&6EU
M?U)[EBU\79+V';[+ZZLZK19>/1DQ[Y0UHMT]JWZWIPX*N/K?AN/@:T;HM>7K
MZ2/#&:I!+K#^Z!IZOU;'Z>U[79EE6!J<BLJ:AA2MJ2I*V+9E?K<G=H5U8Q78
MV9B.C?E#]#KSE#@KKWW-C>(#+/"C/2\C'39F7W=I2694]\L>H:\3/<4/,J-2
M3+5*3$3F?+)'&WF6,]M=6^T\-.:K654N._C:SDE^-4U&S7QW8SBN^1*NP>M'
M96<U!VRQ+7II#*481;\(VJ4JGX)2E"3[HF1D"QZ;U)CLQ0J93$7Z64QE^".U
M1R.-M07J%RM,U'Q6*ERM)+7L02L5'1S0R/8]JHYKE1=R^'!--/1K1K@T^:?@
M2(FFDUQ3XIKBFGR:  ,&0                          #A3'(Z6?G'FA.
M$O$G5_#;)<-M9Y>_H_*-Q=K)X^_@(J5R1U*I=ZVM':MQV&1HRVUFTK&NYF.7
M;E5%,C@U<OEF_LI^-WW7Q?0.&)#ZN.CV+M'*OJRH.<*\=V12G*&DNUKCKK!I
MOA)\'P(WZS>DF7LS#HNQ)QA.>0JY.4(S6[V=DM-))I/6*XF2W^NQ>&WVI-?_
M ,YZ8_MP_78O#;[4FO\ ^<],?VXP;@3%]R[8_P" G^GN_P 9"/W6MM_AZOZ/
M3_A,Y']=B\-OM2:__G/3']N'Z[%X;?:EU_\ SGIG^W&#<##ZK]CK^(L_3W?X
MS#ZV]MI??ZOZ/3_A-KWY/_IK8GI \-<=Q+PN$R>GJ&2R69QL>,R\U2>[&_#9
M";'RR/DHR25U9-)"LD2->KD8J(_9>P^U3P6\VR^Q4TO]U.N_ZS7CWI*Y](,2
MO'SLRBI-5TY-U<$VY-0A9*,4V^+X+F^)9WHYFV9&!AY%K3LNQJ;;&DHISG7&
M4FDN"6KY+@@ #3FZ                        .%4QUNE]YPWI[@KQ#U#P
MYU=PAUS]5<#8;U5VID]/KC\QB[+5EQV8QKY[$,CZ=ZOL]$>QLE>=D]69$FKR
M(9%1CD><3^3D?Q3X<-XF:5QZSZ[X:UI[5FO5B?+:U#HU567+8YD42*^:]B%1
M<QCFM8^26.*_18U\MNNL73]$:\&S-KIVA!RHN][4U9.OL[6_>Y-QDM8M^1+7
M@MY2U2BSE.F=FT*\&V_9LU'(H]\<'7"SM:H_?(Q4D])QCY<-/.W7#1N2:^=_
MUV+PV^U)K_\ G/3']N'Z[%X;?:DU_P#SGIC^W&#8UR*B*BHJ*B*BIW+OW?*=
MB?ON7;'_  $_T]W^,KI]UK;?\HJ_H]/^$SD?UV+PV^U)K_\ G/3']N'Z[%X;
M?:DU_P#SGIC^W&#<!]R[8_X"?Z>[_&/NM;;_  ]7]'I_PF<C^NQ>&WVI-?\
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M/5_1Z?\ "9R/Z[%X;?:DU_\ SGIC^W#]=B\-OM2:_P#YSTQ_;C!N ^Y=L?\
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MB^<FV^+[RR'0[:=V9LS#RKVI775;\VHJ*;WI+A%:)+1)<  #GCI@
M 6+4^<;C,;D,E(QTL>/HV[SXF;(^1E2O)8=&Q7>]1STC5K57L1515[$4OI_
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MT(=IAY%=R2UE&+TLA\NN6ED/YT5ZC^F !J#<@
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M$A$[?@3YP"HB=R%7T_ =&_@[3NP [E9J=A2;WE<P  #(
M
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M<M]JP755T^U4-EYL^*TCAW3EJY<7ICSD^]<.Q;?%>]<U!/*;!QN<D'D_
M                    &*EYV#]:GA7]\J?^J><,%PSH_.P?K4\*_OE3_P!4
M\X8+A:+JL]$5?.W_ &DBIO6[Z:L^CX_[+  )&(Q!DS^:Q?7TUC][BU].XDQF
M#)G\UB^OIK'[W%KZ=Q)R'3ST1G?,_P!^!V75YZ;V=\]+[*9GT@ J,7.
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M\4Y*+X;VJ>EM>C.W/W1PJ<SL;*.V3?9V::^3)Q<HOAO0DTW"3C%RCH]W1IL
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MO6F#>=&/26S_ *=B?VBLY[I=Z)VG_P"GYO\ 9K369@ N84@
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M*^-;G')KCI&<8):N^*\FN6KT4XZ0G)J.Y%Z;WO2 ")29
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M .["J=6)V'8QW@  R
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M)C,&3/YK%]?36/WN+7T[B3D.GGHC.^9_OP.RZO/3>SOGI?93,^D %1BYP
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MJ==_UFO'O24ZZ6^E-H?3,G[61=[H=Z)V;]"QOLH@ '/'2
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MB]'IXI\T^36C7!EV<#.JR::LBF2G5="-D)+OC):KV-<FN:::?%  'E/6
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MFVL%Y6'EXT9*$LC&OHC)IM1=U4ZU)I<6DY:M+CHC3Q]OL';[#:\?WM'HX_\
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M5+RI/5)ZM<'RU  -*;T         '\!Q7_@MJ7^0,S]'63^_/X#BO_!;4O\
M(&9^CK)^E/GQ^5']:/SM\R7R9?J9I\Y_W23^,D_IN*15G_=)/XR3^FXI%Y"@
M,.2]B_4  #Z(M[]PF_BI/Z"FX X!?P$T5]R6G/H>F:?^]^X3?Q4G]!3< < O
MX":*^Y+3GT/3(1ZZ/O>SOEY7[..3YU&>?M/Y.)^O)/UH $"EA
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MZ(_N9A=I='3+RU&RY/G5#3WJCU.*>]8OPDG'5J$6  1Z22
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M2M_5-$UB=WQ?,A<84_)^(@QIW>/47&+N3VJ<F=B7")/'P%TB_$6V$ND2=GS
M$Z)"XQ=WR$"/\A<HT^=0";'W)X]"$YG?\I#C\>/B)T?X@"6SN)C4[2)&G<3&
M=X!73N^'8K(A1_ZOCTDAG> =D[_'P%0Z,]*^TJ(G: 5D.0#$?^(  ,@
M
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M/GJ]7&,-*@]8/32>ULIQKE)85$G&B')626J>1-=\I_ 3\R&BT4G/4 #O"/P
M  7/"8.]E+U/%XNE<R64R-B*GC\;CJL][(7[D[D9!4I4JT<MFU9F>J,B@@BD
MED<O*UJJ?8G0:Z '$;I!:JCTUH/%[U8'Q.S^I[Z/@T_IJD]S4=9R%M&[S65:
M[>KBJ:2Y"X[]SB9 V:Q#L*_)S^22X7]'7%PRX2BS4&N9J[H\OKS,5X9,Q/UV
MRS5,4WE6/"8M-FL;4I<LD[&-==GLRKS)P_2SIUB[+6X_?\IK6-$));J?*5TM
M'V<7W+1SDFFH[OE+O.A_5_F;6:FOWOB)Z2R9Q;4M.<:8:IVR[F]57'1IRWO)
M>,_T"?-DM8:L93U#QOR]G0F$D1D[-(X-U2SJ^Y&JM<D60OS1W,7@6O;S)(V.
M#)W41.KY*LCDECR^>BYT&.%/!G&1XSASHO$:?:UNT^1;$ZYG+S^56.FR&<NN
ML92Y*]BJUSIK3DY.6-$;&UK6_6H*[;>Z7Y^T6_=%S56NJHKUA2O;%/6;7=*Q
MREST:U+,]'>A6S]F17N:A.WX61;I9?+Q\MKR$_BUJ$>_37B  <P=6
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M4G]!3< < OX":*^Y+3GT/3(1ZZ/O>SOEY7[..3YU&>?M/Y.)^O)/UH $"EA
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MA)#/3\!13O\ B_(54[E\=X".[.XJL[RFSN*K "J #"  !D
M
M          %)Y37N*KRF87) I+W(4'=Z%;?L^,IN]'PF01G]Q&D]!+D]/P_C
M(KP"#)Z2%)X^4GR>GQZ"#)W+\/XD_( 6^3O+;,G>7.7O+=.G?\?S %ND3O\
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MIIR@VFE-*3BW%Z:22DG%M:I--,[  _0^#KMV[F2MY!3RO\G"?-U^$O$;*_\
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M'[W%KZ=Q)C,&3/YK%]?36/WN+7T[B3D.GGHC.^9_OP.RZO/3>SOGI?93,^D
M%1BYP                 !PJF$1YS7Y0^7,YRCT?]+WML1@9:V;XB/@<N]_
M.*R.Q@L!*YJ]E7$P2?5:[ ]')/?L8UZMB7'-=-E4^4%Z6]'@=PBUGQ&MMCGM
M8;&218&C*J(S):EOI[DP5%_:U>HDOR12W%9O(RC#9DB;)(QL;M5!K'5^4U%F
M,KJ#-W),AF<YDKN8RUZ;EZRWDLE9DN7+#D:B-;UEB61S6,1K(V*D<;6L:UJ2
M]U4=&^WOEM"V.M>-+=I37G9#2;EQX>\Q::_'E!KC%D*]</2AT8\-FTRTMRX[
M][7..,FUN_\ O3BXM=]<)Q:TFC^= !8HK2   #TN\F/Y,G6'25UB[$XETN%T
M=A9:\FL=9/KI-!B:\RJYF/Q['JV*[G[T3)%I4W.ZN&-%N6U;7:U)?P?H/]#;
M5?'CB-A>'FDH=I[SUMYG*RHON+3VGZKX_JEF;KT:]&L@8]D-2'E5]S(3U:<;
M5?+V;0CHF=%?1_!C0V'T!HC'1T</BHU?--RM]V9;)3-8E[,92=$Y[>1O/C:L
ML\KGN;%'!6C5M>O#&R-^G_3=;-K5%#4LRZ+W==&J(/AVLHOG)\57%\&TY2UB
MMV4F]770-[5M]T9&]'!IGI+36+R)KCV4)=T%P[647JDU".DI;T)_1CZ+FB>#
M^D,9HC0.%APV"QD:(B(Y9KN0M.1%L9+*W9-YK^1MR\TMBQ*J)S.ZN!D-=D4,
M?T$AR"L=UT[)RLLE*<YR<ISDW*4I-ZMMOBVWS;+7440JA&NN$85PBHPA!*,8
MQBM%&,5HDDN"2X(  _,_4
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M&E%Q;36C3::?--<&G[&7/C)22DFFFDTUQ33XII^#0 !@^@
M :N7RS?V4_&[[KXOH'#&T:-7+Y9O[*?C=]U\7T#AB7NIO^'Y7T-_;TD,]=GH
M[%^F+[&T\R0 6**R@ 'S/D?,^1L9_-L?L5-+_=3KO^LUX]Z3P6\VQ^Q4TO\
M=3KO^LUX]Z2G72WTIM#Z9D_:R+O=#O1.S?H6-]E$  YXZ0
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MIB0><W^4+?A<%C^ .E[ZQ9'4T4&9X@35G[30:;CD<_&:><]OOHOJY>B9<O\
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MOG9+G5%KWN.DVM]Q[,AR 0J3N
M       >3GER=;+@NBMQ?E9*D4V1P-7!1>^:WK&YK+X['6HDYE17+)0GMIRM
M1SE3?9-MU36(IX\>/@-C?YR%DI*_19U,V/EVM:DTC5DYDW_8Y,LQ[N7U.WC;
MV]NR;]AKD$+(=4%6FSK9_'R[/]VJE?\ '^LJ[UU7Z[5HK^)A5O\ /NO?]TY
M!+!$(/TO@MPS?K76>C]&1O?&[5VJ].:726/]O F?S%+%/L(J-?R^YV6W3.>K
M'-C;&KW(K6J?FA]L>38FJ,Z0?!9UYO-7_NE:3;LJ.=_A#\I RFNS51?>W'5W
M(O<U4YG>]13R;0N==%]D?.A39..G%ZQA*2T7M1[-G51LR,>N6F[9?5"6KT6[
M.R,7Q7+@^?<;63"8>KCJ=3'T8(ZM*C6@ITZT+4;%7JU8FP5X(F)V-CBB8R-C
M>Y&M1$[BZ'5/2=BD;>O%\R^:6G!<$@ #!D
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M/XR;'Z/'I(4?X_RD^/T $QA(9W$=G<2H_0 5T[U^([^A?B_&4V]ZE7T?'^(
MJM[D*L?I*2=R%6/T@%0
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ME6'CTXM$=VJF"A%=[TYREISE.6LIOODV^\  \)L
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MVA],R?M9%WNAWHG9OT+&^RB  <\=(
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M.&"*.&&&-D4,,3&QQ111M1D<<<;$1D<<;$1K&-1&M:B(U$1-B0 58+=
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M8OBFB\G1W;5>T,*C+K:TM@G.*_B[5PLK??K"::]:TDN#3.0 :<W0
M                                                       *3^\J
ME)_>8[_R_P# %)_<4E]'CTJ57]Q27T>/2ID^N[Z_^!37O7X"-)Z"2O?\1&D]
M /DC/[R"_N)S^\@O[@"&_P#Q?'H4MLGI\>DN3_\ %\>A2VR>GQZ0"WS>/D+?
M)Z?'I+A-X^0M\GI\>D M<O=\I:YO'R%TE_*6N;Q\@!;G]_\ ^:?'W3\^L1QO
M^\_Q0_J/GC[!>O;_ /FH?'_3Z:J\">-R(FZKP?XGHB)VJJKH?.HB(B=JJJ]B
M(>[9?\)Q_GZ?M(G@VO\ P7)^C7?92-8NSN3X$_ =CHQ>Q/@3\!W+LK_G^LH9
M'E^3]2  ,GT"I!^Z1?QT/^U84SJ^=(DZU4W2+:543L5R1KS[(OHWY=M^W;U+
MW&&C$N1M8>'?\'\#_(F)^CZQ_=1^CQZ#\^X9S))IO3TB)LC\#AG[>KFQM9VW
MQ;GZ#'Z/'H*-V>=+Y3_67^K\V/R5^HGQ=_QJ72'T?$6R+O7X5+G#Z/B/@^RZ
M0>/F+C'Z/'H+="I<8_1X] !<(?'RES9^7\1;(?'RESC]7CT $Z/T?%^!2?'Z
M/'H($2]WCT*3X_1X] !,9W$EG<1F=Q)9W( 2&^GX5*GH^/\ $4F^GX2KZ/C_
M ! %5.Y"K'Z2DG<A5C](!4
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MZ>/2 3HN[Y"='Z/'H(,7=\A.C]'CT $IG>2/^KX])'9WDA/0 5V=YC"^=/\
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MM":U<=,6EZ<FU&RYKUZ.J/BDY+E([@ @DL(
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M*4FY2D^+E*3U;;[VV]67@JJC",80BHPA%1C%+11C%:1BEW))))>  !\'V
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MLB[W0[T3LWZ%C?91  .>.D                                    ,
MKSCCR<3>'.NV\8=*8Y8-&\1LC,[4,-:)ZU</KNSUMRY.Y6HYE>'5'+8R:-<K
M&NRK,BL:*DW)'C2;FW$Z671ET[QAX>:IX<ZI@27$ZEQLE3KFM8MC&WXW-L8O
M+TGO:]([V*R$5:]5?RJB2P-:]KHW/8[56]);H]:AX4:\U-P]U3#U.:TQDI:$
M\B1NCAO5]DEHY.HU^ZK3R5.2"Y6=NY.JF1JN<K54LMU9=*?=F+[DNGKD8J23
MD_*LQ^"A+UNMZ5S?AN-ZN3*K]:_1/W%F>[*8Z8V9)N22X5Y/&4X^I6+6R*Y:
M[\4DDC\- !*1$X.KD145%[E3Q\!V !L9?(#>473C3PL32NHK[9N(?#6"CB<P
MD[FMMYK3\C'Q8'436JN\ZNCKR8W)R1MWAO5626&QI?JOG]Z]S5$^3OZ:&6X!
M\5].<0\<DUBC5D7&:GQD+U;]5M+Y"2)N5I\J)RR30MCBR%)CTY5OTJWOH_W1
MNU!X<<0,/JS 8;4^G[T&3P>H,92S&)OUI&R0V\?D*\=JK.QS55-GQ2-5R;\S
M7;L=LYJHE6NL;HQ[@S';5'3&RM;*]%Y-=G.VKAP23>_!<%N2W5KN-EM.K#I7
M^Z."J;I:Y>(HUV:ORK*M-*KO%MI;ECX^7'>>F^D?VH!QN1X286W,YFICJ=O(
M7[,%.C1K3W+MNS(R&M4J58G3V;-B:16QQ000L?++*]R,9&USG*B(JFKQ\K#T
M_+O2%XNYC5$,UANC<,^? Z!H3(]G4Z?K3+_Y4EA=^Y7L_,Q<G98J(Z")]6F_
MF=55[\H'SE?RBJ:.TG4X&Z6O<FIM<TTR&K[%:5O68?1J2OBAH2*QW/%<U-:A
MDB:Q41S,53N/=R>ZZ;WX)K6[=GH]GR%@.JCHQV=;VE='R[4X8R?.-6ND[./?
M8UNQ?![D9?!LXUPZXNEG:VQV71+WNEQLRVN4K>#KJU\*EY<U\>4/A5L[  F@
M@X ']9H+0N7U1G,1IO 4)LGG,[D:F*Q./KMYIK=Z[*V&O"W;?E17NYI)'>\B
MB:^6148QRI\SFHIN3223;;>B22U;;[DEQ;[CZA%R:C%-RDTHQ2U;;:222YMM
MI)+BV>N7D0?)R2<>^*]2YG*<LG#C0=BEG-6R.C>E;,6HI>OQ.E6R^]:Y,K/"
MDF59&_KH\/%88WJ9;4$S-E97@9$QD43&1Q1L;'''&UK(XV,1&L8QC41K6,:B
M-:UJ(C41$39$1#X(\FCT&L5T?>$VGM!U'0W,RD:Y75V:CA2)^9U-D$27(3IV
MN<E*ENS&8N-SE='CJ==9%=8?/)+]^E3.G/29[2S92@W[FIUJQUQT<4_*MT??
M:UO<>*@H1?FEQ.K_ **1V5@0A**65?NVY4N#:FUY-6JX;M,7N\.#GOS7G  '
M&'=                                  Q;?.LOK.</OOBM_J_E3*2,6
MWSK+ZSG#[[XK?ZOY4Z[H'Z8P/GO[DSB>L?T'M'YA?:0,$$ %N5R13.'(  R?
M1[+^0"^RIX=_Q.H?H:R;+DUHWD OLJ>'?\3J'Z&LFRY*V=;WI.KZ)7]K<6AZ
MEO1=WTRS[*D  BHE\                           '\!Q7_@MJ7^0,S]'
M63^_/X#BO_!;4O\ (&9^CK)^E/GQ^5']:/SM\R7R9?J9I\Y_W23^,D_IN*15
MG_=)/XR3^FXI%Y"@,.2]B_4  #Z(M[]PF_BI/Z"FX X!?P$T5]R6G/H>F:?^
M]^X3?Q4G]!3< < OX":*^Y+3GT/3(1ZZ/O>SOEY7[..3YU&>?M/Y.)^O)/UH
M $"EA               #@UA7EL^D0O$GI*<1[\-CW1B]-9)NB,2K5]XV'2Z
M+1R'*U%5G,N;3)-<]G9(V-BO5R]VR7Z07%:#0FA-9ZULM:^#26EL_J.2-Z[)
M,F&Q=K(-@3M:JNL/KMA8U%1SWR-:WWRH:A>[E;5Z::]?G?:O79IKEVS*N\EF
MY:D=/:L2+Z7SSR22O7_K/4FGJ<V:I79F5)?>ZX40?KM;G-KUI5Q7LF05UW;4
MW:,/#3^^V3OL6OP:DH03\4Y62?J<$1@ 3^5T  W /<OS>[HA?W4.D)A\UD*J
M6-,<+JRZTRZ2-YH9\PG6T](X]^SD5'NR[G9KE<R2&:# 6*LR<MA$=LA3''\V
M7Z.+=*\!I]:V8&LR/$G4-[)LE=&U)'87#/?AL:QLO[98G3UKTR1[(ULCWO15
M5ZJ9'!53K(VP\O:ET4]:\7][5I<M8-]K+PU=KGQ^*HKN+>]6&Q%A;)H;6EN7
M^^K&^?OB791]BJ4.'QG)][  .")#
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M5145%0JG%G<@
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M0
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M[.19'CWPNQBKF:==\_$?2]"!'.S%.!O-^J[%P1-YOJK2@1S,Y5:CTR-*.&[
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M3E*+?%_Q>XEZDN"  .(.]
M   !_%<1]5QX+3V=S4CVQLQ&'R63<]^W*U*-.:SNNZ*FW['W*BHO=LI_:GG=
MY6?7+].=&OC5E(GNCG9H#/4ZLC/VT=S*5EQE63L3N98MQN7UHFW,G:J>O Q^
MVOII7\;;77^?-1_XGDS\GL:+KGRJJLL\/,@Y<^[D:N#5VJ9<[E\MG)^99\UE
M,CEYNL5%?UF2N377HY4[%<CIU1=NS?=&]A_/G5K$:B(B=B(B)\")L=B[4(**
MT2T2X)+N26B7Y"A<I-MR?%R;;?BWQ;_*  ?9@&Q6\VVX"-T?T:\9G)H.JR7$
M74F;U?9<^-$E]PM=!@,)$DJISOK.QF%AR,$>_5QRY*RK$YI)'R:ZA8WO]Y&B
MND?LR-J=[I'^]8U/:YRHB>U3;=]#7AG!HWA-PWTM63EAP>BM.4&M5O*J.BQ=
M99$5/6DCG(J]ZKVJFZD0]<.>X86-CIZ=O>Y2]<*8:Z/U;]D'[8K3DR9^I39Z
MLS\K):_@^.H1]4[Y\]/D537AY7+EI]+  KJ69
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M?7IK^]K+$OQJ5VT?]ZM:>O0ZGH3F^Y]K[.L_^ZJJ?JC>^PD_8HV/7U:HV:8
M*>EUP               :N7RS?V4_&[[KXOH'#&T:-7+Y9O[*?C=]U\7T#AB
M7NIO^'Y7T-_;TD,]=GH[%^F+[&T\R0 6**R@ 'S/D?,^1L9_-L?L5-+_ '4Z
M[_K->/>D\%O-L?L5-+_=3KO^LUX]Z2G72WTIM#Z9D_:R+O=#O1.S?H6-]E$
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M3D/:5\/>,66[CIKA9D<W/CSC0M&FN#LE'1ZURBO[38Y *[%F@
M                         8MOG67UG.'WWQ6_U?RIE)&+;YUE]9SA]]\5
MO]7\J==T#],8'SW]R9Q/6/Z#VC\POM(&"" "W*Y(IG#D  9/H]E_(!?94\._
MXG4/T-9-ER:T;R 7V5/#O^)U#]#639<E;.M[TG5]$K^UN+0]2WHN[Z99]E2
M 142^                           #^ XK_P6U+_(&9^CK)_?G\!Q7_@M
MJ7^0,S]'63]*?/C\J/ZT?G;YDODR_4S3YS_NDG\9)_3<4BK/^Z2?QDG]-Q2+
MR% 8<E[%^H  'T1;W[A-_%2?T%-P!P"_@)HK[DM.?0],T_\ >_<)OXJ3^@IN
M . 7\!-%?<EISZ'ID(]='WO9WR\K]G')\ZC//VG\G$_7DGZT "!2P@
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M-_6V7SQZ8U5PK@M(5PC"*\(PBHQ7U)(  _(_8
M                      'X]T@.!NGN)>C-1Z$U53;>P.IL79Q=^%4]^QD[
M%2.U7?\ MH;=.9([52=BMDAL11R,<CF[G["<;'W79*$HS@W&46I1E%Z.,HO5
M--<FFM4S\[:HSC*$XJ4)Q<91DM8RC):2BT^#33T:\#4Q=-WH>:HX%<2-0<.]
M4UY4DQME\V$RJL5*FH]/6'J_$YRA*F\<D=JORLN1,<Y]#(QW,?81EBK(Q/DT
MVA7E4_)DZ<Z2>A'8B>2'#:VP39KNB=4.B5_N"\K463&Y-D>TEG!Y5&I!<C:K
MI:<BQY&JR2:M[GL:U;C]P!U?POU9E=$:YPUG!ZBP\W5V:=AJ]7/"Y5]SY"A/
MLD=W&W6-66G=@5T4S-TW;(Q\;+5=".F->TZ%&;4<NJ*5]?+>2T7;5KOA+X27
MWN7DO@X.50.GO0FW9&0Y0C*>#;)^Y[=-=QO5]A8^Z<5YC?"R/%>4I1C^/  [
MLX(   '1T:+WHB^GM3?;X/5M[#N#&AC0^X>C1Y2?CIPADC30G$O4N/QS'(KM
M/9&XN?TR]%5.L1N SB7\=3DF1&LEM8V&C><UK$;:;R,Y<@?HY^=8:CJ-KU.*
MG#?'YAK6HV?-:,N/QEF1V^RR.PV4?:KM1J>^5D6157NW1O(BM1,1<'-[6Z([
M.S=7?B5.;_C(KL[/:YU[LI?SG)>HZC9'3/:F#HL;,M4%II58^UJ]BKM4XQ]L
M-U]VILK. OG /1>UT^&K)KW]1.3F3]XZ^QMO3D#5V;OS9Z1D^F&)S.Y6MES<
M4S]E<V'E153UWT?K[!:AIP9# 9G%9NA9B;/6NXC(5,C5G@?MR30V*DTL4D3M
MTY9&/5J[ILJ[H:=O8_1.&7%W5>BKB9#1^IL]I>ZDC95GP.6NXM9'L5'-6=E2
M:**RU%:U>2Q'*Q>5N[5V3:/-I=3E$M7B95E3^)?&-L?8I05<HKVJ;)*V7UVY
M,=%F8=5J^/CRE5+33OA-V1D]?"4%I[..X,W.37!\ /.+>DMHCJ8,GG,%Q"Q\
M:[/K:UPZRW',54YUCS&$LXC(-FY41L3[+[D$:^_=6DW<CO?GHS>=(\)]2+7I
M<2=*9_AQ?DV:^_4F35VF^;L:CEN4ZF/R]=)';N7K\)[GKL7W]QZ-<\C[:G5I
MM7&3E&F.3!:^5C2WY?HY*%KU_%A)>LDC9'6KL?+:C*Z6+-Z>3E0[./=_&Q<Z
MEHVEY4X^I-)F4&#\(X%=)WA]Q-QWU5T!K'3^K*2-:^1V&R->U/7:Y>5ONNFU
MR6Z:JY%1J68(E<J*C=]C]V0X2VJ<).$XRA*+T<91<9)^#32:?M1(=5T+(J<)
M1G"2UC*$E*+7BI)M->QG( /S/T
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M!(9W@)G=G<5&=Y285$7M *X ,+D  #(
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M-HT:N7RS?V4_&[[KXOH'#$O=3?\ #\KZ&_MZ2&>NST=B_3%]C:>9( +%%90
M#YGR/F?(V,_FV/V*FE_NIUW_ %FO'O2>"WFV/V*FE_NIUW_6:\>])3KI;Z4V
MA],R?M9%WNAWHG9OT+&^RB  <\=(
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M)LN2MG6]Z3J^B5_:W%H>I;T7=],L^RI  (J)?
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MVKLZ/_WF/+GIYED9K^N)L>P<(<E-R[@
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M)*4)1?)QDM4UZTSD 'Y'[
M    Z/[CN=']P!2*7H7V+^8JE+U@%)R]WPE*3TE5_<4GKW_!^( AO(<GI^ F
MO[B))^( M\B$&3T%P?W$&5/Q?@ +7*GY"WO+G*GCX2W2( 6N9/P%LE_&7:;T
M_&6J8 M4OX%_(09.Q?'H+C,G?X]?Y2WR>OV@&M^\KKI),+TD>*]9C.KAL9^'
M)0)MLCH\ABZ%A[_VK47FLNG7=-T7OW5W,><9[C^<*Z+^I?2(MWFQ+'#GM):=
MR#7;/1)9H([-&S)NY$:N[X&I[Q51%:K51%13PX+D=%,CM=F8$_'%H7UPKC!Z
M^O6+U*1=+\?LMJ[1AX9E\N6G"RQV+1>&DEIZ@ #H#G  ##,,S4?-G]8>Z.$>
MN\$YW,_#\2)L@UJJF\=?.Z:P,4;$[=T:MC"VY$W1/?22;.=W,R0V*8@?FQNN
MEBSG%?3"R-:RWBM.9YD:N1'/EHV[N/<K&J]$<K([RJY$8O*U4551-T,OJ->W
MY2IG6'C]GMC-7QI5V+_W*:Y/_>;+C=6>1VFQ,!]\:[*G_P"U=9!?U)%PC7N+
MG#^,M,:]GP?E+E"IQ9W9=H5+I$O86B)?Q%TA4 N<2_@+C&O86N%>[XRY1+^
M N4:DZ/\Q;HU[O'L+A&O;X]7Y0";&O<3&+VD)G<2T7N )2=WP*5T792@GI\=
MQ510"JU>U4]JE0I[]J+X\(5 "0B@X:O8<@
M
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ME9%>;-\$HRB5(ZPN@\MDW]K2I2P;I>\R?%U3T;=%CYZI)NN3\Z"XMRC(_"0
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M?^J><,%PSH_.P?K4\*_OE3_U3SA@N%HNJST15\[?]I(J;UN^FK/H^/\ LL
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M.&C  ),(J!]2]!FI+8XT\)X86.DEDXA:4:QC>USG?5BJNR)Z^Q3Y:/OKR5>
M^JG22X(TEC61K^(VGK$C$5Z*L-&RMV==X_?MVAK/55141J(KG.:U'*FMVQ/=
MQ,F7Q<>]_DJD_P#@;#9%6_F8<.6]E8\?SKH+U_J-JL "E)?
M   &KE\LW]E/QN^Z^+Z!PQM&C5R^6;^RGXW?=?%] X8E[J;_ (?E?0W]O20S
MUV>CL7Z8OL;3S) !8HK*  ?,^1\SY&QG\VQ^Q4TO]U.N_P"LUX]Z3P6\VQ^Q
M4TO]U.N_ZS7CWI*==+?2FT/IF3]K(N]T.]$[-^A8WV40 #GCI
M                             ?DO';@KI_B-H_46AM54TO:?U/B[.)R5
M?=&O2&RQ4;8KR*B]3:J2I':J3(BK#9ABE1%Y-E_6CC8^Z[)0E&<6XRBU*,D]
M'&47JFFN*::U37)GQ97&<90G%2C).,HR6JE&2T::?!IK@T:DWIC]$[4G!'B-
MJ/AOJE$EO8*TON+)1Q.BK9W"V%=)B<W58Y7<D>0J<DDT"22^X[C;-)9975ED
M?\Q&P>\XB\G"_BMPXCXDZ4H==KWAK7L6[$%:%\EG46C.5\V6Q;(XT5\U_%O1
MN8Q>S7N>R+(4&L=)=A?!KWF/1R(J*BHJ(J*G<J+ZBW'0SI+':>%"YM=O#2O(
M@N&EJ7G)=T;%I..G!:N/.+*9=..C$ME9]E"3]SV>^8LGJ]:F_,;>K<JI>]RU
MXO13?G([@ ZTX\    '"KLFX#/UC@5P/U+Q+UAI_0>CZ*9#4FI\C#C,9!(YT
M=>.27=9;EZ=K)5K8ZA V6[D+75R=14@ED;'(]&QNVK'0VZ*FG^"W#C3/#G3;
M>:E@*+([5Y8TAGR^6FVFRN8LL:YZ-GR-QTMA8^>3J6.CA21Z1HY<>KS:/R<Z
MZ7TM9X[ZMQRQ9_64#Z>A8+4:=;C]'+R.ES;6O9SQ3ZEL-5:JM79<-6JV$<YN
M1Y8LK5$*U]:'2CW5D^XJI:T8LGOM/A9D:-2]3C4FX1_&=CU::TM%U2]$O<>)
M[NNC^^<R*W$UHZL;76"7@[=%9+\7LUS3.0 162\
M                  #%M\ZR^LYP^^^*W^K^5,I(Q;?.LOK.</OOBM_J_E3K
MN@?IC ^>_N3.)ZQ_0>T?F%]I P00 6Y7)%,X<@ #)]'LOY +[*GAW_$ZA^AK
M)LN36C>0"^RIX=_Q.H?H:R;+DK9UO>DZOHE?VMQ:'J6]%W?3+/LJ0 "*B7P
M                          ?P'%?^"VI?Y S/T=9/[\_@.*_\%M2_R!F?
MHZR?I3Y\?E1_6C\[?,E\F7ZF:?.?]TD_C)/Z;BD59_W23^,D_IN*1>0H##DO
M8OU   ^B+>_<)OXJ3^@IN . 7\!-%?<EISZ'IFG_ +W[A-_%2?T%-P!P"_@)
MHK[DM.?0],A'KH^][.^7E?LXY/G49Y^T_DXGZ\D_6@ 0*6$
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MIENL#.JR::\BB:LJM@IPFN3B_P!37*47QBTTTFF<@ \IZP
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M&+W>/856>KU$>-20U-E4 K>A/8I512BWTH5&+V %9BE0HM7M*Q@  &0
M
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M^OIK'[W%KZ=Q)R'3ST1G?,_WX'9=7GIO9WSTOLIF?2 "HQ<X
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M[X^M3@HR?Z2$UW\O$M_U6[05^Q<5:^5CNS'DM=='7-N"YM_>I5O3AIKP6F@
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MCMZ>Z<=2CZYT2U2Y?$LL?-+R3(7 !7,LT
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MVWKL8Z>O6Q'5=!L/M]L;.KX\,JNUZ:<L?W]II]S5?'U:Z<3.Q !3\NL
M          #5R^6;^RGXW?=?%] X8VC1JY?+-_93\;ONOB^@<,2]U-_P_*^A
MO[>DAGKL]'8OTQ?8VGF2 "Q164  ^9\CYGR-C/YMC]BII?[J==_UFO'O2>"W
MFV/V*FE_NIUW_6:\>])3KI;Z4VA],R?M9%WNAWHG9OT+&^RB  <\=(
M                                    4IH62,?'(QLD<C7,>Q[4<Q['
M)RN8YKD5KFN:JHYJHJ.1=E14-;'Y=#R=DW KBW<RF%J<G#KB'/:SVEGPL=U.
M&R#E:_.Z7F=LC&OIW'OO8M.Q),-<KP-66QC[KS90GGOY3_H:X/CAP;U;I'*]
M56R%7'6L[IC,.BZR3#:AQ-::U0M)RJV1:TZL=2R$3')UU*>9J?LC8G-[+H-T
MD>S<Z$Y-^Y[FJLB*X^2WY-B7QJI>5RU<7."\XX;K Z+1VI@3A%+W31K=C2>B
M\M+RJV^Z-L?)?<I;DGYNAJMP4*\W6,8].Q'L:]$]7,U';?$B_F*Y;5,INF
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M-9-ER5LZWO2=7T2O[6XM#U+>B[OIEGV5( !%1+X
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MJR=<OE0DXO\ K1?3#R8W4U70\VVN%D?DSBI+EJN3  /.>@
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M3CU,])G"^S9=LO>[5*[&3?FVQ6];6O59!.Q)<$ZY-+6;,E0'"') !8\
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M7CY0"Y1J36.+?&I,8O8 3F+VE=%[OA(K5[E)*+W@$A%[2HG>ORE!J]A6W[E
M*A712@BE5BF&#N #(
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M=I6MVV*]<J]V:7A5)GNR " 2Q@
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MZ23]:::9>*FZ-D(V0DI0G&,X27%2C))QDO4TTUZ@ #\S]
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MW0[T3LWZ%C?91  .>.D
M !_"<4OX,:C_ )"R_P!'V#^[/X3BE_!C4?\ (67^C[!^E/GQ^5']:/SM\R7R
M9?J9IWL=^]X/XF+^@TF$/'?O>#^)B_H-)A>*/?[64"7-^U@ 'T9(M[]PF_BI
M/Z"FWVZ.GUOM"?<;ICZ$HFH)O?N$W\5)_04V^W1T^M]H3[C=,?0E$A/KG^];
M/^<R?V:2>.HW[[M'YO&_:N/V0 $!EB
M             8MOG67UG.'WWQ6_U?RIE)&+;YUE]9SA]]\5O]7\J==T#],8
M'SW]R9Q/6/Z#VC\POM(&"" "W*Y(IG#D  9/H]E_(!?94\._XG4/T-9-ER:T
M;R 7V5/#O^)U#]#639<E;.M[TG5]$K^UN+0]2WHN[Z99]E2  142^
M                    #^ XK_P6U+_(&9^CK)_?G\!Q7_@MJ7^0,S]'63]*
M?/C\J/ZT?G;YDODR_4S3YS_NDG\9)_3<4BK/^Z2?QDG]-Q2+R% 8<E[%^H
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M%]W:>;='V[ZWVNY61+:=5&W%E[*KJD];<)^YYK7CV:\JB6G/3LWN:]\JY'<
M$=DF
M             '"G@/Y9SR,N&X[X.SK715>IAN+N%K/FAG9"V*IK>E7B<JX'
M,N8K.KR*HUOU'S+DE=!*WW#;CDIV4FI>_)PJ&QV5M6_"OAD8\W"R#_FRC\*$
MX\I0DN#3]JT:36KVQL?'S\>S&R:U958N7PHR7FSA+G&<7QC)>QZIM/3B9S!W
M<9=N8W)59Z.0Q]J>E>I66+%8J7*LKH;%:>-VRLEAE8Z-[5[G-[-TV4M9E0^<
MW] NMI/66'XVZ;HLK8G7DOU)UE!78UD,&KZE=7T\RD4;4;']7\;"Z*_(J-;)
ME*#;,CI;F5F<8KQ;SH]MJO:&)3E5K161\J.NKA9'R;(/Y,D]'\*.[+O*7=(]
MAV;-S;\.SCV4O(GI]\JEY5<_#RHM;R^#)2CW  &[-(#W%\WEZ0LFANDKIO&/
ME<S&\0,=DM'76<R,C=8DA7*XN257=FT=S'(UJ=[GRM8FW-N>'1^K<!>)CM%:
M[T7K%LCX_P!2VK-.Z@D<Q515KXG+U+MJ-=G,58Y:T,T,K>9J/CD>U7-W54U6
MW,!96'DX[6O;4V02_'<7N-<N*GNM>M&VV#M%XF;B9*>G8Y%4Y/EY"DNT3X/A
M*#E%\.39M^@4H94>QCTV5'M:Y-N[9R(J;>SM*I2PO4
M                        4GE-4W*ST*0!27N3Y"BO>GR>/E*WH^<I._
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M 544 K-7L.[5[2EZ?8I4 ) .K5[#L87@  #(
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M:\.*?%,NUL+;5.T,2G+H?D6P3<==77-<)UR_&A+6+\=-5P:  -4;<
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MQ(Q:\]I5EZWNEBRLB.S:):TXLMZ]KE/)W=%%-<U3&4HO_62DM-8)G( )>(9
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MDGCJ-^^[1^;QOVKC]D ! 98@
M      &+;YUE]9SA]]\5O]7\J921BV^=9?6<X???%;_5_*G7= _3&!\]_<F<
M3UC^@]H_,+[2!@@@ MRN2*9PY  &3Z/9?R 7V5/#O^)U#]#639<FM&\@%]E3
MP[_B=0_0UDV7)6SK>])U?1*_M;BT/4MZ+N^F6?94@ $5$O@
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M<6$U)*46I1DDXR33336J::X--<4UP:  ,'T
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MK$<K-7<PS!V !D
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MSQ# [\U2^N_Q$^X*M]-0F>(59ZT/3%WS6/\ 91+;=4OH3'^=R?MY@ $>DE
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M])3KI;Z4VA],R?M9%WNAWHG9OT+&^RB  <\=(
M                   #^$XI?P8U'_(67^C[!_=G\)Q2_@QJ/^0LO]'V#]*?
M/C\J/ZT?G;YDODR_4S3O8[][P?Q,7]!I,(>._>\'\3%_0:3"\4>_VLH$N;]K
M  /HR1;W[A-_%2?T%-OMT=/K?:$^XW3'T)1-03>_<)OXJ3^@IM]NCI];[0GW
M&Z8^A*)"?7/]ZV?\YD_LTD\=1OWW:/S>-^U<?L@ (#+$
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M?T%-P!P"_@)HK[DM.?0],A'KH^][.^7E?LXY/G49Y^T_DXGZ\D_6@ 0*6$
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M6L1LF@L02,F@GAD:CXY898U<R2-[%1S'L<K7-5%151=R80&6+3
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MQWH*AA   R
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MG%Z2A.+A*+\'&233]J)GQ\FNV$;*IPLKDM8SKE&<)+QC*+::]C.0 ?D?L
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MLYP^^^*W^K^5,I(Q;?.LOK.</OOBM_J_E3KN@?IC ^>_N3.)ZQ_0>T?F%]I
MP00 6Y7)%,X<@ #)]'LOY +[*GAW_$ZA^AK)LN36C>0"^RIX=_Q.H?H:R;+D
MK9UO>DZOHE?VMQ:'J6]%W?3+/LJ0 "*B7P
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MUW4^9W_5GL669M?&\G6K%?NJU]R[+C4N6FLKG7HN#T4FN,3(A0Y.$.2J)<$
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MNQA@K@X13D)_E  !D
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M\1/N"K?34)GB%6>M#TQ=\UC_ &42VW5+Z$Q_G<G[>8 !'I)0
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M;FV1TMO2X03T;IIUXJM->5+12L:3DDE&,0 .&)
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M_D#[M>T_Y/A?FW_YQLLOUP/T3_MG?_3&J_\ @P_7 _1/^V=_],:K_P"#&M-
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MT%-OMT=/K?:$^XW3'T)1(3ZY_O6S_G,G]FDGCJ-^^[1^;QOVKC]D ! 98@
M                                        &+;YUE]9SA]]\5O]7\J9
M21BV^=9?6<X???%;_5_*G7= _3&!\]_<F<3UC^@]H_,+[2!@@@ MRN2*9PY
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M%5QCJE)R+>]7'1']RL).U:9>3NV9&NC<-%[W3JOP:;WM-=;)2T;2B  <(2$
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M)HJOKXUW5PLA\F<5):^M:Z/P::*,[0PK,:^['M6EE%LZI_*A)K5>I\UZFF
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ML1SLUQA@K  )@  R
M               ##8!2<XY<[T%,R 4U[?@0Y<N_8AT<OH0 X<NY25=_@0Y<
MOH*;G?(@!U>XC.=L=G.])'>[T@%-Z^@B/=X_&5'O^4B/4 IO?Z?B(#WE61Y"
ME?X]@!0D?^8@2+\WC\)6D>097@$>5WC\);97$B5_CV%OD?V*OR $:9_?[.[X
M5\;%OD=MV>/:5WN^;\/K\>L@R. *,COR'@IY?KI@)H+A.FAL7;2+4?$QT^+=
M&QVT]?2]3JWYVUV;*R.RLE;%(_=%>MM[4:]C9>3W9RF3@IUY[=J9D%6K#+9L
MSR.1L<,$#'2RRO<NR(R.-CG.7T(BFMU\I;TNY>-?%_4NKXY7.P-9S-/:2@5?
M>0:;Q$DS*LK6[JB/R=J6YEIU3OEO*U-HV1M;(?5MT?\ =NT(V3CK1B;MT^'"
M5FOO-?UR6^UWQKDN&NI&W6CTD]P;-G5!Z9&;O8]>CXQK<??[/YL'N)KBIV0?
M<SX):FR=VQR 6E*CH  &0 ?J? [A%DM?ZSTOHG#L<_)ZIS=#"U5:BJL2W)FL
MFLNV1=HZE=)K4SE]ZR*%SW[,:Y4_.ZV-<)3FU&,(N4I/E&,5K)OU))M^P_2J
MJ5DX5PBY3G*,(17.4IM1C%>MMI(R\/-N^BT_ Z#U+Q4R=7J\AKG()A\ Z1JI
M*W2V D5L]EN^RM9ELZZRB)LJ/KXBG9CD6.RB&2VQ#\RX.<+<7HG2VGM(86)L
M.+TWB*&'I,8Q&(L%&NR!)%;V[.F<QTKD55V<]4W7O/U2-OS%->D6UY9^;D94
MM=+;'N)_!KCY-<?JA&*?B]7WEX.C6QH[/P<;#CH^QK2G)?"MDW.V?\ZR4FO!
M:+N)<+?9W=GQEQB:1HF]R?*7&)OY32F\)<+"XQM_(18VEPB;X^$ E1-+A$G;
MN18T_(7"- "0Q/638T[O'M([&]OCT$QB>D KL3TDEB%)J;(2F)\P!W1.WX$*
MS?7ZBDSN^$J]R?#^  [L*B)NIU1-BHQ/2 53%^\ZF^LOHC[X,/T/D#*!,7_S
MJ7ZR^B/O@P?0^0.LZ">E\#Y]?L21QO6%Z$VE]&E^N)@7@ MX4Q   ,HSS5+Z
M[_$3[@JWTU"9XA@=^:I?7?XB?<%6^FH3/$*L]:'IB[YK'^RB6VZI?0F/\[D_
M;S  (])*                     !\6=/;H-Z/Z0/#[):$U;7:U[U]W:>SL
M44;LEIG/0QO;4RV-E<U7,79[ZMZOS)'?Q\]FG,G)+NW[3!^^+E64V0MJG*NR
MN2G"<7I*,HO5-?\ >C7!\#SY6+7?593="-E5L90LA):QE&2T::]GUKFN)J-^
ME=T7-6<&M>9WAYK2DZIF<+/^QSL9(E',8V?=]#-8J9[6I9QU^%.>-[>989FS
MTY^2U6GC9\[FSD\KEY+W"=)#0KH:[:V.XBZ:KVK6B<_(UC$6=S>LDT_E)D:L
MCL+EGL:R3=7>X+2Q9")CG1213:TOB%P_S>D\[EM,:EQ=O"Z@P5Z?&Y?$WHUB
MM4;M=422*1O:US7-5LL,T;GPV*\D5B!\D,L;W6KZ$]+:]J8^KW8952BKZM5Q
M?)6UKGV<WW? EK!_!E*H'3KH79LC)TCO3Q+W*6/;H^"UU=-CXKM()KBW[Y'R
MTEY48_QX .V.&!DS^:Q?7TUC][BU].XDQF#)G\UB^OIK'[W%KZ=Q)R'3ST1G
M?,_WX'9=7GIO9WSTOLIF?2 "HQ<X                        'X1TC.C/
MH?BSI>]H_B!IVAJ/ WF[K7N1_L].PB*D5_&W&<MK'9"NJ\\%RI+%/&J;<RL<
M]COW<'Z4W3KE&<)2A.#4HSBW&49+BG&2T::[FC\[J860E79",X33C*$TI1E%
M\&I1>J:?>FM#7F>4S\WVX@<(5O:LX;1Y+B-P[9))//!4K>Z-7Z7K*J+OD\;5
M:LN9QU?=>LRV*@?+5A8MC)TZ]>.:X8\2]BJU45'-56N:J;.:Y%V5KFKLK7(J
M*BM5$5%145-S<FJWY%\>.\\0/*#>0:X0<<'6\]C8G<.=>S(Z1=2Z;IP+C\I/
MROY?U1Z>58*F31SG-Y[E6;&Y5$CC;[O? UT#YKZ+];#BHT[2BY):)9=<=9:+
MEVU4=-[USK\I\-82>LB!NEO4ZI.=^R6HMZR>'8](M\6^PMD_)U[J[/(7P9QC
MI$UN(/4/IM^1\XW\"5M7M1:;?G]*5N=_ZL])LL97"10,W59\E&V%N0PT:-;S
M/ER-6&M&BM1UCF=L>7+)&N1%:J*B]RHNZ+\"IV$V8.T:,FM6X]L+JWRG7)27
ML>G&+7?&24EWI$$Y^SK\2QTY--E%L><+(N+T\5KPE%]THMQ?<SN #VGB
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M?GF!Y%[[%S@M]QE'_:3'I^4MV]_#LSZ5D?:R+T]'_P" 87T7'^R@  :DVX
M             /X3BE_!C4?\A9?Z/L']V?PG%+^#&H_Y"R_T?8/TI\^/RH_K
M1^=OF2^3+]3-.]COWO!_$Q?T&DPAX[][P?Q,7]!I,+Q1[_:R@2YOVL  ^C)%
MO?N$W\5)_04V^W1T^M]H3[C=,?0E$U!-[]PF_BI/Z"FWVZ.GUOM"?<;ICZ$H
MD)]<_P!ZV?\ .9/[-)/'4;]]VC\WC?M7'[( " RQ
M                       ,6WSK+ZSG#[[XK?ZOY4RDC%M\ZR^LYP^^^*W^
MK^5.NZ!^F,#Y[^Y,XGK']![1^87VD#!! !;E<D4SAR  ,GT>R_D OLJ>'?\
M$ZA^AK)LN36C>0"^RIX=_P 3J'Z&LFRY*V=;WI.KZ)7]K<6AZEO1=WTRS[*D
M  BHE\                           '\!Q7_@MJ7^0,S]'63^_/X#BO\
MP6U+_(&9^CK)^E/GQ^5']:/SM\R7R9?J9I\Y_P!TD_C)/Z;BD59_W23^,D_I
MN*1>0H##DO8OU   ^B+>_<)OXJ3^@IN . 7\!-%?<EISZ'IFG_O?N$W\5)_0
M4W ' +^ FBON2TY]#TR$>NC[WL[Y>5^SCD^=1GG[3^3B?KR3]: ! I80
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MAL]QS,U1LS=-:Z^$J\77P?%3NTX.:\F'%0U\]D.0"*R70
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M_ 1T[?Q?D*C7>A>\ KHNW8IW*2+Z%.R+MV+\0!6:_8JD<[-=L8:!6 W!G4
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M#_6-Q-_YP'ZW:Z(GVL<A_K&XF_\ . ^Z_LW\%G?H<?\ ZD?<3VI_*<'\^_\
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M?H_R-:HU?_@/;/%?N=E<'IYGZFGHUZUJC'^!D",\V<Z4"N:BU>'S6JYJ*_\
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M=&XG+LU$V1-UUANNR)Z5*OZW:Z(GVL<A_K&XF_\ .!8[[K^S./O.=S_!8_\
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MM-23.KCH-E;'GERR;:+.WC5&'8RL>G9N;>]OUPY[ZTTUY,O@ (R)4
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M[6.0_P!8W$W_ )P'W7]F_@L[]#C_ /4F?N)[4_E.#^??_P!.:U>ZJ]3-V?\
MHI/3_P"XIN N 7\!-%?<EISZ'IGE%)YNOT0W-<UW#'(*CD5JI_=&XG=J*FR]
MVL?4>SVG<!5Q6/HXNC&L-+&TZM"G$LDDJQ5:<#*]>-99GR2R*R&-C5DE>^1Z
MIS/>YRJJQUU@],L7:L<2./"^/82N<^VA7'7M%4H[NY;9KIN/773NTU[I.ZM^
M@^5L=YCR;:+/="H4.Q<WIV3MUWM^NOGVBTTUY/4O( (T)2
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M.S3V]G.>G_#O,=\&0%^MGNE#_P!CX??Z92?\%"^;/=*'_L?#[_3*3_@I^O\
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MS_G2:7):(  U!N@
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M^<GQ/ +O&_Q[/R$ICO'CU%KC?M\!,8_Y%\?-^  N;'$ECO06UCB2QP!<&O\
M65T[?A]!":[UE9K@"4UWH7O*J.]"D;?YBJUWH7O *Z+MV>CT*=RBB^A>X[;[
M>U "LCMBJBD=%.R+L8:!7!U1Z'8)^(  ,@
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M                                       '&QR  #C8Y
M                                !QL-CD     XV.0 <;(-CD
M                                         XV.0 <;'(
M
M
M
M
M       .-CD       '&QR
M<;#8Y
M                  !2>GI.A7<FY0,)@I;=BIZBDY.PKN[%W*:F04'>OY2,
MY/02U3T>ON^$CO0 A/;Z"'(GI0N+T])$>WYP"W.;X\>H@2-]!=7H0I6^/'K
M+1*WQ[2WO;\Y>)&%OE;X]H!9YF%NE:7N1I;96>/: 6:9FZ%N>SQX]9>I&_.6
MZ9FP!X8^7-Z"+N+'#)VJ<#22QK;AW#<RU!D,2NM97 *Q)<YAF\C'23N;%$W)
M4H55-K-5[8W-Z^1LN!#&Y'-147=%3=%]:+V[_'WFV=>SPO=\"IZO8:^KRS_0
M';P5XF29' 8_W+H'7,EO+:>9!&YM/$Y'K$DS&GHD1.K@BJ2S-M8ZLU6MBQ]A
MD$,;(:S42=>J;I/PELRZ7+>LQ6_#C*ZI?:Q7SFKX)%?NN3HIYNUJ8\-(U9B7
MU1INT_\ BF_FM/A->/0 )S(    !].]#OI6:BX+Z_P +KW3J];+CI4AR>+>_
MJZ^;PMAS4R.*G=LY(_=$3>:O85KUJVF03\CVL?&_YB!^&5C5W5SJMBIUV1E"
M<'RE&2T:?U/VKFN)^^+E646UW4SE7;5.-E<XO2491>J:_P"*?!K@TTVC:9\"
M^->GN(NDL#K;2MQ+V!U%CX,A2E5$;/$DK4ZVG<B1S_<]^C-SU;U97.=!9ADC
MYG(B.7]A8_\ ,8+?D./*1KPNU8SAMJ_(=7P^UG>:VE;M2M2OI34TZ)'7M=;(
MJ=1B<P](Z>0:CNJKVUK7D8Q'79'9S<;T5.Q45%V5%145%14W145.Q45.U%3L
M5-E3O*C=+>C5FR\N5+UE3/6>/8_AU-\$^[?@_)FN'%)I;LHZW,Z&=*J]K84,
MB.D;H:5Y-2_B[4N.G?V<UY=;^*]U^5&25U8\GQ2=WC8L['DQC]EW]!RYUI?(
MWD^)Y9(G[_B4G1R>/4 7YCR9&\LT4GCQZ"<QX!>8Y/'J)C'^@LT<GC\1.9)X
M]0!=V/)3'>@M;)"6QW=N 7)CB0UWH+<U_CQWDAK@"X-<5D[?Q>/&Q":_UE9K
MM@"6U?0OQ>TJ([8CHOR'=';>U "NGK3XT*B.W*"+ZCOV+[%_"#.I5.[7^LH(
M[;L4J P2-P4$4J(_UF =P -0  9
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MX1/0=N]=O0@!4:FR'=B=IU*K$[##8.X "0  ,@
M
M
M
M
M
M
M
M
M                          %%Z=I6.KDW0QJ"@J%/O3VH52FO8OL7O,@H
MN3YBDOX20J;%%4[53U]WCY@"(J>@BO:3GIZ2.]/2 6Z1I$D;X[.S]'XRY/3Y
MR&]OCQZP"UR,($K"[2-[_6GA/R$&1NX!9Y&D"5A=Y&D.1@!8Y6%OD;NA>I6%
MOD;L 61[.]#XEZ?G0ZQ''+AGG-"Y+J8+TB-R>F<K)&CW874M&.5,;D&*JM<D
M3TFFHWF->SK\=;M0N<U'\S?N69A D9Z?&QZ,3+LHMKNJDX653C.$ES4HO5/U
M^M/@UP? \V9AUY%5E%T%.JV$J[(/E*,EHUXK@^#6C3T:::-4EQ$X?YC2>?S&
MF-04Y,?F\#D;6*R=.1'(Z"W4D6*1$YVM5T;]DDADY426%\<K?>N0_CC,"\X,
M\G7]5Z+N.VD<<U<GB:L%7B'6J,1LE[#56)!1U,^-J?LUK#PI%1R$_OI78EE5
MTBK'CFHW#]+>]%>D%>TL.O(AHIZ*%U?X.Z*6_'3GNOA*#?.$HMZ/5%+>EO1N
MW96;;BSU=>N_CV?A*)-[DM=$M]:;MB7!3B].&C8 '1G-   '56(J*B]J*FRI
MX[OB,V'R%GE,UX@8&/A-K>_SZWTS5_\ P;R5F7>75&FJ\3&MKRN>O-)FL)RN
MCF<CE6]CG59N1)ZUN27"@/ZG0^N<SIC,XS46G<E;PV=PMR'(8K*49.KM4KE=
MR/BFC54<Q[=TY)8)F25[$+GP6(I8))(W<QTKZ-5;3Q943TC9'RZ+=-778N7+
MCN27DSBN:T:6]&+74]#^E-NR<R.1#6=4M(9-2?WVK7CIW=I#SJV_A:Q;492U
MVLK'DR-YYD>3)\H;A.D!H>/(H^M1UO@HJ]76F B56+5N/8K8LK2A>YSW8?++
M')+4D:^5L,K9J<DBS0./2UCOS^/'R%2L_ MQ;K,>^#KMJDXSB^Y]S7C&2TE&
M2X2BU)<&BY6SMHTY=%63CS5E-T5.$UWI\T_"47K&47QC).,DFM"[1OV+A')O
MW%ECD)<4FWCT'C/:7V.3N\?$7".0L<<GYT)K) "^1O\ SDR-Y9HY":QX!>(Y
M/'J)K)"S1R$UC_'J +PQY(:\M3)"6U_CQW?C +FQY(:_Y"V-<26/ +@UWJ*S
M7_H(+7^HK-=Z@"8GK3Y#NCMR,U_K*F_Z0"2CO6=D3U=OL(Z.V[RHB^H K(X[
M%'??O^4Y3L^  K([8J(\H(]#L8T!(W!013LCP"J#JCD.QD  #4
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MFQ"H8  !D
M
M
M
M
M
M
M
M
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M;(=T3<X*C$](9@J
M
M
M
M
M
M
M
M
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M+9/'CN+.R0E,D]0!=6O]16:_XBV,D^+QX[B0U_S^/C +DU_K*S7EM:_8K-D
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MN+UPJY)^7-?^9:?#<B_O//>DNT6BC!RE,;Z?1X[2=#'Z3I%'NJ>K\9<&,]!
M98L[L9\A<(F>/:4HV=WCXRXQ1@%2-A.C9^<IL;^8G1L\>L J1,\>PGQM])28
MST?*36-]'J[_ !X[0"I&WQ\Y,8TIL82V-]/R %1C?026IZ#HUNQ(8WYP#NU-
MOB*K4^<Z(WM^ K-3< [)V)OZ5[CNU-CJG:OL0J '*)N5SHQ#N8  !D
M
M
M
M
M
M
M
M
M                                                     &&"D]#H
M5U3<H*$_Z@4O8OQ'14]!5<AU7M[?E,@C[>CTIW>TH/3TDIR>E.]"FY-TW^4
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MA58GI^0 [(FQ4]&WI4-3TKW'9J>GU@'9$V.S4W."LU-D#!V
M
M
M
M
M
M
M
M
M                                                     *;T])4!
MA@CE-4V7V%9R;'13(*3D^0HJFWP*5T]2_$=%3T $9S?01U3<F*GH^0H/;Z?E
M (+V_*17M+BYOI(SV^E "V/9[/'CN(<C/271[2(]OR>CQ^$ M,C/'XB ]GR%
MYD9Z"%*P M#V;EODC\>LO,C"'(SQ^, L<D9"DC1?1^8O4D?C\9!D9V@%DD9M
MV+\OK3\I^+<>N ^E^)6E<OHS6.,ARV"S-9U>S!(B-FA?MO!=HV.5SZF0I2;3
MT[4?OX9F(JHYO,UW[O+&B^.Y2WOC]"]B^CQ^(_2JV4)1G"3A.$E*,HMJ491>
MJE%KBFGQ37)GYW4PLC*$XQG"<7&<))2C*,DU*,D]4TTVFGS7 ULGE%/)YZHZ
M/NL'8?(]?E=*922:;26JFUG1U\G4:Y56C>5J+!6SM%G*EZHQ_+*Q6VZ^\,KF
M1>?)M(NDET;M)\5](Y316M,9'DL-DXT]"-MT+D:;U<GC;*)UE/(4W^_@L1JB
MHG-$_FBDD8NO9\H3Y/;5O1]U<[#9A),IIG)/EFTIJR&!64\O3:YR^Y+2-164
M\W48W:]1<Y$<B>ZJO657HK+,= ^G<-H06-D.,,V$?5&.1&*XS@N"5B7&RM>N
M<%NZQA5?K#ZNY[,G+*Q(RG@3EQ7&4L64GYDGQ;J;X5V-\.$)O>W93^ P<(IR
M2816      ?NW1SZ3&MN$VIZFKM!YN?#9>LK6RM1$GQ^3J([>3'Y>A(O47Z,
MS5>Q\4B))&CW25I:]A&3,SO_ "<?E6]$<>\?%C%?7TWQ$J5.MRFD+5EBNN)$
MU/=.0TY-+U;\KCV+N^6-C5N48W-6W"UCFRNUY1>M-:DR.&R-++XB]:QF5QMJ
M*[C\C1G?6N4K<#D=%8K3Q*V2*1BIV*U>U%5J[M547B^EO0K&VI7JUV63%:5Y
M$4M?5"Q<-^O7NU4H<7!K62EW/0WIWE;(LW5K=B3EK;C2EP7C.EO55V>.BW9I
M:33:C*.UT:_XE)#)#%W\F;Y>JAG_ *GZ$XW3U\3G%ZJIB->M1(<3F'+RQQ5M
M20HG)B<DYW9'DXE3'7-TCGCHSM1]O)XJVXY8XYHI&30RL9+#-$]LD4L4C4<R
M2.1BJR2-[51S'M<K7M5'-54[2LFW-@96SKG3DUN#X[DUQKLCKIO5RY27BN$H
M\I)/@6KV!TBQ-IT*_$M4X\IP?DV53^)9#76+\/@RYQE)<2]-?O[%_$262^W\
MGCYRTM>26R&F-X7IDGQ+\Q)9(65DJ^O\!*9-X]/CX0"],D)C)?'Y2R-D^,DL
ME +VV1"NV3XBS,E\?F)3)@"[-D)+)2TMD^(K))\0!=VRE9LGM+2V0KME +JV
M5/'C8K-E\=A:DF*K9/B +HDGQ>/'<5$?[?Q%M;*OQ%1LJ>/&P!<NL._6%O;)
M[?'Q'=)?'Z "X))[?'QG=)"W))X_2=TD]2@%PYT'.A"23V_@.4D )R/]IVZS
MV_@(/..M\;@$]'KZSGG4@\XYT )W.IPLGMV(7.AQUGL )O6>W\!U63VD/K4\
M*.< EJ]#CG(:R>-CCK/;^  E]8=5D]I#5_CO_(=5D\?H[0"4LB'7K"(LGC])
M3=)[0"6K_'CL*:R)X_,1%E3QXV*;I?B );GE%TJ>/&Q%=)[2DZ4 DK(472$5
MTOC\Q0=+X4 E.E\>@CNE\>@CND^,H.D *[I/'H([I"@^8BOE )+Y2(^7QZ2@
M^4C/D *KY",^3U_(A1?-\7M7Q^$AOD_+ZP"M)+ZNWV>A/'K4B/>4W2$=S_T@
M'9\A0>_Y3KNJ]C4W5=D3;M7=?0B'@[Y2SRVNE.$K,CH_0*TM8<2&M?7F>R1)
MM.Z3F<BM67+6(55,CDX?VT6%JR)R/Y7Y"Q!'RP6=GLG8^3G71HQJI662YZ<(
MPCWSG)\(07>WZDM6TGJ]L[:QMGT2R,NV-5<>"U\Z<M-5"N/G3F]'I&*;X-O2
M*;7H'TWNGYH#@/I[ZKZOR#9<K=BF73^E:,D3\[GIHD:CO<U5SN:"C$]\;;63
MG1E2NLC(U>Z5\<;L"?IN=/CB!QYU&_,ZNOK7Q%6>1=/:2HO<S!Z?JJBM8V&/
M9KKV1?'NMS+7$=:L2OD2%*M/J*<'SIQBXR:HX@:BR&J]8YFYGL]DWHZU?N2<
MSDC;S=35K1IM%5I5T<K:U2!K((6JO*WF<]7?FA9?H=T#Q]F15L]+LQKRK6O)
MKUYPH36L5W.;TG-?%B]PJMTWZPLC:TG5#>HP8R\FE2TE=H^$\AKA+QC6M80?
M'RY*,P #OB/      !N?0G1>Z+^K^,&L,?HK1>/?=R5U>MM67M>F/P^.8]K;
M.5RMAJ*VM2KHY.U51]B9T=>!'2R-0M_1OZ.&KN+&K\7HG16,?D<SDY/?.7=E
M+&4F*WW3E<K9V5E/'5&+SS3/[7+R0PMDGDCB?L)/)Z^3UTET?M(MPN%1F3U'
MDV03:KU7+ D=S-W8V[I# CN9]/#U'N>W'X]K^5J?X18ZVU(^0X/IMTTJV73N
M0<;,RR/O-7-07X:W1\()Z[L>=DEHO)4G&0.@70:W:]RG-2KP:I>_6K@[&M'V
M-3[Y/AOR7"N+U?E.*?\ 4]!'H,:1X#Z*J:7TY RQDYV06=3ZCE9M>U%F$C1L
MUN7F5RP4HG*Z/'4(W)#3K(U/?SNFFE^WV,^53JQGREPBBV_&OXBK>7EV7VSN
MNG*RRR3E.<GJY-]__!)<$M$DDDBV^'B58]5=-,(UU514(0BM(QBN22_K;YMZ
MMMMZG,46R?A)L;#B-A.CC/.>DYCC\>LN,;-CI%&38V@':-OYR=%&=(X_'K)S
M&>@ [1L^0FQM\?D0Z,C[O'CVDQK=_'CY #LQOR$MC?2=&-^0E,;Z0#LU-BNQ
M#JQ/22$[/A ")OV>@JHGH.$38J=WPK\P!SW]GH0J'#4V.R)N =F(53A$V.3
M  ,@      'P3Y0+RA&DNCIIC$ZJUACLSDJ&7S+<+7BPD,$UB.RZM-:1\C9Y
MH6I%R0.3=KE=S*B;;=I][&+]YU-]9C0_WP(?H?(&^Z+[/JR]H8N-<FZKK5":
MB]V6FC?!]W(YWI;M.W#V;F95#BK:*7.#DMZ.\FN<>&J+Q^NF>!G^2O$#^;\;
M_P 0'ZZ9X&?Y*\0/YOQO_$# 8!8'[E.R/B7_ *=_\BN/W7]M?'QOZ.O\9GS_
M *Z9X&?Y*\0/YOQO_$!^NF>!G^2O$#^;\;_Q P& /N4[(^)?^G?_ "'W7]M?
M'QOZ.O\ &9\_ZZ9X&?Y*\0/YOQO_ ! ?KIG@9_DKQ _F_&_\0,!@#[E.R/B7
M_IW_ ,A]U_;7Q\;^CK_&9]'ZZ9X&?Y*\0/YOQW_$#^FT_P"=!]'FRJ>[\9K_
M !B*]6JOU @N;,V14D_P:_NN[MV\J>^3O[=]C7X@^9=4^R6M$LA>M7<5^6#7
MY4?4>N';*:;>+)>#H>C_ "6)_D9LHN'_ )PAT5L\YL<G$"QI]SE:B)J+3N<H
MMYG*UJ-=+!2N11=KMW22R,B:C7.=(C4W7TFX+]+KA9Q&1WZ@N(NBM7R1L22:
MKI[4N(REZJQ>U/=F/JVY+M)53MY+5>%_+L[EV5%74;;=I5J325YX;5>22O:K
M2-FK68)'PV*\K%YHY8)XE9+#(QWOFOC>U[7;*CD5#49G4[AR3[#*R*GW=HJ[
MH_6HJE_[WU&XPNN[-BU[HP\:Y=_92LID_9O.Y?[IN3!N:S?HE^73Z0W"F:I
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M7#7D9\_ZZ9X&?Y*\0/YOQO\ Q ?KIG@9_DKQ _F_&_\ $# 8!U_W*=D?$O\
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MV=ET"ZQ-I;0VG3BY,J75.%TI;E*A+6%<I1\K>?>D9=( (,)^
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MM5PL=&0__+WZ0E)^%<TW79ZE&6_IQ<$CU=!QN<G%'=@
M
M
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MHUKZNXRGHTUP:>J:X--<FGW-/BO7Q,T;R1'G#WU3L8KAIT@<E!#=E;%C]/\
M$ZQU=>O=G3DBJT-9*U(X*UJ=/V.+4+6LKV)D;]5&Q2S/NNS!8)V2L9)&YLD<
MC6OCD8Y'L>QZ(YKV.:JM<US516N151R*BIV&FQ<U%394147?=%[45%[TV[OB
M[C+U\@=Y:2;&6L/P*XLY9TN,N2PXWAYJW)6.9^/M2O2.KI/,6YE5SZEF1S8L
M%>GDWK2JW&3O6.2HL<%=/NKN,8SS=GU[NZG._&@N&[SE93%<E'G*M<--7#33
M=+ =776;*4J]G[2LU<FH8^5-K5M\(U7R>FK?*%CXMZ1FVWO&:\#A%.2#2P
M       !BK^=?_6GX6_?,E_JCGS!7-@+YRYP UQQ#X:<.,=H72F;U9?H<09;
M]VG@Z,MZ>K2_4QFJWNJ9D:>\A]T3Q0\[NQ9)&M[U,-S^]F=(;[3/$'^8+/Y"
MRW5GM+'JV35"R^FN7:WO=G;7"6CL>G"4D^/=P*M]:^S<FW;%DZL:^V'84+>K
MILG'51>JWHQ:U7>CX=!]Q?WLSI#?:9X@_P P6?R#^]F=(;[3/$'^8+/Y#O\
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M[?\  ?#H/N+^]F=(;[3/$'^8+/Y!_>S.D-]IGB#_ #!9_(/W:P_Y5C_IZ?\
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M]#9'R\?[:!)/5-Z<QOFLG[&1ET@ JP6X
M  /*SRVWV+/&/[EW_P"^536!&S]\MM]BSQC^Y=_^^536!%BNIW^ Y/TI_95%
M9NNWTAB?1']M,'"]RG)PO<I+KY,A=\F9NGFFG\"^,OW6:9^AKIENF)%YII_
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ML/DL6K#T:CI[,\DDT\BNEE>Y[G.6Y %1V]2YR6G!=P !@R
M
M
M
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M.-G[426/<H7:>5C7:0O7CI'5JQ+XU<II=^G(^PFR+\7CXBJU_J7;QZBV-?\
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M:LN6FB??"O=33W9.:YO2JKVJJJJJO:KE7O5RKVJJ^E5W5?2 "22,
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M4^"WW,6/IS+&L"-G[Y$3[%/@M]S%CZ<RQ$/7'_ <7Z6OL;2:>I'^'Y?T3_\
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M@?LFKWWJ=7_3VC386E8NM?TL_H]/Z["UO4]Z&C])R/UQ  (T)3
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MQ&X;?RGQ%_\ $G5A[=E-^E/I/:/T[+^WL+Q]%O1FSOH.)]A6  :$WP
M/*#RX?V+/%[[GXOI*D>KYY0>7#^Q9XO?<_%])4C;]'_X?A?2L?[6!IND7H_.
M^B9/V,S6&IW(<G"=R')=!<D477)'*=Z&;-YIA_!+C3]TND?HC*F$RG>AFS>:
M8?P2XT_=+I'Z(RI'_6AZ&R/EX_VT"2>J;TYC?-9/V,C+I !5@MP
M                     >5GEMOL6>,?W+O_ -\JFL"-G[Y;;[%GC']R[_\
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M%1DX+A5#1-\(1U;X\9RDUHFD@ .3.R
M
M
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M'^^!#]#Y R@3%^\ZF^LQH?[X$/T/D#K.@OI? ^?7[,CC>L+T)M+Z-+]<3 P
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MZ$/UG.%OW Z4^A*9"G7-]YP?G;OV*R=>HW[_ +1^:Q_VK3ZC ! 18P
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MAZMQZ6?5V4IM^.B\"1.JW:KQ=L8\6](92GC3XO36:4J^')OM802\%)Z<S/U
M!58MX               >07E[/L2>,7\GZ8_KUI<UEALT_+V?8D\8OY/TQ_7
MK2YK+"R'4]Z-O^G6?V?&*N]=?I;'_P#3JO[3E@ $KODR('R9G&^:=?6XXM?=
M[C?ZMTC+#,3SS3KZW'%K[O<;_5ND9894CI]Z8SOG(?95ER^KGT)L[YF7VM@
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M/_2W;/6VI>W]TF<B=B;'[:4\Z4[>GM'-NR)-[FNY3#NA3%M07M?GS\9RD^7
MNST1Z.U[+P:<6*6^EOWS7\9?-)V2]B?DP7=",5Q>K8 '.G3
M           &*WYU]]:3A=]\]W]3]1F"F9UGG7WUI.%WWSW?U/U&8*9:+JL]
M$5?.W_:2*F=;OIJWYC'_ &&#A?1X]"G)PI(DN1&+Y&R6\W4^Q&X;?RGQ%_\
M$G5A[=GB)YNI]B-PV_E3B+_XDZL/;LIOTI])[1^G9?V]A>/HKZ,V=]!Q/L*P
M #0F^      !Y0>7#^Q9XO?<_%])4CU?/)_RXB[=%CB]]S\7TE2-OT?_ (?A
M?2L?[6!IND?H_.^B9/V,S6')W(<G"=QR707)%%UR1RG>AFS>:8?P2XT_=+I'
MZ(RIA,IWH9LWFF'\$N-/W2Z1^B,J1_UH>ALCY>/]M DGJF].8WS63]C(RZ0
M58+<                              'E9Y;;[%GC']R[_P#?*IK C9^^
M6V^Q9XQ_<N__ 'RJ:P(L5U._P')^E/[*HK-UV^D,3Z(_MI@X7N4Y.%[E)=?)
MD+ODS-T\TT_@7QE^ZS3/T-=,MTQ(O--/X%\9?NLTS]#73+=*E]87IC-^55]A
M47'ZM/0>S_F[/M[0 #C#N@        #Q0\XB^Q"XI?Y[PW_\4]%&M<3O7XC9
M1^<1?8A<4O\ />&__BGHHUKB=Z_$6/ZG_1MWTZW^SXI6#KM]*8OT&'V^0=@
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M26L*V]-=*8RW=.6]OR7G,  XL[H
M
M
M
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MPARDA 1_9OLNWK]!RC_::TV9<$D3QN=^L3U_/^4M_.ISS@%PY_4J_,=N=?\
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MTI)/P(MVQTMVEGZK+R[;(-Z]DFJZ?5[U6HUO3N<HMKQ.J-1.S;L.P!T!SN@
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M?I)4<149$3(XO'CN .D<7C\A-9'L=V1^/426,_. =6,^7\!+9'X_(=F1DQC
M#JQA+9'Z0R,EM9\OCY_8 <,9X\?-ZR2UH:STJ26M]( :TD-;Z0UGK*[6[]H
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M*X1BN27>]67#V1LC'P<>O%QJU756M$N;DWQE.;YRG)ZN4GQ;]6B  ->;(
M      &#!YV!]<[A/]PF9_K AG/F#!YV!]<[A/\ <)F?ZP(=_P!6/IC'^1D?
M86$<]:_H++^5C?VFHQ34[D.3A.Y#DM25$7)%&Q^YO_[COZ*FVSZ$/UG.%OW
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M[;'K^/.4OZM="]^R,-8^+C416BIHJJ7/X%<8]^KXZ:\7JWQ?$  \!L0
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M!3KG&4)PDM5*,EI)/U-<#1X^1.JR%M4G"RN49USCPE"<6G&2?BFE_P 3; ]
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MG07]+5!AUF8IYI9^_..7\3H+^EJ@X7K)]"YG_L?VBHD'JN].87^T?V6XS/
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M]B$H I07N0
M
M
M                                                    *+F[%8&&
M".4U3;M0K.;L=3(**IZ4[OP%-S=RLJ;=J=QU5OI0 C[;_"4G-)*MW*;OG_"
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M+FLL-FGY>S[$GC%_)^F/Z]:7-9860ZGO1M_TZS^SXQ5WKK]+8_\ Z=5_:<L
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MTUTY]N//_P"CF-_M(^Z?L?\ E$OT-W^6/N4;<_DU?](I_P 1Y2^;0_914?N
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M3TBLNJ+?#@K'V;;UX)+?U?J7#CP-G<BG(!3LNT
M     8K?G7WUI.%WWSW?U/U&8*9G6>=??6DX7??/=_4_49@IEHNJST15\[?]
MI(J9UN^FK?F,?]A@;@X7QX\=I(K9&+&XW0R$N@+YOMJ;CWPKT]Q2QO$[!:;I
MZALY^O'A[VF<ADK-5<#J'*:?D=)<@S-.*5+,F+?:8C8&=7',V-RO<QSE^Q_U
MIEK3[=>E_P#0K+?\Q''Y73[9--EE-N7&-E4Y5V1[+(>[.$G&4=8TN+TDFM4V
MO!M';8O5SMJZJNZK#WJK80MKEVV.MZ%D5*+T=R:UBT]&DUR:3X&)-N@W0RV?
MUIEK3[=>E_\ 0K+?\Q#]:9:T^W7I?_0K+?\ ,1^'W1]C?RV/Z')_R#]_N8;>
M_D/_ ,^-_G&)-N@W0RV?UIEK3[=>E_\ 0K+?\Q#]:9:T^W7I?_0K+?\ ,0^Z
M/L;^6Q_0Y/\ D#[F&WOY#_\ /C?YQB3;H-T,MG]:9:T^W7I?_0K+?\Q#]:9:
MT^W7I?\ T*RW_,0^Z/L;^6Q_0Y/^0/N8;>_D/_SXW^<8DVZ#<RV?UIEK3[=>
ME_\ 0K+?\Q'S#TS/-S=4\&^&FJ^)5[BII_/5=*T&7YL34TMD:%BZUUB&OU45
MN;-6HH7(LR.YGP2-5&JFVZH?K1U@;(MG"NO,C*=DXPA'L<A:RDU&*U=*2U;T
MU;2\3\<CJXVW57.VS"W:ZX2LG+M\=Z1A%RD]%<V]$F]$FWW&.*#A#D[),XDY
M3O0S9O-,/X)<:?NETC]$94PF4[T,V;S3#^"7&G[I=(_1&5(_ZT/0V1\O'^V@
M21U3>G,;YK)^QD9=( *L%N                              #RL\MM]B
MSQC^Y=_^^536!&S]\MM]BSQC^Y=_^^536!%BNIW^ Y/TI_95%9NNWTAB?1']
MM,'"]RG)PO<I+KY,A=\F9NGFFG\"^,OW6:9^AKIENF)%YII_ OC+]UFF?H:Z
M9;I4OK"],9ORJOL*BX_5IZ#V?\W9]O:  <8=T         >*'G$7V(7%+_/>
M&_\ XIZ*-:XG>OQ&RC\XB^Q"XI?Y[PW_ /%/11K7$[U^(L?U/^C;OIUO]GQ2
ML'7;Z4Q?H,/M\@[  EDAXV$'FP7V-UC[X.I_]GC3(P,<_P V"^QNL??!U/\
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M*H[GJY"G6O5G]GOZ]N%D\+NQ53WT<C5[%5/4I>"D[6G#P+WIZ\5R8 !@R
M
M
M
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MBW+PKL>;KOIMIL7.%M<JY?DFDSN #TGF
M                  .'+LFZ]B)WKV?CV/WS@CT6.)'$FVRGH/1&HM42O_\
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M #6_*5$3TKW!$]*G9$W[?0 $3?X$[BH#LUNX!PB;E9$V")L<F&@  9
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MGW\^8 !^1^H      ,&#SL#ZYW"?[A,S_6!#.?,&#SL#ZYW"?[A,S_6!#O\
MJQ],8_R,C["PCGK7]!9?RL;^TU&*:G<AR<)W(<EJ2HBY(HV/W-__ ''?T5-M
MGT(?K.<+?N!TI]"4S4F6/W-__<=_14VV?0A^LYPM^X'2GT)3(4ZYOO.#\[=^
MQ63KU&_?]H_-8_[5I]1@ @(L8         8Q?G2O .34'!?2FO:L/66>'>LH
MX[TGIAT]K"LW$W7-V17*OU>JZ7YD3WJ0I+(]41B*8$2&W*Z67 &AQ2X;:UX?
MY%K%KZJT]D<4U[]D2"W/7?[AM-?RN6-U:XV"9LK$ZR/DYHU1R(IJ6M::-R6G
M,UF-.YBN^IE\!E<CA,I5D8Z.2MD<5<FHW89&/1',?'8@D:K7(BHJ;*FZ%C.J
M+:RMPK<1ORL:URBO]5=K):+U6JQM\O*BN_4K%US['=6?3F17D9=6Y)Z+[]0E
M'B_74ZTM=7Y#XZ+1?S8 )<(<,KSS6SI@0X'6&L.#65LI'4UHQFJ],MDD1L::
MCQ%1E/+UHFN>UG7Y/"PTI5Y6OED^HL36MY6O5,Y/<T\_#/B3G-&:BPFK-,WY
M<7J#3F3J9C$7XE=S5[U*5LL2O:US>NKR\JPVZSEZJW5EGK3(Z*5[5VE/DZ.G
M;IOI"<-<3KC!R5X,FUD6/U=@62\UG3NI(86.O496.VE6K*YWNK%V7MY;="6&
M1J\Z2M97?K7Z-RJR%M"N+=61NPNT7"NZ,5&+?@K8):/X\9:O62ULMU/=*(W8
MKV;;+2[&WIT)O[YCRDY-+Q=4V]5\24=.$6?>  (?)J         !CL^<E]+^
M#0?!!=!4K#$U%Q5MKAXX&R-ZZ'36.?!<S]YT?8_J7[T\:V1KF[3WV)L]B2-/
M>OB;Q+P>C=/YC56ILE5P^ P&/LY3+9*Y(D5>G2JQK)++(]VR;[(C8V)N^21S
M8V(Y[FHNKE\ICTY,GT@^+>=UY96Q!A(T9A-&XJ9SML3I>A)*ZG'U3MDBM9":
M:QEL@O+SK;NOB<J1P0QQR+U;=')9N="^<7[GQ)1MF].$K4]:JUXO>6_+\6+3
MTWD1EUI=*(X.SYT0E^^<V,J813\J%4EI=:US2W6X1?QY)KS7I\!HAR 6C*F
MR??-9^!;\QQ@UAKV:-5J:-TB[%U7NC58URFIKD+7*R3;9)Z]#&S)R[[]5==O
MWH8P*KMW]QL</-VNBM+PZZ.^&SF2J.JYWB=;EUO<9(U6S,PUG_!M*,?VKNVQ
M@HJ^6C[&N8W*]2]$=&I'O69M58^RKH)Z3R91QX>R7E6</#LXRBWW.4>]HD?J
MJV4\K;%,VM88D9Y,WH]$XK<J6O+5V34DN]0EP>C/>$ %62W(
M  !Y!>7L^Q)XQ?R?IC^O6ES66&S3\O9]B3QB_D_3']>M+FLL+(=3WHV_Z=9_
M9\8J[UU^EL?_ -.J_M.6  2N^3(@?)F<;YIU];CBU]WN-_JW2,L,Q//-.OK<
M<6ON]QO]6Z1EAE2.GWIC.^<A]E67+ZN?0FSOF9?:V  ''G;
M  '\WK+_ *'RO\FWO]UE-.)BOWK6_B(?]FTW'>LO^A\K_)M[_=933B8K]ZUO
MXB'_ &;2=^I;S=I>W#_5E$ =>?+9G^V?_C$\ $XE?C(C\V!^R:O?>IU?]/:-
M-A::]+S8'[)J]]ZG5_T]HTV%I6+K7]+/Z/3^NPM;U/>AH_2<C]<0 "-"4P
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M>DT-J8%5Z:[:"563#OC=%:2>GQ;/OD'\66C\J,DNP .6.N
M          ,5OSK[ZTG"[[Y[OZGZC,%,SK/.OOK2<+OOGN_J?J,P4RT759Z(
MJ^=O^TD5,ZW?35OS&/\ L,'"^CQZ%.3A?1X]"DB3Y$8ODS9+>;J?8C<-OY3X
MB_\ B3JP]NSQ$\W4^Q&X;?RGQ%_\2=6'MV4WZ4^D]H_3LO[>PO'T6]&;.^@X
MGV%8 !H3?       \H/+A_8L\7ON?B^DJ1ZOGE!Y</[%GB]]S\7TE2-OT?\
MX?A?2L?[6!IND7H_.^B9/V,S6&IW(<G"=R')=!<D477)'*=Z&;-YIA_!+C3]
MTND?HC*F$RG>AFS>:8?P2XT_=+I'Z(RI'_6AZ&R/EX_VT"2>J;TYC?-9/V,C
M+I !5@MP                              >5GEMOL6>,?W+O_P!\JFL"
M-G[Y;;[%GC']R[_]\JFL"+%=3O\  <GZ4_LJBLW7;Z0Q/HC^VF#A>Y3DX7N4
MEU\F0N^3,W3S33^!?&7[K-,_0UTRW3$B\TT_@7QE^ZS3/T-=,MTJ7UA>F,WY
M57V%1<?JT]![/^;L^WM  .,.Z         /%#SB+[$+BE_GO#?\ \4]%&M<3
MO7XC91^<1?8A<4O\]X;_ /BGHHUKB=Z_$6/ZG_1MWTZW^SXI6#KM]*8OT&'V
M^0=@ 2R0\;"#S8+[&ZQ]\'4_^SQID8&.?YL%]C=8^^#J?_9XTR,"GW33TMM#
MZ39^LNIT$]#;-^B5?L@ ','6'\3Q%X<X/5N"RNF=2XRIF<#G*4^.RN+O1)-5
MNT[+%9+#*Q?6B[M>U6OC>C9(W,>UKDUK/E<O)59SHV:Q:^FZUE^&>I+EA='Y
M^6-5EJ.V?873.:E;S1_5:A UZ0656/ZKTZ[[T<,4D=J"'9N'X7TD>CCI'BQH
MO-Z"UOB8,OI[.UNJL02M3K:UB)R34LE0G_=*>2QUID5NC<A<R6O/$QS7;;HO
M8]#>EMFRLC7RIXUKBLBI/FEP5D->"LAS7)37D2:U4H\1TXZ%U;8QMWR:\JI-
MXUS7)\W59IQ=4VEKS<'I.*;3C+41(IR>@?E(/)Y:MZ.?$"WI3.Q6+VGKRR7=
M&:K;"J4=0X=SW<K72L:D,&:QZI[GS&,7DFKR)';CC?CKE&U8\_"UN%FU9%5=
M],U959%2A./)I_UIKDT]'%III--%/\S"NQK;*+X2KNJDX3A):-23_(T^<9+5
M2333:9PJ'O!Y/_RO-_1_";B'P(X@VI[VC\YHO4-'068?UDUK2V9M49F18&=$
M1RR:=R;WN=6DYD?A[J*Q&RTKJ^X/" XV\>/'Q'FVKLBC,J[*Z"DE.-D'RE"R
M#UC.$M.$D^'A*+<9:Q;1Z=D[7OP;NVQY[LG&=<T]=RRN:W9USCKY46N*7P9*
M,HM2BF=(4V8U%[T:U%^1"H ;,UJ!F*>:6?OSCE_$Z"_I:H,.LS%/-+/WYQR_
MB=!?TM4'"]9/H7,_]C^T5$@=5WIS"_VC^RW&9X "J)<       UU'G)7 Q=)
M])&YG(H.JHZ_TUB-1PO1/>RWJB283*;O3L65):$+W-_;,CFA5?>O8J^ QGU^
M<[=$=^LN$6#XEXRJLV8X692P^^L356232&I?<=7,.<C4_9$QV1HX7(H^55;5
MJ19)8D1UA_/@*%L.KO:BRME8SUUG1'W-8N].KA#\M3KEX<>!3OK*V0\3;&5Y
M.E>0UE5/31-6\;/R7*Q?D?>#JYB*BHJ=BILOP+W_ #'8'<'!FR7\@)TPX^*W
M1]P-"[/UFI^&TB:%U Q[T=-/7Q\$<VG<LJ*YTKX\C@Y:L4L\B-ZW*T,LQF[8
M4<[VY-8+Y('RBTW1TXJ5LWDY+<F@M21PX37-*LV2=T./69'5<_!4B:^6Q;P,
MKY+'4UV+9LTY+E:%LDLD43MF_IO4N/S./HY;$W:N2Q>2JU[V/R%&>*S3NTK4
M;9JUJK9A<^*>">)[)(I8W.8]CD<U512JO6'T<E@9]DXQTQLJ4KJ9+S5*3UMJ
M]3A-MI?$E'UEO.K7I1#:&SZZY2_?.)&--\6_*<8K2JWQ:G!)-_A(S7@W>P <
M"2(
M
M
M                                                "FYOI0J QR!'
M.JM^4K.;Z4*9G4%)>WV*=%3UE9S=SI[%^)09*"IM\'J.BH2%38IJWTH#!%<T
MI*W<F;?$OJ*3F $%S/E([V%P5/0I2<SXT +:Z/QZ/S$=T?CQ^+XRYN81W,]7
MCX "V/B(SF%V<SQX_"1W,]?C\2@%I?%X]'QD5T9>'1^HCK& 6=T9'=&7=T7Z
M/R$9T0!:7P^PBNB+RZ/]"E!T8!97Q>/21W1_&7I\)%?$ 6=T7Q>Q>XCNA^%/
M@[OF_(7ET106, LSHUV3TH45B^7QZ_Q%X='\7P%!T'Q_,OCY "RV*C)8Y(I8
MV2Q2-5DL4C6OCD8[L<R2-R*U[7)V.:Y%:J=BHIYP]([R2W 7B>Z6SGM"TL9E
MI4=_Y=TM(_3F51[D7:61^/1E.XL>ZK''D:=RNBJKEA7<],'1?#[$7Q^,I*SU
MH>O#VA?CS4Z+K:9KX54Y0?L;BUJO%/@SQYNSZ,F#KR*:KZW\"VN-D?;I)-)K
MN:XKN,/_ (]^;+9:JDUKACQ&ARD:<SH<-K2@RE>V_P 6),WB$]PV9%[.:27$
M8R-.U49W(>*G'CR7_'CARZ=^H.'.=LT(%=OE].P+J/&.8Q-W3++B4L6((&I^
MVFN5:T:+_C;;*;*CJD_-^DIJSX_'PD@[+ZU=ITZ*[LLJ"_"15=FGJG5NK7US
MA-^.K(VVOU/[*R-94=MAS?'WF;G7KZZ[=_1>J$H)=VBX&I@9,URJB.:JHJM<
MB*FZ.:NSD<G>BHJ*BHJ(J*BHJ;H5#9_\;.ACPHXC<S];\/=*:BLN[/JC=Q%:
M/+(BHC=FYBJROE4:B(FS4N<J<J>]W0\D^,OFY?!//=?/I?(ZIT39DYGQQT[T
M>6QS9%1>5ON3*1S2,@3LYHXK#9.SWLJ*I(6S^M_ LT611?CR[VMVZM?SH[D_
M_B(WVEU+;0JU>-D8^3%<E+>HL?\ -EVD/RV_U\\&P&1UQ?\ -J.*^,5\VB]9
MZ-U; WF=[FRJ9#2N3<G9R1PHL.:QD\BKOS/L9''1[)S)LJ]6GF;Q-\E'TBM(
M)._,<)]2R5ZZ.=)<PGU/U+22-O=)[IT_=R4;6JB;HDBL>FZ(]C7;M3M\'I=L
MS)T[+.QFWRC.Q53_ #+=R?\ N^'B<#G]#-K8K]^V?E)=\JZW?!:>,Z>T@OKD
MM>.G)GGN#^AU/I#+X23J<UB<IAY=^5(\KC[F.>JIZ$;<AA55[%[$W[C^=1R*
MFZ*BIZT7L.AC)-)III\FGJG[&CG)Q<7NR3BUS36C7U/B<@ ^CYU &X
M         W  &X U &Y-Q&-LY"9*V/K6;]E>U*]&O-<G5-T3=(:S))%3=43L
M;WJB>DPVDM7P2YM\C*6K22U;X)+BWKRT1"!]I<,O)Q\=]9-9)IWA3K&Y ]41
MMJUC?J1217)[WGN9F3'UH]T[4ZR5O8BJNR(JIZ4<(_-Q^.N;=!)JC):+T-5>
MB+/%9RLFI,Q7W3M1*6!ADQ$SF_XW+J-C57;D<Y.TT.=TIV=C:]MFXT6N<5;&
M<^6OWN#E-_F^HZ# Z)[4R6E1@94T]&IRIG77H^"]\L4*_7YW+CRXG@*='RM:
MF[G-:GK<J(GSF:=P<\VFX98Q(9M;:RU1JRPU/V>MCFU=-XR14VV6)L'NS)1;
MKONU]^5.79$5%W5?6S@CY-G@9P]=#-IGAEI6*_ B=7ELGC8L[EF/3;]EBOYA
MMV:K,O:G64_<R\JN8FS7O1>*VAUN;.JU5$+\F2Y-155;_G6>6OT3_7IWFS>I
MG:=NCR+,?%B]-4YNZQ+O\FM=FVN7WW3U^.OLX$="/BWQ,6)VB.'^I<W4FV5F
M5;CY*6$5NZ<SFYG()5QLO5I[Y[*]B:5&[*D:JK4=[5<!O-K>(F86&QQ!UE@M
M'57;.DHX:O)J7+\J[+RH]TF.QL+E3WJN=8F6-_=%*B;.S2FQ;(C41$:B;(B=
MB(B=R(B=B;>A-MMMMO45NJ(^VGUM;0MU6/"K%CW-+MK?SK%V?Y*D2-LCJ:V9
M1H\F=^9-::J4G35KZH5-3T]4K9(\<NCKY"[H_: 6"U8T]=UWEX%Y_JGKJW%E
M&-D3M18<-2K8[!0I&_WT#W8Z6U$C6<]N5[>=WKC@=.4,75BHXRC4QU&!$;#4
MHUX:E:)$1$3D@@9'$WL1$549NNW:JE_:Q/05&Q^OQX^(CS:&ULG+EOY-]M\N
M[M)RDEKW1BWNQ7JBDO429L[9&+APW,7'IHCWJJN,7+3ODTM9/UR;?K(Z1>LJ
MM9ZD_%X^$EL@]:?E*[8D^'QZ$3])KS8D1L._CL\=I(;"GP? 2D85VQ>/2 1F
ML]A7;%X7\A);%X[R4R'QZ?S $5L?CTDED)*;%X0K-C^( HMC3]!(;'^CL*S8
MO'I)#(O'I *#(R4R+Q^4K-CV)#(_D *38_C*[(_65V1IZ$*S6>/'X #HQOQ>
M/G^(KMC]7C\Q4:PD-9\@!38PD-9\9V8SU%9K=@#AK/654;N=FL]96VV[_D .
MK6_I*B)O\ 1N_?\ (540 ZHFQ4VV[^_U'/=V)WG*-]8,A&^E3N#NUH,'#6[E
M8 QS]@  ,@                        &+]YU-]9C0_P!\"'Z'R!E F+]Y
MU-]9C0_WP(?H?('6=!?2^!\^OV9'&]87H3:7T:7ZXF!@ "WA3$&S]\B)]BGP
M6^YBQ].98U@1L_?(B?8I\%ON8L?3F6(AZX_X#B_2U]C:33U(_P /R_HG_P#-
M6>J8 *ZEEP   #^,UQQ%P&F:,^4U'F\3@<=5B=/8O9?(5<=4AA9^WDDGMRQ1
ML8W_ !G*[9#%O\IKYR'I/"8S)Z.X VOU4:FLLL4K6OO<\L6FL&CTZF23 K8;
M#-G\BU%>ZO?@C;AH',BG@M9+G5L6ZV+T>R]H6*O&IE/BE*S1JJM/OLL?DQ27
M'37>?**;X&BVYTDPMG5.W*OA#1-QK33ML?Q:ZUY4FWPUTW5SDTN)Y*><K=*;
M':[XZU-(8>Q#;H\+<+)@;UB%>9OZI<K89?S=/K$562+C(X<?3FY5W@NI>J2(
MV6N]#'=)5_(6+=BQ;MSSVK=N>:W;M697SV+5JS*^:Q9L32*Z2:>>:1\LTLCG
M/DD>Y[U<Y>98I;C86RX86)1BP>]&F"CO/AO2?E3GIW;\W*6G=KH4RV[M>>?F
M9&98MV618Y[J^!%)1KAKW[E<8QU[]-01K2[1R+Z$8Y5^)J^/623]_P"BCP#M
M\4^)NA.'=..21^K]48G$6EB<C7U\3+99+G;R*JILF.PL.0O.1%YE2ORL1SW-
M0V&1=&N$K)M1A7%SG)\E&"<I/ZDFS6TT2MG"J"<IVSA7"*YRE.2C%+Q;;2T-
MJ-T0-.R8CA-POQ4T;8IL=P\T72GC:U&(V>MIS&PSIRIW+UK'J[TJ[=555[3Z
M+*<,+(V,CC8V..-K6,8QJ-8QC41K6,:U$:UK6HB-:B(B(B(B;%0I#=9OSG/X
MTI2_.;?_ !+[TU[D(0^+&,?S4E_P  /S/U      !@P>=@?7.X3_ '"9G^L"
M&<^8,'G8'USN$_W"9G^L"'?]6/IC'^1D?86$<]:_H++^5C?VFHQ34[D.3A.Y
M#DM25$7)%&Q^YO\ ^X[^BIML^A#]9SA;]P.E/H2F:DRQ^YO_ .X[^BIML^A#
M]9SA;]P.E/H2F0IUS?><'YV[]BLG7J-^_P"T?FL?]JT^HP 0$6,
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M2=D-7X0G."BWX;^XO6B.<3KKV=.W<MQ\JFMO17-5S2X\YPA)R2\=SM'ZC8_
M^-^@UTY]"=(#0];7&AKDJP),M#-86^UD.9TYF8XXY9\5E:S'R-;(D<D<U6U"
M^6I?J216JLSV.5&?9!%N3C64V3JMA*NRN3C.$EI*,ES33_[:XK@2]BY5=U<+
M:IQLJLBIPG%ZQE%\4T_^VN3X@ 'X'[@
M
M
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MORG*(5-MN_Y #AK=SGO39#E$W^#T;'=$ ")L<A$*S6[?"&P=6L]94 ,   R
M                           8OWG4WUF-#_? A^A\@90)B_>=3?68T/\
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M\^Y*OP</S5_R/KW5;^%L_23_ .9^D_W9]9_Y8:K_ -(\S_;1_=GUG_EAJO\
MTCS/]M/S8#W)5^#A^:O^0]U6_A;/TD_^9^D_W9]9_P"6&J_](\S_ &T?W9]9
M_P"6&J_](\S_ &T_-@/<E7X.'YJ_Y#W5;^%L_23_ .9^D_W9]9_Y8:K_ -(\
MS_;3[X\EAQ4U5<Z2'!*K<U1J2Y5GXBZ?CGK6L[E;%>:-;"JK)H)K;XI6+LF[
M)&N:NW<>7QZ#>2>^R7X&_?'T]_O#C5;=QJU@YC5<$UB9#3W5P?8S]1N.CV3;
M^Z&#[Y9H\S%33G)IIWUIIK7DUP9M240Y *:%X0         6O-X6GDJ=K'Y"
MK7O4+U>:I=I6X8[%6W5L1NAGKV()6NCF@FB>Z.6*1KF/8Y6N:J+L70&4].*X
M-&&M>#6J?!HUTWEIO(TY#@'EIM<Z&JW\EP?S-]WOE1;4N@;]ZP[W-A,G*W>=
MV$DD>E3!Y>RUW*ON;%Y*W+D9JLV0\!D<GCQZC<::HTOCLWCKV(S%&ID\5DZL
M]'(XZ_7BM4KM.S&L5BM:KS-?%-!-&YS)(WM5KFKLJ&$'Y5?S=/.Z7LY37_ 6
MI+GM+.ZV]E.'J/5^?P':KYI=,N?O]6L2U%5_U-?(W*T416U?JC J1U+ ]!^L
MB%L88FT)J%RTC7DS>D+ER4;7P4+%\=M1L[]V?&=;>G_5=91.S-V96[*):RMQ
M8)NRE\Y2I2U<ZGS=<5OUM^2I0X0Q205[E2:O--6L0S5[-:5]>S7L1206*\\3
ME9+!/!*UDL,T3T5LD4C6O8Y%:YJ*BHE F5,A('"^/'C\1R P=(F]7(V:/>.9
MBHK)HU6.5CD5%1S)&;/:J;;[M5%[/B/U+%\<-<46\E'6NL*3.5K>2GJC.UF<
MC-^5O+#?8WE;NO*W;9JJJIMNJ'Y@#\[*(2\Z*DO"24E_6F?I5;.MZPG.#\82
M<7^6+7K_ "L_2LKQIUI?[+^LM6WDY49M=U-F[:<K7*]K?\(O2>]:YRN:WN:Y
M5<G:JJOYCU3>=7\J*]W:YZIN]R[;>^<OOG=B;(JJO9V=B=A4 KHA!:1BHKPB
ME%?D21BVR4WK.<YOQE)R?=WMM]R_(CA#D _4^ USFN:]CG,>QS7LD8Y6O8]B
MHYCV.3M:]KD1S')LK7-14[4W79C^1(Z?T?'C@WCYLI;BDUUH=:FF-9P=8BV)
MIHJW_DC/.B5RRI7SU*!\C9W[MDR%/*0-DDDJ3<NLWW/='S>?B?Q!TWT@L;'H
MS3V9U+@L_2^H?$"IBXT=4Q^"GDZZEG<A-/+7H0/PUV/W166Q8CGEKR9&O3;,
M^:2"6/\ K%V%7F;.LGY,;L52OJG)J*X:=I6W+1:617#BO?(U\=.#D+JRZ13P
M=J55I2E3FN-%U<8N3U>O96I+5ZU2;<M$_>W9PUT:V0 .$4Y*KEO@
M#%;\Z^^M)PN^^>[^I^HS!3,ZSSK[ZTG"[[Y[OZGZC,%,M%U6>B*OG;_M)%3.
MMWTU;\QC_L,'"^CQZ%.3A?1X]"DB3Y$8ODS9+>;J?8C<-OY3XB_^).K#V[/$
M3S=3[$;AM_*?$7_Q)U8>W93?I3Z3VC].R_M["\?1;T9L[Z#B?85@ &A-\
M   #R@\N']BSQ>^Y^+Z2I'J^>4'EP_L6>+WW/Q?25(V_1_\ A^%]*Q_M8&FZ
M1>C\[Z)D_8S-8:G<AR<)W(<ET%R11=<D<IWH9LWFF'\$N-/W2Z1^B,J83*=Z
M&;-YIA_!+C3]TND?HC*D?]:'H;(^7C_;0))ZIO3F-\UD_8R,ND %6"W
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MMN%.4U5KKY*G7"<HQ?+3>UEHN3E)OF  1(3*
M
M
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MB1>Q"?U7L^<[I#[/FW ("1J5$A\?H)Z1>PJ)![ " D7A$*B1>%+@D)42- "
MV%2LV$FI'["HD?Z$ (C82JD9*;%["LD0!$2,JMB\*3&Q>$*K8@"(V(D,B\>@
MDMC]GC\!6;& 1FQE=L?L)#6>S?Q\JE9&>/S?E ([8T\>-BNV,K)'ZBLD8!1:
MWV?!X[BJC"NV/XBJUGL *36?(5FL]151A41 "FUFQ51NY41GQE1$3T_(@!T:
MS])43V=OM]!V1-_8GJ.Z)Z@#JC?2O>=T3<[<J)W_ "'/?\ !U^ J(TY1-CD
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MO"U&105Z\+610Q1L1&LCC:UK6HB(B(74 CMO7B^9):6G!+1+@DNX  P9
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MD=7/07*V/;ESR+*+%?"J,>QE-M.N4V][?A#GO+334_J@ 1D2L
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MN:)BZ.]"MG;,XXU"=NFCR+7VES7>E)K2"??&N,(OO3.$0Y .7.L
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MDWP)^Z)[)LP-G8N);*$K**W"4JVW!MSE+R7)1>FC7-(  T)T(
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M:S@_GC,_VT?W@OHK?:S@_GC,_P!M'W8=G?@,O\RK_.'W%-I_RC"_/N_R#6?
MV8/]X+Z*WVLX/YXS/]M']X+Z*WVLX/YXS/\ ;1]V'9WX#+_,J_SA]Q3:?\HP
MOS[O\@UGP-F#_>"^BM]K.#^>,S_;1_>"^BM]K.#^>,S_ &T?=AV=^ R_S*O\
MX?<4VG_*,+\^[_(-9\>@WDGOLE^!OWQ]/?[PXSN_[P7T5OM9P?SQF?[:?W_"
MKR+G1RT3J7!ZNTUH"+'9_3F2K9;#WF97*R.JWZC^L@F2.6V^*3E<G[21KF.3
ML5%13Q;2ZU\"[&R*8TY2E;1;5%N%6BE97**;TM;T3?'1-Z=Q[]E]3VT:,K&O
ME?AN-.13;)1G;O.-=L9M+6E+5J/#5I:GJ@#A%.2OI8\            '&QR
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M=&UKR;+&;%PY8V'B8\VG.C&HIFXZN+E77&$G%M)Z-IZ:I/3N0 !K#9@
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MGH^6A+W1SH+LW9FDL>C>NTXY%S5EW+1[LM%&O5-IJJ,$TVGKJ=>5#L <J=@
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M&,=7NPC&.KTU8 &A.B
M
M
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M^KO]8!PC?7V'*+Z$.R-]9VV .J,.X*B,]?R '5K=RJB;'(,   R
M
M
M
M
M
M
M
M
M
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M)L<G9&[@'4[M:=T:B'8QJ#A$V.0#(
M
M
M
M
M
M
M
M
M
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MLB;')V1J@'4[(W<J(W8[&-0=4:AV &GB  #(
M
M
M
M
M
M
M
M
M
M
M   !PJ'( *:L.BHJ%<&$".<*FY75J*=.0R"AU8[?A*JIL< %'L]J?@.>7U+N
M5-CJK "DJ>M#JK4*VRA?:GS@%#EV[E.JHOJ3Q\96[/TG/)\ !'[/:-O:5U13
MJJ)Z@"@L7L^0Z]7\)7Y$'*OK (W(<<BDE47V*<;?^Z 1N5?4=50E*B>WY#CL
M\( 1>5/4<<B>HF<OM0<OM3Y0"%R(.1"9R? HZOV?@ U(?(@Y$)?5>SYSCJ_9
M^$#0B\B#D0E=5[#GJO9\X,:$3D0<B$SJ_8.K]B?,#.I$Y$]0Y4]1,Y?:GRCE
M]J $5$]2'/*OJ)&R>OQ\QRB)[0"AR*<]7[2OM[/E.R(OJ1 "@D?PG9(O9\I5
MV7UA& '3E]J#L]JE3E3U'9$ *2)[/PG;9?65>11M[0"GR(=D0J(GJ3Y3GWWP
M '1&>OL'9\/X#NC#N 4TW]"#D]94 !PC40Y._(IV1B %-$W.Z,*@,,'"-1#D
M R
M
M
M
M
M
M
M
M
M
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M4ZOVG9&H8U!21J^H[(PJ@<?^_P#M?\0=.1#ML<@R
M
M
M
M
M
M
M
M
M
M
M                                              #C8XY4]1V !TY$
M..K*@,+4%'E4XV7U%<&01P2#C8 H K\J>HXY$]1C7_O_ /P%$%7D0<B#7_O1
M@I'&R>HK<B''5^T:_P#>C!2V3U#8J]7[3GD&O_>C!2!5Y$'(@U_[T8*0*W(G
MJ'*GJ&H*(*^WL.0"ALOJ.>5?45@9!2Y#GD*@,/4'7D0YV3U'("  !D
M
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MN6LX16B<HKGKQ/N( '/G2@
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MA5.Z=M:UH483A#=C8]-^3<TTX*4-$_+UT3]F@ <L=8
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M$56EJE9RL;U6G9J4.?E<-'[T  Y0[
M \(_* ^7JX=\ .(D_#?):5U'JK,4</B\IE;&#M8N&MC)\NV:Q5Q=AMV9DWNW
MZG-I9-Z(U(TJY*FK7.<YZ-^(Y/.O^&2-5?[E>O5V151/JA@.U43N_?/I[CJ<
M3H3M6^N%U6'9.NR*G7+>K2E&2UC)*4T]&N*U7+B<?F=/MCX]ME%V=7"VJ;A9
M#=M>[.+TE%N-;CJGP>CX/AS1E< _/.$G$[$:VTMIS6. L);PFJ<'B]0XFRG_
M *;'9BE#?IO5/\5RP3LYV+VL<BM5$5%0_0SF)P<6XR34HMQDGP::>C37<T^#
M.NA-22E%IQDDXM<4TUJFGWIKB@ #Y/H             $/(Y"O4KSVK<\-:K
M6ADGLV;$K(8*\$+%DEFFFD<V.***-KGR2/<UC&-5SE1$50@V3!N8['33\Y"X
M+<//=F(X?/?Q8U+"Q[&RX*;J-'5K*<R-9/J9['19%K>5KGOP4.2K<K^1+:3,
MDA9\=^10\JEQ@Z0_26U+6UQFH*VE:7"/564Q&BL)6CIZ?QUZ'6O#NI6O2<R2
M7\IE(:5ZW62_D;4W5LM6TI5Z,5J6%>MKZ$[0]R79MM/N>BFMV:W:PLL2[H5Z
M;W'5>5-1CIR;>B?'RZ=;.>93@4WK(R+K.STHTG76TG)]I:GN:I1:W8N4M=$U
M%<5EU@X0Y.2.P                                   W  /'WIR^6\X
M&<#WW<1<SR:SUK362*31VD)(<C<I68W<KX,[DVN7%8&6-R;25;UGZIMW:Y,>
MZ-W6)X!]'ORZ?&#CKTF.$NF()J^A.'>0U>D%G2N#Y9;>9K-QV0FC;J'.SQ>[
M++4DAC>M''ICZ*KNRS'=1K'IUFS>A6T,FFS)[%TX]=5ESMNU@IQK@YZ51T<Y
MN26D6H[FO.:..VGT[V;C7U8O;J[)MNKH5-&ECA*R<8)VRU4*U'>U<7+?TY0;
M,WX ')G8@   XW.3%,\KEYPE>X7ZORO"_@YC\-E=2:>E;2U3JO-PS7\3B,LC
M4=9PF,Q\$]1N0R./:]L61M36?<M&_P!91=!/8J6X6;C8FPLG:%W88L-^>F])
MM[L(032<IR?):M+O;;T2;X&DV]TAQ=FT>Z,NS<AO*$4DY3G-IM0A%<6]$WW)
M):MI&5F# QZ)GG/O%7#9^E!Q>QF"U=I*Q.R/(WL'B4PNI,9#)(G67*T=>P[&
MY-E9B[I0?4J32M1R-MJ]6M7.@T#KK$:HP>'U+@+\&4P6H,70S>&R597+7OXO
M*58KM"Y"KFM=U=FK-%,SG:UZ-<B/:UVZ)Z^D/17,V9*"R81W;-=RRN6_7)KF
MM=(M27/=E&+:XI-<3Q]&NE^#M6,Y8DY;U6G:561W+(*7)Z:M2B]&MZ$I+5:-
MI\#^N !SATX                               ,5.[YUGPR@GG@7A=KM
MRP32P*YN0P.SEBD=&KF[V$795:JIOV[+ZS<;)V!F9W:>Y*)7=EN]INN"W=_>
MW==Z4>>Y+EKR-'MKI+@[.[/W;D1H[;?[/>C.6_V>[OZ;D9>;OQUUTYK0RK 8
MI7ZZ_P"&7VK->?\ S^ _M(_77_#+[5FO/_G\!_:3<_<_VQ_(;/SZO\PT7W2M
MA_Z0K_1W_P"496H,4K]=?\,OM6:\_P#G\!_:1^NO^&7VK->?_/X#^TC[G^V/
MY#9^?5_F#[I6P_\ 2%?Z._\ RC*U!CP]#CSB/07&7B;I+ACB>'^K\/DM76\A
M4JY+)7,/+2JNQ^$R>;D?8CK3/G<V2#%RPL2-JKULD:NV:CE/L;RFWE6M,=&%
MFC)-1Z6SNI?U9OSL=-,)8H0+37!-Q3YUL^[I(T>DR96/JNK553JI.9$W::VW
MHMM"&35ASQIK)N@[*ZMZ&]*"WVY)J6ZDE7/G)/R>7%&UIZ7;-LQ+<Z&5!XE,
MU7;=NV;L)MPBHM."DVW9!<(OSEZ]/5@&.IT3/./>&7%7B)I?AXS1NJ=+6=5W
MGXNCF<S;Q,F.AR#JT\M&M.E29\R.R%F*.A7<B<J6+$76;,YE3(J0\>U=C96%
M.->53*F<H[\8RW7K'5QU3BVN::YZH]VQ]NXFT*Y6X=\;ZX3[.4HJ2W9I*6C4
MHQERDGRT>O!\SD &L-L <*>$O3_\O=PYX!<0K'#C(:9U#JW,X_%X[(Y>; VL
M9%7Q-C*1OM5<5;2[+')[N7'+4R3V,16-J9"F[FYY'-9L=F;)R<VSL<6J5UBB
MYN,=%I&+2<FY-))-I<7S:7-FLVMMG%P:NWR[HT5.:@IR4GK.2;44HJ4FVHM\
M%R3?)'NV#QM\FIY9;2728U)J/3>G='ZCTW8TW@X,Y8L9JSC9HK$-B^R@V&!M
M*61[9&O?SN<_9O*FR;KW>R*'QM'9M^);*C(K=5L5%N#<6TI+>7FMKBFGS/O9
M>U<?-ICD8MJNIDY*,XJ23<6XR6DE%\&FN1R #PFP
M
M
M
M
M
M
M
M             !B_>=3?68T/]\"'Z'R!E F+]YU-]9C0_P!\"'Z'R!UG07TO
M@?/K]F1QO6%Z$VE]&E^N)@8&Q#\V6^Q@I?=WK+_>:AKO#8A^;+?8P4ON[UE_
MO-0FKK<]%P^ET_9WD%=3'IBSZ#=]MCF0: "M):<
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M4[ZN?36S_GG]E,V H *AES@                                 <'(
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M7]!,S9EN1E9FY"=M2IKIA)3:CO1G*<Y1\E/6,5%1<N<FVN!4 !$Q,@
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M1],7_-T?91)3ZIO0F/\ .9'VTP "/"20
M
M
M
M
M
M
M
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MXN<M$ZUJ]$]%KQ)TQ.MO95UM5,%E;]UM=4-ZE);]DXPCJ]_@MZ2U?<N)G.
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MYS(^VF  1X22
M
M
M
M
M
M
M                                             #%^\ZF^LQH?[X$/
MT/D#*!,7[SJ;ZS&A_O@0_0^0.LZ"^E\#Y]?LR.-ZPO0FTOHTOUQ,# V(?FRW
MV,%+[N]9?[S4-=X;$/S9;[&"E]W>LO\ >:A-76YZ+A]+I^SO(*ZF/3%GT&[[
M;',@T %:2TX-=9YR]]E%>^X#1OX<N;%,UUGG+WV45[[@-&_ARY)G5/Z5_P!F
MM_:K(KZXO0S^E8_]\\!&O5KFN3O:Y')W+LK5147945%V5$[%147N7L[#^QXB
M\2<[JS,7-0ZFRMO,YF^L7NK(79.>:1L$+*]>)J-1L<4%>".."O7A9'##$QL<
M4;6IL?QAF(^;?>2VPV8H+T@->XVODT2_-1X;8:] DM6N['RNBR.K;4,J*R>R
MZVWW%@V.CY*K:MK(HLTEJFZI/G2/;=&S<>>9<MYP][K@M%.R<]&JHR:>ZI;N
M])\E&&]I+=2*Z=&-@9&U,J.%1+<4O?+92U==<(+1VR@FM]QW]V"X-RGNJ45)
MM>)71J\B3TD>*5"KF,-H&7 8._$DU++ZVMMTQ7MPN_:3P4+,4V<?6E;M)7M_
M4E*MJ%S):TTT3T<OU[FO-C^DM6K.GKR\/+\L;5<M2#4]R*:39NZLA?8PD<#G
MJJ(UJ220M55W5[4[%V&JIV'8@G(ZV]I2FY5UXU<->$.SG/1=RE*4UJ_%I17@
MER+!8W4OLJ,$K)Y5MBYS[6,$V_"$8:))\4FY-<G)FI#Z3'0[XG<',K%A^)>B
M\UI6S963W!9NPLGQ.4;&JHY^+S5)]G%9!4;L^2&O;=:KM>SW77KO<C$^:MS;
MQ](?HZZ/XJ:1RVA]<X:KG-/9B!8YZUAB=;6G1'>Y\A0L(G6T<E2>[K:=RNYD
MT,B=CE8Y[':MGIX=$C)\#>*^K.&V2EDMLPEQDN(R4C6M?E,!D(TMX>^]&(C>
MMDJ2-BL\K6-]U0SHV.-NS$E+H/TZCM53IMKC3E5QWW&+;KMKX1<X;S;BXMI2
MA)RT3BU)K51B3I]U>RV.X74SE=AW3W%*>G:U6:.2A9NI1DI1BW"Q*.K3BXI[
MKG[S^;9>4AR6F]9P\!-4Y"2?2NKO=<^AGV95<F U3#')=GQ$+GJO5XW4-:.P
MZ"%'(V',PPLB8YV4E6/.M-/-PSXB7M(:DT_JO&ODCR&FLUC<[4=$]8Y.OQ=R
M&XUC7HJ*U9$A6)514V:]>U$-N]POUS6U/IO :CIO9)5SN&QN7@?'OU:QY"G#
M:;R<W;RIUNR;]O81KUM;#ACY=.77'=CEQFK4EP=U;CK/VSA..OQI1E)ZMLE/
MJ:V_9D8=^';-SEASAV3?G*BU/=AZU7.$TOBQE&/!*)_=@ B4F4\D/+J_8J\6
M_P"1Z/TSCC6.IZ?'H0V<7EU?L5>+?\CT?IG'&L=3T^/0A8OJ>_@%_P!+G]C2
M5CZ[/26-]"C]O<?UF+U[FJ&&S6GJ>3M5<)J.?#V<[C89.KK9:7 /OR89;J(G
M--'CY<G=FA@<[J.OE9/)&^6"!\7Z7T?>C!Q#XK9A<#PXT;G=7Y1B-=8BQ%-7
MU<?&_FY)LKE)W08O$0/5KFQS9.Y4CD>G)&Y[U1J_U/0QZ+&:XT\3=*<-\%(E
M>QJ+(-CNY!S'2,Q.&K(MC+Y1[&M=SK3HLE?!$Y&QS6E@AEDBCD=*S:4]%WHM
MZ,X/:-Q&AM#8BOBL/BJT4;WQQL]VY6XV-K;.6RUI&I)>R5Z1JS6;,RN<KG<D
M?5PLCC9N>FG3>O9*5=54;<NY.Q1;W80CYBLMW=)2UW5&,4TY1@]9Q48ZZ+H)
MT!MVRY6VVSIPZ&JMY+>G.6O:.JG>\F"6^YSFU)*4^$).4FL$#2WFS?29R%:.
MS;BT%AG2,1R5+VJ)YKD:KONV9M#$V:T;F]G[G:F1?0OI7Y[Z1GD'^DMPVQ]C
M,6]$Q:MQ-2-\UNWH.^NH[%:!CMNMDPR5ZF;E1&IUDB4<==ZB/=\SFQ-=(FS+
M.%(MIZV]IJ:E.&+.&O&'9RCJO!25F\GX-[WK3)=NZF-DN#C">77-I)6=K&6C
M7?N.O=:;XR2T[TG'AIIL7HK7.:Y%:YCE8]KD5KF.:JHYCFN1'-<U45'-<B*U
M45%1%0_5>!G&_4W#?5N"UQH_(R8O46G;T5['V6*[JW\B[3T[<;7,Z^A>A5]6
M[7<J)-7D>W=KN5S<O?SD/R7>%^H4_2"T/BX<=EL?8KP<1Z%&'JJN7Q]J1*];
M4ZP1-2*/*4;+X8,G.C8_=].9LUA[[%1BRX6*$Y=']NT;6PU=&"W)[U5U,]);
MD]-)URX:2BXO5/1*4)+5)MQ4 =)-@9.Q\YT3F]^O=MHOKUAOPUUA9#BW"491
MTDM6XSBTI-:2>V=Z#?2PP_&_A7I#B7AFI!#J''O6_0YN:3$YO'V)L=F\7-OL
MY'4LG5M11/<FUBMU%J)7P6(I'_6AA\^:A\>)IL/Q3X93R.=%C<CC-;8UBJG+
M$F6@3#91K47WR];)C,>_L]ZQ6N5>V7<S!BKG2O9"P-H96+'[W79K5J]6JK$K
M*TWWN,)*+?#5K4MMT/VT]H;-Q,N>G:65Z6Z+1=K7)UV-+N3G!R2XZ)Z:O0
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MIO0F/\YD?;3  (\))
M
M
M
M
M
M
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MS<EKRJ::ZH:]W;RE*37=JE2ERU2EP>C9_9  KZ60!\W],1/_ #2\3ON!U=]
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MS32?]1R #@"1@
M
M
M
M
M
M
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M,;7_  0?KL[/?:4Q?^F-K_@AB,_4:[_V&[_\G9__ '0^HUW_ +#=_P#D[/\
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M;%(C+K;]*Q^BT_MVDL=3?H=_2[_U5@MN9_>=O_-I_P#9.+D6W,_O.W_FT_\
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MI;&/UPKA!_D::)XZNJG#8FSTTTW2Y\?"=DYI_7%I_6  <>=J:C_IE_7CXO\
MWUN)']=,V?3'D=?LHN"?W8I]$90^9^F7]>/B_P#?6XD?UTS9],>1U^RBX)_=
MBGT1E"XNT?1-W_I]O]ED4HP/3=/_ *I7_:XFTH !3HNN   #6J><)_9;<3?\
MST)_433YLJS6J><)_9;<3?\ ,]"?U$T^2MU/^D[OH-OV^,0]UV>BL?\ ]0J_
MLV6>)66_>MG_ #>;_9N-REC/WM7_ (B+_9M--;EOWK9_S>;_ &;C<I8S][5_
MXB+_ &;3?]=/+9O^V?\ XIHNHSEM3VX?ZLHG  @HGX&)KYU)T7'931&A^+V.
MJK)8TCF5TIJ.6-O;#I_4:/DQ=V=W8B05-0UZ^-395>MC4$"(WD;(YN64?.'2
M^Z/U'BKPQUQP]R+46#56G<CBXWJV-75[LD*R8ZW$LGO&3T[\=:S!*NW52Q,D
M145J*;[HQM?W#GXV5\&NQ*SUU3UA:O;N2DUZTCGNE6QEM#9^5B:>594W7ZK8
M:3J?Z2,=?5J:CQZ(J*BINBHJ+\'I^8V3OD .E1_=-Z.NG*UNTZQG>']F?0N8
M61SG3*W%Q06,//(YR(KDL82W0<CVIU:/9)"UROAD1-<!JC2][!Y3)X3*1+!D
M\/?N8O(0*CD6*[0L25;+-G(UVR31/Y55K55NR[)N9'/FPW2@=I+C1G>'EVPV
M/$<3=/M]SLDDY6MU1I9UB[C'1(Y>1'6\5>S=61C6I)8E;0W>J5V,=8;K)V2L
MS95ED/*GC..37IWPBM+4GX.IRGPYN$2M'5;MEX6UZZYZQAE[V+8GW3;UI;7<
MU;%0X\E9+OT,VOI@=("EPKX6Z]XB7U8L6D=+Y;+P0O?U?NW)0U7LQ&-8]>QL
MV4RLE+'0*NR==:CWV3NU+&I-1W\SD<CF<K8=<RF8OW<KD[;_ -O:R.1LRW+M
MAW_O3V9I9%3T*[8SD/.F>D\F$X;Z0X64Y=KNN<TN;RK&O<CDP6F'12QL>C7;
M+'8RUFFO)*SE?[FYF*JQ.:F"HYR-155=D:FZJOH1$[54U75'LGLL&S*E'R\J
MS2+:_B:=8K3VV.W7QT7@C<]<VV>VVA5AQEK#$J3FD_X^_2;U7BJE5IX;TO%F
M4QYK;T46Y_B5JGBYD:JR4M 8MV!T],]$6-NIM2UY(<C9B7F1S+%'3CIZG:BL
M=#GIMT1[&JW.Z/)7R(O1:7A5T<M X^Y66MGM4X]FN=0,D8C+$-[4\<60JT9T
MY4D;+C<4^A1GB>KNJMPV49LUW*GK40]TYVQ[MVGDV)ZUUR["GO79TMQU7JG/
M?L_GDV=7^Q/<&RL6EK2RR'NB[Q[6Y*33T[X1W*_9!  '(G9F(/YVE4D73O!"
M=&[Q1Y_6T+W;M[))L;@)(F\JKS+S-KRKNB;-Y=E5%<W?"G,]KSJ3AY+D.!VB
M]1P1/E=IKB;0BMN:U%2OC<[I_/TWSO>J[M:N4@P]9$1-G/LLW7=J(N!*6DZK
MK5+8U*7'<LOB_:[93T_)-/ZRI/6W6X[;O;7"=./*/K2J4/VH-%ZHZ9R=J-)J
MN-R-F%5<ULU:C:GB56+LYJ210O8JM7L<B.W:O8NRDS]1.;_]2YC^:[_]G,[7
MS7/B)C\]P-U+IB>"K)>T;KK(-6.1D<LON#4-2MEZEE4>Q7,CEMKDZS$W7=]*
M5W9OL9+OZGL?_P!AI_\ RT'_ -AHMN=:<\++R,66"I.FQP4O=&[OQT4H2T[)
MZ;T&I::O37F=#T>ZI*\_"QLR.?*"OJ4W!8Z>Y+BIQU[5:[LU*.NBUTU-/;^H
MG-_^I<Q_-=_^SC]1.;_]2YC^:[_]G-PE^I['_P#8:?\ \M!_]@_4]C_^PT__
M ):#_P"PU7W9W_H]?TG_ /I-S]PV'^D9?T9?YQI[?U$YO_U+F/YKO_V<?J)S
M?_J7,?S7?_LYN$OU/8__ +#3_P#EH/\ [!^I['_]AI__ "T'_P!@^[._]'K^
MD_\ ](^X;#_2,OZ,O\XT],FB<WRK_P"1<QW+_P#TN_ZO\W-J#Y,'!V,=T>.#
M-2TQ8YX^'>F9)(U:]CF>Z,=#9:U[)&L>U[62M1[7-14=NG;WK]J?J>H?]AI_
M_*P__876*-&-:UK4:UJ(UK6HC6M:B;(U&IV(B(FR(B(B)V;''=,>G;VM535[
MF5"JL=FO:]IO-QW=/,AII]9VG0GJ]CL:Z^Y9+O=U4:M'4J]U1EO:^?+77@N[
MD5  1\20            <;'5C&M1&M:C6M1$:U$1$1$[D1$[$1/1L=P
M
M
M
M
M
M
M
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MTECU3?"$++4]W>F^'D[R@]%-QUX9JH.$7?X/0OK.3C3N
M
M
M
M
M
M
M
M                                             8OWG4WUF-#_ 'P(
M?H?(&4"?!W3\\GIHKI&Z9Q>E-<9+5&,QV(S#<U6ETM>QE"Z^VVM-51DTF5PV
M:A=7ZN=RJR.O%)SHU>MY=VKONB^T*\3:&+DW:JJFW?GNK>EINM<%W\6<[TMV
M9;F;-S,6E1=M]+A#>>['>;7-]RX&J@-B'YLM]C!2^[O67^\U#\O7S5OH\?Y7
M<9/])-'_ /()[,=!CH2:4Z/^@XN'NC+^H,EA8LMD\RVSJ:WC[N4]U95\<EB-
M9\9BL-56!BQ-2%J4TD:F_/+(NRI)/3_IQ@;1P8T8TK78LBNS2=6XMV,+4^.K
MXZS7 B_JXZ [1V9M">3E1I5<L6RI=G;OO?E95)<-V/#2$N)]B@ A@G(&NL\Y
M>^RBO?<!HW\.7-BF>,/3B\AAPCX_Z\EXB:RS_$3'9N;$8S".K::S.G:.+;5Q
M7NGW.]L&2TIE[7NA_NJ3KW.NNC=LSDBCV=S=IT#VYC[/S_=&2YJOL;(>1'?E
MO2<&N&J\'WG"]8>P,C:6SGC8J@[>WJL]\GN1W8;VOE:/CQ6BT-:A%^WC_C(_
M]HTW!7"+^">F/N>POT;6,>AOFKO1Y:K7?JMXR*K7-<B+J31ZINU45-__ , >
M[=/T&2!IO!Q8S'T,; Z1\&.IU:,+I7-=*Z&I!'7C=*YC(V.D5D;5>K8V-5RJ
MK6-39J;[K'Z6X>TXXBQ78^Q=SGVE>YYZKW=.+U\UZ^!SW5AT-S=E2S7F*I*^
M-"K[.SM/O;MWM?)CIY\=.>O$O0 (M);!AQ^=K_O;@/\ YUQ%_P!AHTS&U/-;
MRAWDL^'O28CTG'KW+ZQQ;=&R9J3%_J2R6'QZSNSK<8RY[O7+8#.=:D:8JO[G
M2!*O(KYNLZU',2/J.AFUJ<':6-E7[RJK[;>W([TO+HMKCI'5:^5):\>6K[CD
MNG.QKMH;+R<3'47=:Z-Q3EN1][R*K9:RT>GDP>G#GP-6R;,CR!/V)7"/_-=5
M?UYU,?%?ZU;Z/'^5O&3_ $ET?_R#X^=/<GHB=%S3W!;AWIWAGI6WF+V!TS'D
M(Z%K/V:=O+2MR65O9B?W78Q]#%U)%99R$S(NIHP(V!L3'H^1KI']SUA=-<':
M6'73BNUSCE0M:G7N+<C5=!Z/5\=9QX?\B/>K3H%M#9>?=D9<:57/$LICV=N^
M]^5V/-:K=CHMVN7'QT1])@ AXF\\D/+J_8J\6_Y'H_3..-8ZGI\>A#;C]+#H
MS8'C%P_U%PXU/:R]+!ZFK0U;]K!6*=7*Q1PVH;35J3WZ&2J1O62!B.6:E.U6
M*Y$:BJCD\+$\U;Z/'^5O&3_231__ " 3!U>],\'9N+;5E2M4YY$K(JNO?6ZZ
MZX\7JM'K%\/ A3K*Z"[0VIF4WXD:7"&-&J7:6]F]Y662X+=EJM)+CP/@+S2G
M^$/'C^1N&W^^ZZ,UH\O/)X^28X<=&>[JV[H/,ZURDNLJV$JY1NK<GA<A'!'@
M)<M-3=03$Z>P;XGR.S%E+*SOLM>UD'5,B5LBR^H9Q/37:].=M*_*QW)U6*G=
MWX[LO(IKA+6/'3RHOOY'?=!MCW8&S,;$R%%75=KOJ$M^/EW636DM%KY,EW(
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MV?=#-S+NTR:VW553*2IK<EHY3FU&5LM&UNZ1K6KU5G!KA#D B<F0&.IYS_\
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M0WJ7&+;:?%[STY>!L>B'5GM7"VEB95\<?LJ;'*;A?O2TW)1X1W%KQ:UX^)[
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M#:CQ=S":@Q6/S>'R$+ZU[&96G!>H6X)&JU\5BK9CDAE8YJJBH]B]_9LICO\
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M7R227))(L?35&N$*X+2,(QA%-N348I12;DVWP2XMMOFVV  ?F?H
M
M
M
M
M
M
M
M
M
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M^T^NI78G9XV1GSCI+)FJ:6UQ[*EO?DO5.U[K7C5X:'( (<)O
M                                                   !;<S^\[?^
M;3_[)Q<BVYG]YV_\VG_V3C*YHP^3-.?E/WW<_P \M_[Q*>NGD!_LO^#'^<Z_
M_P#";7QY%Y3]]W/\\M_[Q*>NGD!_LO\ @Q_G.O\ _P )M?%R>D_HO:'T#+_L
M]A2+H=Z5V9].Q/MH&S. !34N\
M
M
M
M
M
M
M
M
M
M
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M*\N?=QG/>D_6P #6FT
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M##LHRLW(=N13.NV%5'DTPL@U*+E.2W[=))/@JH]S4D=@ 1"34
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
3                      ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
